

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp311

Request ID: cder_mpl1r_wp311

Request Description: In this report, we characterized dispensing and administration patterns of 28 New Molecular Entities (NMEs) approved from July 1, 2020, to December 31, 2020, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on August 14, 2025. We included aggregate results from all 13 data partners in this report. The study period included data from January 1, 2020, to April 30, 2025. Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals initiating any of the 28 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between July 1, 2020, to December 31, 2020, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of procedure codes used to define exposures in this request and Appendix C for a list of non-proprietary and proprietary names of medical products. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F and G for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Overview for Request: cder_mpl1r_wp311

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table 1a Aggregated Characteristics of Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1b Aggregated Characteristics of Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1c Aggregated Characteristics of Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1d Aggregated Characteristics of Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1e Aggregated Characteristics of Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1f Aggregated Characteristics of Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1g Aggregated Characteristics of Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1h Aggregated Characteristics of Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1i Aggregated Characteristics of Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1j Aggregated Characteristics of Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1k Aggregated Characteristics of Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1l Aggregated Characteristics of Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1m Aggregated Characteristics of Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1n Aggregated Characteristics of Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1o Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1p Aggregated Characteristics of Atoltivimad Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1q Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1r Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1s Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1t Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1u Aggregated Characteristics of Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1v Aggregated Characteristics of Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1w Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table 1x Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table of Contents

<u>Table 1y</u>	Aggregated Characteristics of Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1z</u>	Aggregated Characteristics of Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1aa</u>	Aggregated Characteristics of Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1ab</u>	Aggregated Characteristics of Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table of Contents

<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1a</u>	Patient Entry into Study by Month for Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1b</u>	Patient Entry into Study by Month for Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1c</u>	Patient Entry into Study by Month for Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1d</u>	Patient Entry into Study by Month for Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1e</u>	Patient Entry into Study by Month for Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1f</u>	Patient Entry into Study by Month for Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table of Contents

<u>Figure 1g</u>	Patient Entry into Study by Month for Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1h</u>	Patient Entry into Study by Month for Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1i</u>	Patient Entry into Study by Month for Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1j</u>	Patient Entry into Study by Month for Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1k</u>	Patient Entry into Study by Month for Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1l</u>	Patient Entry into Study by Month for Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1m</u>	Patient Entry into Study by Month for Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1n</u>	Patient Entry into Study by Month for Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1o</u>	Patient Entry into Study by Month for Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1p</u>	Patient Entry into Study by Month for Atoltivimad Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1q</u>	Patient Entry into Study by Month for Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1r</u>	Patient Entry into Study by Month for Lonafern in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1s</u>	Patient Entry into Study by Month for Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1t</u>	Patient Entry into Study by Month for Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1u</u>	Patient Entry into Study by Month for Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1v</u>	Patient Entry into Study by Month for Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1w</u>	Patient Entry into Study by Month for Berotralstat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1x</u>	Patient Entry into Study by Month for Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1y</u>	Patient Entry into Study by Month for Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1z</u>	Patient Entry into Study by Month for Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1aa</u>	Patient Entry into Study by Month for Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1ab</u>	Patient Entry into Study by Month for Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date
<u>Appendix B</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request
<u>Appendix C</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Table of Contents

Appendix D List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Appendix E List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Appendix F.1 Specifications Defining Parameters in this Request

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Appendix F.3 Specifications Defining Utilization Parameters in this Request

Appendix G Design Diagrams of Cohort Entry Requirements in this Request

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remimazolam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,707	N/A ²
Demographic Characteristics		
Age (years)	68.7	12.1
Age		
0-17 years	35	0.7%
18-24 years	50	1.1%
25-40 years	181	3.8%
41-64 years	1,034	22.0%
≥ 65 years	3,407	72.4%
Sex		
Female	2,248	47.8%
Male	2,459	52.2%
Race ³		
American Indian or Alaska Native	43	0.9%
Asian	34	0.7%
Black or African American	185	3.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	775	16.5%
White	3,635	77.2%
Hispanic origin		
Yes	44	0.9%
No	3,482	74.0%
Unknown	1,181	25.1%
Year		
2020	0	0.0%
2021	41	0.9%
2022	114	2.4%
2023	1,619	34.4%
2024	2,841	60.4%
2025	92	2.0%
Health Characteristics		
Acute Myocardial Infarction	73	1.6%
Alzheimer's Disease	35	0.7%
Non-Alzheimer's Dementia	157	3.3%

Table 1a. Aggregated Characteristics of Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remimazolam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,203	25.6%
Diabetes Mellitus	1,245	26.4%
Heart Failure	1,311	27.9%
Hyperlipidemia	1,964	41.7%
Hypertension	2,612	55.5%
Depression	1,057	22.5%
Ischemic Heart Disease	1,428	30.3%
Rheumatoid Arthritis/Osteoarthritis	1,109	23.6%
Stroke/TIA ⁴	183	3.9%
Breast Cancer	190	4.0%
Colorectal Cancer	119	2.5%
Prostate Cancer	229	4.9%
Lung Cancer	181	3.8%
Endometrial Cancer	37	0.8%
Acquired Hypothyroidism	693	14.7%
Anemia	1,377	29.3%
Asthma	313	6.6%
Benign Prostatic Hyperplasia	336	7.1%
Chronic Kidney Disease	1,028	21.8%
COPD ⁵ and Bronchiectasis	649	13.8%
Glaucoma	454	9.6%
Osteoporosis	254	5.4%
Obesity: diagnosed or identified by weight management procedures	1,252	26.6%
Obesity: identified by weight management-related dispensings	232	4.9%
Overweight	365	7.8%
Smoking: diagnosed or identified by smoking cessation procedures	1,514	32.2%
Smoking: identified by smoking-related dispensings	28	0.6%
Alcohol Abuse or Dependence	162	3.4%
Drug Abuse or Dependence	149	3.2%
History of Cardiac Arrest	40	0.8%
History of Coronary Angioplasty or Bypass	511	10.9%
Liver Disease Based on CCW ⁶ Definition	412	8.8%
Liver Disease Extended Definition (CCW + Additional Codes)	417	8.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.8
Mean number of emergency room encounters	0.7	2.1

Table 1a. Aggregated Characteristics of Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remimazolam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.3	11.1
Mean number of filled prescriptions	20.8	18.8
Mean number of Non-Proprietarys dispensed	9.4	5.9
Mean number of unique drug classes dispensed	8.8	5.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Characteristics of Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fostemsavir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,519	N/A ²
Demographic Characteristics		
Age (years)	57.2	11.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	931	61.3%
≥ 65 years	411	27.1%
Sex		
Female	319	21.0%
Male	1,200	79.0%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	14	0.9%
Black or African American	584	38.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	276	18.2%
White	632	41.6%
Hispanic origin		
Yes	122	8.0%
No	1,108	72.9%
Unknown	289	19.0%
Year		
2020	278	18.3%
2021	421	27.7%
2022	245	16.1%
2023	285	18.8%
2024	277	18.2%
2025	13	0.9%
Health Characteristics		
Acute Myocardial Infarction	27	1.8%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	31	2.0%

Table 1b. Aggregated Characteristics of Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fostemsavir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	53	3.5%
Diabetes Mellitus	289	19.0%
Heart Failure	152	10.0%
Hyperlipidemia	562	37.0%
Hypertension	603	39.7%
Depression	401	26.4%
Ischemic Heart Disease	234	15.4%
Rheumatoid Arthritis/Osteoarthritis	167	11.0%
Stroke/TIA ⁴	37	2.4%
Breast Cancer	12	0.8%
Colorectal Cancer	39	2.6%
Prostate Cancer	30	2.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	86	5.7%
Anemia	415	27.3%
Asthma	87	5.7%
Benign Prostatic Hyperplasia	89	5.9%
Chronic Kidney Disease	343	22.6%
COPD ⁵ and Bronchiectasis	129	8.5%
Glaucoma	68	4.5%
Osteoporosis	37	2.4%
Obesity: diagnosed or identified by weight management procedures	188	12.4%
Obesity: identified by weight management-related dispensings	39	2.6%
Overweight	113	7.4%
Smoking: diagnosed or identified by smoking cessation procedures	393	25.9%
Smoking: identified by smoking-related dispensings	22	1.4%
Alcohol Abuse or Dependence	49	3.2%
Drug Abuse or Dependence	153	10.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	88	5.8%
Liver Disease Based on CCW ⁶ Definition	109	7.2%
Liver Disease Extended Definition (CCW + Additional Codes)	110	7.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.9	23.2
Mean number of emergency room encounters	0.6	2.5

Table 1b. Aggregated Characteristics of Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fostemsavir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.3	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.5	15.1
Mean number of filled prescriptions	39.4	26.2
Mean number of Non-Proprietarys dispensed	11.9	6.3
Mean number of unique drug classes dispensed	9.7	5.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Decitabine and Cedazuridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,272	N/A ²
Demographic Characteristics		
Age (years)	75.9	8.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	312	7.3%
≥ 65 years	3,941	92.3%
Sex		
Female	1,660	38.9%
Male	2,612	61.1%
Race ³		
American Indian or Alaska Native	11	0.3%
Asian	96	2.2%
Black or African American	257	6.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	355	8.3%
White	3,539	82.8%
Hispanic origin		
Yes	68	1.6%
No	3,576	83.7%
Unknown	628	14.7%
Year		
2020	396	9.3%
2021	978	22.9%
2022	907	21.2%
2023	917	21.5%
2024	1,030	24.1%
2025	44	1.0%
Health Characteristics		
Acute Myocardial Infarction	110	2.6%
Alzheimer's Disease	46	1.1%
Non-Alzheimer's Dementia	172	4.0%

Table 1c. Aggregated Characteristics of Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Decitabine and Cedazuridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	859	20.1%
Diabetes Mellitus	1,191	27.9%
Heart Failure	1,007	23.6%
Hyperlipidemia	2,184	51.1%
Hypertension	2,862	67.0%
Depression	869	20.3%
Ischemic Heart Disease	1,441	33.7%
Rheumatoid Arthritis/Osteoarthritis	963	22.5%
Stroke/TIA ⁴	190	4.4%
Breast Cancer	231	5.4%
Colorectal Cancer	131	3.1%
Prostate Cancer	293	6.9%
Lung Cancer	121	2.8%
Endometrial Cancer	30	0.7%
Acquired Hypothyroidism	783	18.3%
Anemia	4,173	97.7%
Asthma	223	5.2%
Benign Prostatic Hyperplasia	598	14.0%
Chronic Kidney Disease	1,173	27.5%
COPD ⁵ and Bronchiectasis	747	17.5%
Glaucoma	413	9.7%
Osteoporosis	308	7.2%
Obesity: diagnosed or identified by weight management procedures	822	19.2%
Obesity: identified by weight management-related dispensings	50	1.2%
Overweight	545	12.8%
Smoking: diagnosed or identified by smoking cessation procedures	1,735	40.6%
Smoking: identified by smoking-related dispensings	17	0.4%
Alcohol Abuse or Dependence	139	3.3%
Drug Abuse or Dependence	133	3.1%
History of Cardiac Arrest	19	0.4%
History of Coronary Angioplasty or Bypass	556	13.0%
Liver Disease Based on CCW ⁶ Definition	445	10.4%
Liver Disease Extended Definition (CCW + Additional Codes)	448	10.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	33.1	19.1
Mean number of emergency room encounters	0.8	1.6

Table 1c. Aggregated Characteristics of Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Decitabine and Cedazuridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.8	14.4
Mean number of filled prescriptions	22.0	16.1
Mean number of Non-Proprietarys dispensed	10.4	5.6
Mean number of unique drug classes dispensed	9.7	5.1

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Abametapir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A ²
Demographic Characteristics		
Age (years)	-	-
Age		
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ³		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	-
2023	-	-
2024	-	-
2025	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease	-	-
Non-Alzheimer's Dementia	-	-

Table 1d. Aggregated Characteristics of Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Abametapir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA ⁴	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD ⁵ and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related dispensings	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related dispensings	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Liver Disease Based on CCW ⁶ Definition	-	-
Liver Disease Extended Definition (CCW + Additional Codes)	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-

Table 1d. Aggregated Characteristics of Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Abametapir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of Non-Proprietarys dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1e. Aggregated Characteristics of Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tafasitamab-cxix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,836	N/A ²
Demographic Characteristics		
Age (years)	76.9	9.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	145	7.9%
≥ 65 years	1,676	91.3%
Sex		
Female	847	46.1%
Male	989	53.9%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	45	2.5%
Black or African American	83	4.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	179	9.7%
White	1,515	82.5%
Hispanic origin		
Yes	40	2.2%
No	1,541	83.9%
Unknown	255	13.9%
Year		
2020	*****	*****
2021	657	35.8%
2022	499	27.2%
2023	400	21.8%
2024	241	13.1%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	30	1.6%
Alzheimer's Disease	20	1.1%
Non-Alzheimer's Dementia	88	4.8%

Table 1e. Aggregated Characteristics of Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tafasitamab-cxix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	387	21.1%
Diabetes Mellitus	509	27.7%
Heart Failure	487	26.5%
Hyperlipidemia	903	49.2%
Hypertension	1,156	63.0%
Depression	349	19.0%
Ischemic Heart Disease	622	33.9%
Rheumatoid Arthritis/Osteoarthritis	380	20.7%
Stroke/TIA ⁴	85	4.6%
Breast Cancer	94	5.1%
Colorectal Cancer	60	3.3%
Prostate Cancer	106	5.8%
Lung Cancer	52	2.8%
Endometrial Cancer	12	0.7%
Acquired Hypothyroidism	332	18.1%
Anemia	1,159	63.1%
Asthma	91	5.0%
Benign Prostatic Hyperplasia	227	12.4%
Chronic Kidney Disease	446	24.3%
COPD ⁵ and Bronchiectasis	248	13.5%
Glaucoma	183	10.0%
Osteoporosis	119	6.5%
Obesity: diagnosed or identified by weight management procedures	336	18.3%
Obesity: identified by weight management-related dispensings	15	0.8%
Overweight	243	13.2%
Smoking: diagnosed or identified by smoking cessation procedures	646	35.2%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	36	2.0%
Drug Abuse or Dependence	57	3.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	219	11.9%
Liver Disease Based on CCW ⁶ Definition	207	11.3%
Liver Disease Extended Definition (CCW + Additional Codes)	209	11.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	30.9	16.9

Table 1e. Aggregated Characteristics of Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tafasitamab-cxix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.3	15.6
Mean number of filled prescriptions	24.5	17.0
Mean number of Non-Proprietarys dispensed	11.9	6.2
Mean number of unique drug classes dispensed	11.1	5.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Belantamab Mafodotin-blmf		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,351	N/A ²
Demographic Characteristics		
Age (years)	70.9	8.7
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,068	79.1%
Sex		
Female	637	47.2%
Male	714	52.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	204	15.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	156	11.5%
White	963	71.3%
Hispanic origin		
Yes	30	2.2%
No	1,113	82.4%
Unknown	208	15.4%
Year		
2020	38	2.8%
2021	754	55.8%
2022	539	39.9%
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	26	1.9%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	55	4.1%

Table 1f. Aggregated Characteristics of Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Belantamab Mafodotin-blmf		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	223	16.5%
Diabetes Mellitus	325	24.1%
Heart Failure	348	25.8%
Hyperlipidemia	490	36.3%
Hypertension	836	61.9%
Depression	324	24.0%
Ischemic Heart Disease	310	22.9%
Rheumatoid Arthritis/Osteoarthritis	267	19.8%
Stroke/TIA ⁴	44	3.3%
Breast Cancer	53	3.9%
Colorectal Cancer	*****	*****
Prostate Cancer	61	4.5%
Lung Cancer	16	1.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	220	16.3%
Anemia	1,027	76.0%
Asthma	92	6.8%
Benign Prostatic Hyperplasia	131	9.7%
Chronic Kidney Disease	464	34.3%
COPD ⁵ and Bronchiectasis	159	11.8%
Glaucoma	182	13.5%
Osteoporosis	83	6.1%
Obesity: diagnosed or identified by weight management procedures	220	16.3%
Obesity: identified by weight management-related dispensings	12	0.9%
Overweight	145	10.7%
Smoking: diagnosed or identified by smoking cessation procedures	412	30.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	23	1.7%
Drug Abuse or Dependence	68	5.0%
History of Cardiac Arrest	12	0.9%
History of Coronary Angioplasty or Bypass	91	6.7%
Liver Disease Based on CCW ⁶ Definition	83	6.1%
Liver Disease Extended Definition (CCW + Additional Codes)	84	6.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	38.5	20.2

Table 1f. Aggregated Characteristics of Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Belantamab Mafodotin-blmf		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	13.4	15.3
Mean number of filled prescriptions	30.5	16.9
Mean number of Non-Proprietarys dispensed	13.1	5.9
Mean number of unique drug classes dispensed	12.2	5.2

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Characteristics of Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Nifurtimox		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A ²
Demographic Characteristics		
Age (years)	60.0	8.0
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2020	0	0.0%
2021	*****	*****
2022	*****	*****
2023	*****	*****
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1g. Aggregated Characteristics of Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Nifurtimox		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.6	9.2

Table 1g. Aggregated Characteristics of Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Nifurtimox		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.9	1.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	11.9	21.3
Mean number of filled prescriptions	26.1	34.0
Mean number of Non-Proprietarys dispensed	13.8	12.0
Mean number of unique drug classes dispensed	12.4	9.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1h. Aggregated Characteristics of Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Risdiplam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,654	N/A ²
Demographic Characteristics		
Age (years)	24.3	13.1
Age		
0-17 years	728	44.0%
18-24 years	239	14.4%
25-40 years	403	24.4%
41-64 years	239	14.4%
≥ 65 years	45	2.7%
Sex		
Female	878	53.1%
Male	776	46.9%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	54	3.3%
Black or African American	80	4.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	533	32.2%
White	961	58.1%
Hispanic origin		
Yes	186	11.2%
No	1,086	65.7%
Unknown	382	23.1%
Year		
2020	458	27.7%
2021	895	54.1%
2022	120	7.3%
2023	103	6.2%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1h. Aggregated Characteristics of Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Risdiplam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	57	3.4%
Heart Failure	17	1.0%
Hyperlipidemia	59	3.6%
Hypertension	102	6.2%
Depression	186	11.2%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	33	2.0%
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	23	1.4%
Anemia	94	5.7%
Asthma	87	5.3%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	42	2.5%
Glaucoma	*****	*****
Osteoporosis	44	2.7%
Obesity: diagnosed or identified by weight management procedures	93	5.6%
Obesity: identified by weight management-related dispensings	12	0.7%
Overweight	25	1.5%
Smoking: diagnosed or identified by smoking cessation procedures	40	2.4%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	26	1.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	16	1.0%
Liver Disease Extended Definition (CCW + Additional Codes)	17	1.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.7	14.8

Table 1h. Aggregated Characteristics of Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Risdiplam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	51.3	56.3
Mean number of filled prescriptions	13.4	17.8
Mean number of Non-Proprietarys dispensed	4.7	4.8
Mean number of unique drug classes dispensed	4.5	4.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Oliceridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	59	N/A ²
Demographic Characteristics		
Age (years)	72.1	11.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	48	81.4%
Sex		
Female	44	74.6%
Male	15	25.4%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	29	49.2%
Unknown	30	50.8%
Year		
2020	0	0.0%
2021	0	0.0%
2022	*****	*****
2023	*****	*****
2024	36	61.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1i. Aggregated Characteristics of Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Oliceridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	12	20.3%
Heart Failure	*****	*****
Hyperlipidemia	27	45.8%
Hypertension	28	47.5%
Depression	17	28.8%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	32	54.2%
Stroke/TIA ⁴	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	*****	*****
Anemia	14	23.7%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	12	20.3%
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	16	27.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.7	9.0

Table 1i. Aggregated Characteristics of Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Oliceridine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.4	3.8
Mean number of filled prescriptions	20.4	9.4
Mean number of Non-Proprietarys dispensed	10.3	4.0
Mean number of unique drug classes dispensed	9.5	3.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1j. Aggregated Characteristics of Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Viltolarsen		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	52	N/A ²
Demographic Characteristics		
Age (years)	13.1	6.0
Age		
0-17 years	38	73.1%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	0	0.0%
Male	52	100.0%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	26	50.0%
Hispanic origin		
Yes	*****	*****
No	28	53.8%
Unknown	*****	*****
Year		
2020	*****	*****
2021	36	69.2%
2022	*****	*****
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1j. Aggregated Characteristics of Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Viltolarsen		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	13	25.0%
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.6	8.6

Table 1j. Aggregated Characteristics of Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Viltolarsen		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.2	0.4
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	30.0	41.0
Mean number of filled prescriptions	16.8	18.4
Mean number of Non-Proprietarys dispensed	4.8	4.7
Mean number of unique drug classes dispensed	4.6	4.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1k. Aggregated Characteristics of Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Satralizumab-mwge		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	328	N/A ²
Demographic Characteristics		
Age (years)	54.5	15.1
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	63	19.2%
41-64 years	143	43.6%
≥ 65 years	106	32.3%
Sex		
Female	276	84.1%
Male	52	15.9%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	110	33.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	73	22.3%
White	130	39.6%
Hispanic origin		
Yes	23	7.0%
No	222	67.7%
Unknown	83	25.3%
Year		
2020	*****	*****
2021	105	32.0%
2022	58	17.7%
2023	61	18.6%
2024	87	26.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1k. Aggregated Characteristics of Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Satralizumab-mwge		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	13	4.0%
Diabetes Mellitus	80	24.4%
Heart Failure	29	8.8%
Hyperlipidemia	102	31.1%
Hypertension	143	43.6%
Depression	86	26.2%
Ischemic Heart Disease	27	8.2%
Rheumatoid Arthritis/Osteoarthritis	60	18.3%
Stroke/TIA ⁴	22	6.7%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	51	15.5%
Anemia	105	32.0%
Asthma	19	5.8%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	36	11.0%
COPD ⁵ and Bronchiectasis	28	8.5%
Glaucoma	37	11.3%
Osteoporosis	21	6.4%
Obesity: diagnosed or identified by weight management procedures	95	29.0%
Obesity: identified by weight management-related dispensings	13	4.0%
Overweight	36	11.0%
Smoking: diagnosed or identified by smoking cessation procedures	61	18.6%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	21	6.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	19	5.8%
Liver Disease Extended Definition (CCW + Additional Codes)	19	5.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.0	12.8

Table 1k. Aggregated Characteristics of Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Satralizumab-mwge		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.8	1.5
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.2	0.5
Mean number of other ambulatory encounters	16.5	28.9
Mean number of filled prescriptions	27.4	21.9
Mean number of Non-Proprietarys dispensed	10.7	6.4
Mean number of unique drug classes dispensed	10.0	5.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11. Aggregated Characteristics of Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Clascoterone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	48,919	N/A ²
Demographic Characteristics		
Age (years)	27.7	11.2
Age		
0-17 years	11,033	22.6%
18-24 years	13,465	27.5%
25-40 years	17,542	35.9%
41-64 years	6,485	13.3%
≥ 65 years	394	0.8%
Sex		
Female	43,522	89.0%
Male	5,397	11.0%
Race ³		
American Indian or Alaska Native	102	0.2%
Asian	2,690	5.5%
Black or African American	2,181	4.5%
Multi-racial	2,962	6.1%
Native Hawaiian or Other Pacific Islander	15	0.0%
Unknown	18,871	38.6%
White	22,098	45.2%
Hispanic origin		
Yes	2,457	5.0%
No	17,241	35.2%
Unknown	29,221	59.7%
Year		
2020	0	0.0%
2021	1,513	3.1%
2022	13,217	27.0%
2023	17,183	35.1%
2024	15,607	31.9%
2025	1,399	2.9%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	17	0.0%

Table 11. Aggregated Characteristics of Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Clascoterone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	38	0.1%
Diabetes Mellitus	638	1.3%
Heart Failure	89	0.2%
Hyperlipidemia	1,370	2.8%
Hypertension	1,031	2.1%
Depression	7,338	15.0%
Ischemic Heart Disease	169	0.3%
Rheumatoid Arthritis/Osteoarthritis	920	1.9%
Stroke/TIA ⁴	40	0.1%
Breast Cancer	137	0.3%
Colorectal Cancer	16	0.0%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,096	2.2%
Anemia	2,126	4.3%
Asthma	822	1.7%
Benign Prostatic Hyperplasia	12	0.0%
Chronic Kidney Disease	175	0.4%
COPD ⁵ and Bronchiectasis	70	0.1%
Glaucoma	441	0.9%
Osteoporosis	86	0.2%
Obesity: diagnosed or identified by weight management procedures	2,820	5.8%
Obesity: identified by weight management-related dispensings	1,095	2.2%
Overweight	1,787	3.7%
Smoking: diagnosed or identified by smoking cessation procedures	755	1.5%
Smoking: identified by smoking-related dispensings	46	0.1%
Alcohol Abuse or Dependence	309	0.6%
Drug Abuse or Dependence	383	0.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	14	0.0%
Liver Disease Based on CCW ⁶ Definition	204	0.4%
Liver Disease Extended Definition (CCW + Additional Codes)	218	0.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.7	9.2

Table 11. Aggregated Characteristics of Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Clascoterone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.6	3.7
Mean number of filled prescriptions	8.1	9.1
Mean number of Non-Proprietarys dispensed	4.3	3.7
Mean number of unique drug classes dispensed	3.9	3.4

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1m. Aggregated Characteristics of Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Somapacitan-beco		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,172	N/A ²
Demographic Characteristics		
Age (years)	15.6	9.9
Age		
0-17 years	1,033	88.1%
18-24 years	46	3.9%
25-40 years	30	2.6%
41-64 years	40	3.4%
≥ 65 years	23	2.0%
Sex		
Female	323	27.6%
Male	849	72.4%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	35	3.0%
Black or African American	*****	*****
Multi-racial	151	12.9%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	517	44.1%
White	458	39.1%
Hispanic origin		
Yes	65	5.5%
No	219	18.7%
Unknown	888	75.8%
Year		
2020	0	0.0%
2021	0	0.0%
2022	0	0.0%
2023	383	32.7%
2024	686	58.5%
2025	103	8.8%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1m. Aggregated Characteristics of Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Somapacitan-beco		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	17	1.5%
Heart Failure	*****	*****
Hyperlipidemia	41	3.5%
Hypertension	12	1.0%
Depression	78	6.7%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	16	1.4%
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	79	6.7%
Anemia	41	3.5%
Asthma	44	3.8%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	11	0.9%
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	12	1.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	49	4.2%
Obesity: identified by weight management-related dispensings	15	1.3%
Overweight	23	2.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.3	10.6

Table 1m. Aggregated Characteristics of Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Somapacitan-beco		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.1	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.2	9.5
Mean number of filled prescriptions	9.5	9.3
Mean number of Non-Proprietarys dispensed	3.5	3.0
Mean number of unique drug classes dispensed	3.3	2.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1n. Aggregated Characteristics of Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Copper Cu 64 Dotatate Injection		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	18,172	N/A ²
Demographic Characteristics		
Age (years)	68.7	10.3
Age		
0-17 years	17	0.1%
18-24 years	82	0.5%
25-40 years	548	3.0%
41-64 years	4,086	22.5%
≥ 65 years	13,439	74.0%
Sex		
Female	10,136	55.8%
Male	8,036	44.2%
Race ³		
American Indian or Alaska Native	43	0.2%
Asian	231	1.3%
Black or African American	1,888	10.4%
Multi-racial	125	0.7%
Native Hawaiian or Other Pacific Islander	21	0.1%
Unknown	2,090	11.5%
White	13,774	75.8%
Hispanic origin		
Yes	310	1.7%
No	14,152	77.9%
Unknown	3,710	20.4%
Year		
2020	*****	*****
2021	3,204	17.6%
2022	4,872	26.8%
2023	5,572	30.7%
2024	4,347	23.9%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	152	0.8%
Alzheimer's Disease	110	0.6%
Non-Alzheimer's Dementia	462	2.5%

Table 1n. Aggregated Characteristics of Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Copper Cu 64 Dotatate Injection		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,989	10.9%
Diabetes Mellitus	5,645	31.1%
Heart Failure	2,310	12.7%
Hyperlipidemia	8,317	45.8%
Hypertension	11,010	60.6%
Depression	3,893	21.4%
Ischemic Heart Disease	4,337	23.9%
Rheumatoid Arthritis/Osteoarthritis	3,439	18.9%
Stroke/TIA ⁴	560	3.1%
Breast Cancer	972	5.3%
Colorectal Cancer	902	5.0%
Prostate Cancer	809	4.5%
Lung Cancer	973	5.4%
Endometrial Cancer	133	0.7%
Acquired Hypothyroidism	3,121	17.2%
Anemia	6,150	33.8%
Asthma	1,212	6.7%
Benign Prostatic Hyperplasia	1,441	7.9%
Chronic Kidney Disease	3,210	17.7%
COPD ⁵ and Bronchiectasis	1,955	10.8%
Glaucoma	1,699	9.3%
Osteoporosis	1,096	6.0%
Obesity: diagnosed or identified by weight management procedures	5,082	28.0%
Obesity: identified by weight management-related dispensings	656	3.6%
Overweight	2,123	11.7%
Smoking: diagnosed or identified by smoking cessation procedures	5,220	28.7%
Smoking: identified by smoking-related dispensings	64	0.4%
Alcohol Abuse or Dependence	439	2.4%
Drug Abuse or Dependence	528	2.9%
History of Cardiac Arrest	48	0.3%
History of Coronary Angioplasty or Bypass	1,306	7.2%
Liver Disease Based on CCW ⁶ Definition	3,510	19.3%
Liver Disease Extended Definition (CCW + Additional Codes)	3,522	19.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.1	14.0

Table 1n. Aggregated Characteristics of Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Copper Cu 64 Dotatate Injection		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.4	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.7	9.0
Mean number of filled prescriptions	19.0	15.8
Mean number of Non-Proprietarys dispensed	9.0	5.6
Mean number of unique drug classes dispensed	8.4	5.1

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pralsetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	227	N/A ²
Demographic Characteristics		
Age (years)	67.5	9.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	57	25.1%
≥ 65 years	159	70.0%
Sex		
Female	121	53.3%
Male	106	46.7%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	18	7.9%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	40	17.6%
White	149	65.6%
Hispanic origin		
Yes	*****	*****
No	167	73.6%
Unknown	*****	*****
Year		
2020	*****	*****
2021	66	29.1%
2022	50	22.0%
2023	55	24.2%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1o. Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pralsetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	19	8.4%
Diabetes Mellitus	50	22.0%
Heart Failure	28	12.3%
Hyperlipidemia	87	38.3%
Hypertension	132	58.1%
Depression	36	15.9%
Ischemic Heart Disease	46	20.3%
Rheumatoid Arthritis/Osteoarthritis	35	15.4%
Stroke/TIA ⁴	14	6.2%
Breast Cancer	18	7.9%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	151	66.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	74	32.6%
Anemia	72	31.7%
Asthma	14	6.2%
Benign Prostatic Hyperplasia	25	11.0%
Chronic Kidney Disease	36	15.9%
COPD ⁵ and Bronchiectasis	31	13.7%
Glaucoma	21	9.3%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	34	15.0%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	17	7.5%
Smoking: diagnosed or identified by smoking cessation procedures	77	33.9%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	34	15.0%
Liver Disease Extended Definition (CCW + Additional Codes)	35	15.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.1	13.6

Table 1o. Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pralsetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	1.0
Mean number of inpatient hospital encounters	0.5	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.0	7.5
Mean number of filled prescriptions	20.9	12.9
Mean number of Non-Proprietarys dispensed	9.7	5.1
Mean number of unique drug classes dispensed	9.0	4.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of Atoltivimab Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Atoltivimad Maftivimab and Odesivimab-ebgn		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A ²
Demographic Characteristics		
Age (years)	-	-
Age		
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ³		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	-
2023	-	-
2024	-	-
2025	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease	-	-
Non-Alzheimer's Dementia	-	-

Table 1p. Aggregated Characteristics of Atoltivimad Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Atoltivimad Maftivimab and Odesivimab-ebgn		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA ⁴	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD ⁵ and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related dispensings	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related dispensings	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Liver Disease Based on CCW ⁶ Definition	-	-
Liver Disease Extended Definition (CCW + Additional Codes)	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-

Table 1p. Aggregated Characteristics of Atoltivimad Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Atoltivimad Maftivimab and Odesivimab-ebgn		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of Non-Proprietarys dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1q. Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remdesivir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	993,583	N/A ²
Demographic Characteristics		
Age (years)	70.5	12.8
Age		
0-17 years	5,098	0.5%
18-24 years	7,326	0.7%
25-40 years	48,929	4.9%
41-64 years	221,807	22.3%
≥ 65 years	710,423	71.5%
Sex		
Female	505,231	50.8%
Male	488,352	49.2%
Race ³		
American Indian or Alaska Native	7,785	0.8%
Asian	22,262	2.2%
Black or African American	111,374	11.2%
Multi-racial	3,443	0.3%
Native Hawaiian or Other Pacific Islander	2,825	0.3%
Unknown	139,835	14.1%
White	706,059	71.1%
Hispanic origin		
Yes	47,069	4.7%
No	787,956	79.3%
Unknown	158,558	16.0%
Year		
2020	175,941	17.7%
2021	388,701	39.1%
2022	215,494	21.7%
2023	129,985	13.1%
2024	81,663	8.2%
2025	1,799	0.2%
Health Characteristics		
Acute Myocardial Infarction	19,479	2.0%
Alzheimer's Disease	35,401	3.6%
Non-Alzheimer's Dementia	116,296	11.7%

Table 1q. Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remdesivir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	162,906	16.4%
Diabetes Mellitus	330,716	33.3%
Heart Failure	234,691	23.6%
Hyperlipidemia	410,781	41.3%
Hypertension	568,109	57.2%
Depression	235,216	23.7%
Ischemic Heart Disease	276,501	27.8%
Rheumatoid Arthritis/Osteoarthritis	204,621	20.6%
Stroke/TIA ⁴	55,967	5.6%
Breast Cancer	25,305	2.5%
Colorectal Cancer	12,577	1.3%
Prostate Cancer	28,707	2.9%
Lung Cancer	21,315	2.1%
Endometrial Cancer	3,489	0.4%
Acquired Hypothyroidism	143,149	14.4%
Anemia	288,805	29.1%
Asthma	61,732	6.2%
Benign Prostatic Hyperplasia	77,548	7.8%
Chronic Kidney Disease	217,941	21.9%
COPD ⁵ and Bronchiectasis	192,236	19.3%
Glaucoma	79,167	8.0%
Osteoporosis	51,226	5.2%
Obesity: diagnosed or identified by weight management procedures	253,518	25.5%
Obesity: identified by weight management-related dispensings	20,899	2.1%
Overweight	77,301	7.8%
Smoking: diagnosed or identified by smoking cessation procedures	256,653	25.8%
Smoking: identified by smoking-related dispensings	4,418	0.4%
Alcohol Abuse or Dependence	27,147	2.7%
Drug Abuse or Dependence	42,666	4.3%
History of Cardiac Arrest	5,419	0.5%
History of Coronary Angioplasty or Bypass	92,296	9.3%
Liver Disease Based on CCW ⁶ Definition	48,768	4.9%
Liver Disease Extended Definition (CCW + Additional Codes)	49,465	5.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.4	17.4

Table 1q. Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Remdesivir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.2	0.5
Mean number of other ambulatory encounters	9.8	19.4
Mean number of filled prescriptions	24.0	23.6
Mean number of Non-Proprietarys dispensed	9.3	6.1
Mean number of unique drug classes dispensed	8.8	5.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1r. Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lonafarnib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A ²
Demographic Characteristics		
Age (years)	15.4	10.1
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2020	0	0.0%
2021	*****	*****
2022	*****	*****
2023	0	0.0%
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1r. Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lonafarnib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.1	10.0

Table 1r. Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lonafarnib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	1.3	2.1
Mean number of inpatient hospital encounters	0.2	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	16.1	35.8
Mean number of filled prescriptions	8.3	9.3
Mean number of Non-Proprietarys dispensed	3.9	3.0
Mean number of unique drug classes dispensed	4.0	3.2

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1s. Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lumasiran		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	41	N/A ²
Demographic Characteristics		
Age (years)	31.7	19.2
Age		
0-17 years	19	46.3%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	11	26.8%
≥ 65 years	*****	*****
Sex		
Female	19	46.3%
Male	22	53.7%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	21	51.2%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	23	56.1%
Year		
2020	0	0.0%
2021	19	46.3%
2022	*****	*****
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1s. Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lumasiran		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	11	26.8%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	13	31.7%
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.4	35.8

Table 1s. Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lumasiran		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.4	0.6
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	18.7	40.1
Mean number of filled prescriptions	11.3	9.6
Mean number of Non-Proprietarys dispensed	5.1	3.5
Mean number of unique drug classes dispensed	4.9	3.4

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Setmelanotide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	57	N/A ²
Demographic Characteristics		
Age (years)	21.3	13.2
Age		
0-17 years	37	64.9%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	39	68.4%
Male	18	31.6%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	26	45.6%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	30	52.6%
Year		
2020	0	0.0%
2021	*****	*****
2022	*****	*****
2023	15	26.3%
2024	20	35.1%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1t. Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Setmelanotide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	16	28.1%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	43	75.4%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.3	9.8

Table 1t. Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Setmelanotide	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.7	17.6
Mean number of filled prescriptions	15.4	17.4
Mean number of Non-Proprietarys dispensed	5.6	4.5
Mean number of unique drug classes dispensed	5.4	4.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1u. Aggregated Characteristics of Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Naxitamab-gqgk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	36	N/A ²
Demographic Characteristics		
Age (years)	9.9	8.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	*****	*****
Sex		
Female	13	36.1%
Male	23	63.9%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	20	55.6%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	23	63.9%
Year		
2020	0	0.0%
2021	15	41.7%
2022	*****	*****
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1u. Aggregated Characteristics of Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Naxitamab-gqgk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	14	38.9%
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	30	83.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	38.6	14.1

Table 1u. Aggregated Characteristics of Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Naxitamab-gqgk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	1.0	1.4
Mean number of inpatient hospital encounters	4.2	3.1
Mean number of non-acute institutional encounters	0.1	0.1
Mean number of other ambulatory encounters	22.9	28.4
Mean number of filled prescriptions	25.0	14.2
Mean number of Non-Proprietarys dispensed	11.4	5.5
Mean number of unique drug classes dispensed	10.4	4.7

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Characteristics of Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Gallium 68 PSMA-11		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	66,552	N/A ²
Demographic Characteristics		
Age (years)	74.4	7.1
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	4,804	7.2%
≥ 65 years	61,736	92.8%
Sex		
Female	72	0.1%
Male	66,480	99.9%
Race ³		
American Indian or Alaska Native	132	0.2%
Asian	897	1.3%
Black or African American	7,062	10.6%
Multi-racial	300	0.5%
Native Hawaiian or Other Pacific Islander	195	0.3%
Unknown	7,156	10.8%
White	50,810	76.3%
Hispanic origin		
Yes	971	1.5%
No	52,832	79.4%
Unknown	12,749	19.2%
Year		
2020	*****	*****
2021	*****	*****
2022	8,842	13.3%
2023	26,891	40.4%
2024	28,909	43.4%
2025	1,108	1.7%
Health Characteristics		
Acute Myocardial Infarction	364	0.5%
Alzheimer's Disease	530	0.8%
Non-Alzheimer's Dementia	1,769	2.7%

Table 1v. Aggregated Characteristics of Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Gallium 68 PSMA-11		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	7,753	11.6%
Diabetes Mellitus	14,955	22.5%
Heart Failure	7,077	10.6%
Hyperlipidemia	30,297	45.5%
Hypertension	35,650	53.6%
Depression	7,100	10.7%
Ischemic Heart Disease	17,627	26.5%
Rheumatoid Arthritis/Osteoarthritis	10,276	15.4%
Stroke/TIA ⁴	1,505	2.3%
Breast Cancer	2,117	3.2%
Colorectal Cancer	855	1.3%
Prostate Cancer	59,995	90.1%
Lung Cancer	657	1.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	4,568	6.9%
Anemia	14,718	22.1%
Asthma	1,680	2.5%
Benign Prostatic Hyperplasia	16,844	25.3%
Chronic Kidney Disease	9,502	14.3%
COPD ⁵ and Bronchiectasis	4,351	6.5%
Glaucoma	7,413	11.1%
Osteoporosis	1,435	2.2%
Obesity: diagnosed or identified by weight management procedures	13,151	19.8%
Obesity: identified by weight management-related dispensings	1,790	2.7%
Overweight	8,393	12.6%
Smoking: diagnosed or identified by smoking cessation procedures	16,566	24.9%
Smoking: identified by smoking-related dispensings	98	0.1%
Alcohol Abuse or Dependence	1,515	2.3%
Drug Abuse or Dependence	1,360	2.0%
History of Cardiac Arrest	147	0.2%
History of Coronary Angioplasty or Bypass	5,646	8.5%
Liver Disease Based on CCW ⁶ Definition	2,001	3.0%
Liver Disease Extended Definition (CCW + Additional Codes)	2,018	3.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.4	12.0

Table 1v. Aggregated Characteristics of Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Gallium 68 PSMA-11		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.8	6.1
Mean number of filled prescriptions	14.6	12.4
Mean number of Non-Proprietarys dispensed	7.2	4.6
Mean number of unique drug classes dispensed	6.8	4.2

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Berotralstat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	489	N/A ²
Demographic Characteristics		
Age (years)	48.0	15.8
Age		
0-17 years	34	7.0%
18-24 years	46	9.4%
25-40 years	102	20.9%
41-64 years	178	36.4%
≥ 65 years	129	26.4%
Sex		
Female	357	73.0%
Male	132	27.0%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	45	9.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	137	28.0%
White	292	59.7%
Hispanic origin		
Yes	36	7.4%
No	309	63.2%
Unknown	144	29.4%
Year		
2020	*****	*****
2021	187	38.2%
2022	96	19.6%
2023	103	21.1%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1w. Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Berotralstat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	62	12.7%
Heart Failure	20	4.1%
Hyperlipidemia	89	18.2%
Hypertension	127	26.0%
Depression	109	22.3%
Ischemic Heart Disease	41	8.4%
Rheumatoid Arthritis/Osteoarthritis	78	16.0%
Stroke/TIA ⁴	13	2.7%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	53	10.8%
Anemia	73	14.9%
Asthma	57	11.7%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	32	6.5%
COPD ⁵ and Bronchiectasis	22	4.5%
Glaucoma	19	3.9%
Osteoporosis	11	2.2%
Obesity: diagnosed or identified by weight management procedures	106	21.7%
Obesity: identified by weight management-related dispensings	18	3.7%
Overweight	37	7.6%
Smoking: diagnosed or identified by smoking cessation procedures	68	13.9%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	26	5.3%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	17	3.5%
Liver Disease Extended Definition (CCW + Additional Codes)	17	3.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.3	15.4

Table 1w. Aggregated Characteristics of Berotrastat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Berotrastat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	6.4	18.5
Mean number of filled prescriptions	19.9	21.9
Mean number of Non-Proprietarys dispensed	7.9	6.9
Mean number of unique drug classes dispensed	7.4	6.1

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1x. Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tirbanibulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	8,271	N/A ²
Demographic Characteristics		
Age (years)	62.5	8.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	4,665	56.4%
≥ 65 years	3,349	40.5%
Sex		
Female	4,365	52.8%
Male	3,906	47.2%
Race ³		
American Indian or Alaska Native	16	0.2%
Asian	16	0.2%
Black or African American	13	0.2%
Multi-racial	102	1.2%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	2,978	36.0%
White	5,146	62.2%
Hispanic origin		
Yes	55	0.7%
No	4,395	53.1%
Unknown	3,821	46.2%
Year		
2020	0	0.0%
2021	1,621	19.6%
2022	2,588	31.3%
2023	2,275	27.5%
2024	1,721	20.8%
2025	66	0.8%
Health Characteristics		
Acute Myocardial Infarction	16	0.2%
Alzheimer's Disease	33	0.4%
Non-Alzheimer's Dementia	89	1.1%

Table 1x. Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tirbanibulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	349	4.2%
Diabetes Mellitus	731	8.8%
Heart Failure	265	3.2%
Hyperlipidemia	2,065	25.0%
Hypertension	1,999	24.2%
Depression	806	9.7%
Ischemic Heart Disease	970	11.7%
Rheumatoid Arthritis/Osteoarthritis	1,038	12.5%
Stroke/TIA ⁴	80	1.0%
Breast Cancer	131	1.6%
Colorectal Cancer	18	0.2%
Prostate Cancer	140	1.7%
Lung Cancer	16	0.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	574	6.9%
Anemia	816	9.9%
Asthma	196	2.4%
Benign Prostatic Hyperplasia	327	4.0%
Chronic Kidney Disease	299	3.6%
COPD ⁵ and Bronchiectasis	140	1.7%
Glaucoma	527	6.4%
Osteoporosis	226	2.7%
Obesity: diagnosed or identified by weight management procedures	915	11.1%
Obesity: identified by weight management-related dispensings	282	3.4%
Overweight	691	8.4%
Smoking: diagnosed or identified by smoking cessation procedures	505	6.1%
Smoking: identified by smoking-related dispensings	18	0.2%
Alcohol Abuse or Dependence	83	1.0%
Drug Abuse or Dependence	86	1.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	195	2.4%
Liver Disease Based on CCW ⁶ Definition	124	1.5%
Liver Disease Extended Definition (CCW + Additional Codes)	128	1.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.6	10.5

Table 1x. Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tirbanibulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.2	3.7
Mean number of filled prescriptions	12.6	14.2
Mean number of Non-Proprietarys dispensed	6.0	4.8
Mean number of unique drug classes dispensed	5.6	4.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1y. Aggregated Characteristics of Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Margetuximab (anti-HER2 mAB)		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	417	N/A ²
Demographic Characteristics		
Age (years)	63.9	10.9
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	17	4.1%
41-64 years	177	42.4%
≥ 65 years	223	53.5%
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	54	12.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	90	21.6%
White	249	59.7%
Hispanic origin		
Yes	16	3.8%
No	290	69.5%
Unknown	111	26.6%
Year		
2020	0	0.0%
2021	111	26.6%
2022	106	25.4%
2023	108	25.9%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1y. Aggregated Characteristics of Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Margetuximab (anti-HER2 mAB)		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	21	5.0%
Diabetes Mellitus	59	14.1%
Heart Failure	97	23.3%
Hyperlipidemia	100	24.0%
Hypertension	163	39.1%
Depression	92	22.1%
Ischemic Heart Disease	42	10.1%
Rheumatoid Arthritis/Osteoarthritis	35	8.4%
Stroke/TIA ⁴	18	4.3%
Breast Cancer	415	99.5%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	21	5.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	61	14.6%
Anemia	205	49.2%
Asthma	21	5.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	41	9.8%
COPD ⁵ and Bronchiectasis	29	7.0%
Glaucoma	19	4.6%
Osteoporosis	25	6.0%
Obesity: diagnosed or identified by weight management procedures	62	14.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	34	8.2%
Smoking: diagnosed or identified by smoking cessation procedures	80	19.2%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	16	3.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	62	14.9%
Liver Disease Extended Definition (CCW + Additional Codes)	63	15.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.0	13.2

Table 1y. Aggregated Characteristics of Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Margetuximab (anti-HER2 mAB)	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	0.4	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.4	9.2
Mean number of filled prescriptions	21.3	14.3
Mean number of Non-Proprietarys dispensed	9.4	5.3
Mean number of unique drug classes dispensed	8.8	4.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1z. Aggregated Characteristics of Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Relugolix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	32,426	N/A ²
Demographic Characteristics		
Age (years)	66.2	12.5
Age		
0-17 years	21	0.1%
18-24 years	522	1.6%
25-40 years	3,042	9.4%
41-64 years	6,520	20.1%
≥ 65 years	22,321	68.8%
Sex		
Female	7,492	23.1%
Male	24,934	76.9%
Race ³		
American Indian or Alaska Native	66	0.2%
Asian	631	1.9%
Black or African American	4,482	13.8%
Multi-racial	377	1.2%
Native Hawaiian or Other Pacific Islander	50	0.2%
Unknown	6,957	21.5%
White	19,863	61.3%
Hispanic origin		
Yes	694	2.1%
No	21,172	65.3%
Unknown	10,560	32.6%
Year		
2020	0	0.0%
2021	3,721	11.5%
2022	6,248	19.3%
2023	9,075	28.0%
2024	12,559	38.7%
2025	823	2.5%
Health Characteristics		
Acute Myocardial Infarction	198	0.6%
Alzheimer's Disease	243	0.7%
Non-Alzheimer's Dementia	765	2.4%

Table 1z. Aggregated Characteristics of Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Relugolix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	3,303	10.2%
Diabetes Mellitus	6,202	19.1%
Heart Failure	3,083	9.5%
Hyperlipidemia	12,172	37.5%
Hypertension	14,477	44.6%
Depression	4,098	12.6%
Ischemic Heart Disease	7,792	24.0%
Rheumatoid Arthritis/Osteoarthritis	4,134	12.7%
Stroke/TIA ⁴	748	2.3%
Breast Cancer	994	3.1%
Colorectal Cancer	336	1.0%
Prostate Cancer	24,426	75.3%
Lung Cancer	243	0.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,979	6.1%
Anemia	7,323	22.6%
Asthma	983	3.0%
Benign Prostatic Hyperplasia	7,420	22.9%
Chronic Kidney Disease	3,608	11.1%
COPD ⁵ and Bronchiectasis	1,833	5.7%
Glaucoma	2,853	8.8%
Osteoporosis	610	1.9%
Obesity: diagnosed or identified by weight management procedures	6,799	21.0%
Obesity: identified by weight management-related dispensings	1,215	3.7%
Overweight	3,640	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	6,751	20.8%
Smoking: identified by smoking-related dispensings	70	0.2%
Alcohol Abuse or Dependence	636	2.0%
Drug Abuse or Dependence	593	1.8%
History of Cardiac Arrest	100	0.3%
History of Coronary Angioplasty or Bypass	2,655	8.2%
Liver Disease Based on CCW ⁶ Definition	848	2.6%
Liver Disease Extended Definition (CCW + Additional Codes)	858	2.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.7	12.8

Table 1z. Aggregated Characteristics of Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Relugolix		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.0	6.9
Mean number of filled prescriptions	14.8	12.9
Mean number of Non-Proprietarys dispensed	7.2	4.7
Mean number of unique drug classes dispensed	6.7	4.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1aa. Aggregated Characteristics of Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ansuvimab-zykl		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A ²
Demographic Characteristics		
Age (years)	-	-
Age		
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ³		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	-
2023	-	-
2024	-	-
2025	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease	-	-
Non-Alzheimer's Dementia	-	-

Table 1aa. Aggregated Characteristics of Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ansuvimab-zykl		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA ⁴	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD ⁵ and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related dispensings	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related dispensings	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Liver Disease Based on CCW ⁶ Definition	-	-
Liver Disease Extended Definition (CCW + Additional Codes)	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-

Table 1aa. Aggregated Characteristics of Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ansuvimab-zykl		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of Non-Proprietaries dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1ab. Aggregated Characteristics of Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Vibegron		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	243,455	N/A ²
Demographic Characteristics		
Age (years)	74.3	11.0
Age		
0-17 years	60	0.0%
18-24 years	526	0.2%
25-40 years	3,482	1.4%
41-64 years	34,019	14.0%
≥ 65 years	205,368	84.4%
Sex		
Female	164,172	67.4%
Male	79,283	32.6%
Race ³		
American Indian or Alaska Native	703	0.3%
Asian	5,787	2.4%
Black or African American	19,407	8.0%
Multi-racial	1,551	0.6%
Native Hawaiian or Other Pacific Islander	408	0.2%
Unknown	23,825	9.8%
White	191,774	78.8%
Hispanic origin		
Yes	6,005	2.5%
No	186,953	76.8%
Unknown	50,497	20.7%
Year		
2020	0	0.0%
2021	13,802	5.7%
2022	41,089	16.9%
2023	89,044	36.6%
2024	95,900	39.4%
2025	3,620	1.5%
Health Characteristics		
Acute Myocardial Infarction	1,581	0.6%
Alzheimer's Disease	7,683	3.2%
Non-Alzheimer's Dementia	24,683	10.1%

Table 1ab. Aggregated Characteristics of Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Vibegron		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	32,870	13.5%
Diabetes Mellitus	72,083	29.6%
Heart Failure	36,420	15.0%
Hyperlipidemia	119,903	49.3%
Hypertension	147,329	60.5%
Depression	76,607	31.5%
Ischemic Heart Disease	59,713	24.5%
Rheumatoid Arthritis/Osteoarthritis	77,311	31.8%
Stroke/TIA ⁴	11,915	4.9%
Breast Cancer	9,734	4.0%
Colorectal Cancer	2,347	1.0%
Prostate Cancer	15,005	6.2%
Lung Cancer	2,304	0.9%
Endometrial Cancer	1,234	0.5%
Acquired Hypothyroidism	43,464	17.9%
Anemia	62,331	25.6%
Asthma	15,852	6.5%
Benign Prostatic Hyperplasia	36,156	14.9%
Chronic Kidney Disease	40,905	16.8%
COPD ⁵ and Bronchiectasis	26,836	11.0%
Glaucoma	32,952	13.5%
Osteoporosis	21,435	8.8%
Obesity: diagnosed or identified by weight management procedures	68,795	28.3%
Obesity: identified by weight management-related dispensings	14,594	6.0%
Overweight	27,717	11.4%
Smoking: diagnosed or identified by smoking cessation procedures	47,988	19.7%
Smoking: identified by smoking-related dispensings	897	0.4%
Alcohol Abuse or Dependence	4,543	1.9%
Drug Abuse or Dependence	8,579	3.5%
History of Cardiac Arrest	542	0.2%
History of Coronary Angioplasty or Bypass	15,087	6.2%
Liver Disease Based on CCW ⁶ Definition	8,784	3.6%
Liver Disease Extended Definition (CCW + Additional Codes)	8,991	3.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.8	13.7

Table 1ab. Aggregated Characteristics of Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Vibegron		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.2	14.2
Mean number of filled prescriptions	28.0	24.8
Mean number of Non-Proprietarys dispensed	11.3	6.0
Mean number of unique drug classes dispensed	10.5	5.4

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Remimazolam</i>	5,211	5,211	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fostemsavir</i>	20,177	19,918	98.7%	54	0.3%	205	1.0%	0	0.0%
<i>Decitabine and Cedazuridine</i>	21,797	21,170	97.1%	573	2.6%	*****	*****	*****	*****
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	28,144	28,144	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Belantamab Mafodotin-blmf</i>	5,353	5,353	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Nifurtimox</i>	22	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Risdiplam</i>	26,408	24,058	91.1%	*****	*****	*****	*****	*****	*****
<i>Oliceridine</i>	65	65	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	1,280	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Satralizumab-mwge</i>	3,821	3,541	92.7%	81	2.1%	199	5.2%	0	0.0%
<i>Clascoterone</i>	96,572	95,653	99.0%	651	0.7%	246	0.3%	22	0.0%
<i>Somapacitan-beco</i>	9,487	8,901	93.8%	459	4.8%	*****	*****	*****	*****
<i>Copper Cu 64 Dotatate Injection</i>	26,673	26,673	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Pralsetinib</i>	1,843	1,831	99.3%	*****	*****	*****	*****	0	0.0%
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	1,102,129	1,102,129	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lonafarnib</i>	83	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lumasiran</i>	223	199	89.2%	*****	*****	*****	*****	0	0.0%
<i>Setmelanotide</i>	279	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Naxitamab-gqgk</i>	300	300	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	79,342	79,342	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Berotrastat</i>	5,468	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tirbanibulin</i>	12,139	12,116	99.8%	12	0.1%	11	0.1%	0	0.0%
<i>Margetuximab (anti-HER2 mAB)</i>	2,390	2,390	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Relugolix</i>	238,115	233,925	98.2%	702	0.3%	3,446	1.4%	42	0.0%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-
<i>Vibegron</i>	1,309,247	1,005,289	76.8%	35,050	2.7%	268,506	20.5%	402	0.0%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Remimazolam</i>	5,211	1	1	1	1	1	1.0	0.0
<i>Fostemsavir</i>	20,177	1	30	30	30	90	29.8	7.4
<i>Decitabine and Cedazuridine</i>	21,797	1	28	28	28	140	27.1	6.5
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	28,144	1	1	1	1	30	1.1	1.5
<i>Belantamab Mafodotin-blmf</i>	5,353	1	1	1	1	28	1.1	1.4
<i>Nifurtimox</i>	22	3	28	30	30	90	31.1	16.8
<i>Risdiplam</i>	26,408	1	24	24	24	105	24.3	5.1
<i>Oliceridine</i>	65	1	1	1	1	1	1.0	0.0
<i>Viltolarsen</i>	1,280	1	1	1	1	56	3.6	7.3
<i>Satralizumab-mwge</i>	3,821	1	28	28	28	90	30.6	13.6
<i>Clascoterone</i>	96,572	1	30	30	30	420	29.4	5.9
<i>Somapacitan-beco</i>	9,487	1	21	25	28	105	24.6	9.3
<i>Copper Cu 64 Dotatate Injection</i>	26,673	1	1	1	1	1	1.0	0.0
<i>Pralsetinib</i>	1,843	1	30	30	30	90	29.0	5.5
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	1,102,129	1	1	1	1	28	1.0	0.0
<i>Lonafarnib</i>	83	3	30	30	30	60	31.5	8.4
<i>Lumasiran</i>	223	1	1	1	30	90	17.5	26.9
<i>Setmelanotide</i>	279	1	28	30	30	60	27.9	6.1
<i>Naxitamab-gqgk</i>	300	1	1	1	1	1	1.0	0.0
<i>Gallium 68 PSMA-11</i>	79,342	1	1	1	1	1	1.0	0.0
<i>Berotrastat</i>	5,468	1	28	28	28	56	27.3	3.5
<i>Tirbanibulin</i>	12,139	1	5	5	30	90	12.0	11.4
<i>Margetuximab (anti-HER2 mAB)</i>	2,390	1	1	1	1	21	1.2	2.2
<i>Relugolix</i>	238,115	1	30	30	30	365	29.6	8.3
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	1,309,247	1	30	30	30	180	38.7	26.8

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Remimazolam	5,211	5,211	100.0%	0	NaN	0	NaN	0	NaN
Female	2,501	2,501	48.0%	0	NaN	0	NaN	0	NaN
Male	2,710	2,710	52.0%	0	NaN	0	NaN	0	NaN
Fostemsavir	20,177	19,918	100.0%	54	100.0%	205	100.0%	0	NaN
Female	3,241	3,209	16.1%	*****	*****	*****	*****	0	NaN
Male	16,936	16,709	83.9%	*****	*****	*****	*****	0	NaN
Decitabine and Cedazuridine	21,797	21,170	100.0%	573	100.0%	*****	*****	*****	*****
Female	7,881	7,607	35.9%	*****	*****	*****	*****	*****	*****
Male	13,916	13,563	64.1%	*****	*****	*****	*****	0	0.0%
Abametapir	0	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-
Tafasitamab-cxix	28,144	28,144	100.0%	0	NaN	0	NaN	0	NaN
Female	13,326	13,326	47.3%	0	NaN	0	NaN	0	NaN
Male	14,818	14,818	52.7%	0	NaN	0	NaN	0	NaN
Belantamab Mafodotin-blmf	5,353	5,353	100.0%	0	NaN	0	NaN	0	NaN
Female	2,516	2,516	47.0%	0	NaN	0	NaN	0	NaN
Male	2,837	2,837	53.0%	0	NaN	0	NaN	0	NaN
Nifurtimox	22	*****	*****	*****	*****	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
Risdiplam	26,408	24,058	100.0%	*****	*****	*****	*****	*****	*****
Female	13,621	12,191	50.7%	*****	*****	0	0.0%	*****	*****
Male	12,787	11,867	49.3%	*****	*****	*****	*****	0	0.0%
Oliceridine	65	65	100.0%	0	NaN	0	NaN	0	NaN
Female	49	49	75.4%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	16	16	24.6%	0	NaN	0	NaN	0	NaN
Viltolarsen	1,280	*****	*****	*****	*****	0	NaN	0	NaN
Female	0	0	0.0%	0	0.0%	0	NaN	0	NaN
Male	1,280	*****	*****	*****	*****	0	NaN	0	NaN
Satralizumab-mwge	3,821	3,541	100.0%	81	100.0%	199	100.0%	0	NaN
Female	3,176	2,934	82.9%	69	85.2%	173	86.9%	0	NaN
Male	645	607	17.1%	12	14.8%	26	13.1%	0	NaN
Clascoterone	96,572	95,653	100.0%	651	100.0%	246	100.0%	22	100.0%
Female	84,934	84,116	87.9%	584	89.7%	*****	*****	*****	*****
Male	11,638	11,537	12.1%	67	10.3%	*****	*****	*****	*****
Somapacitan-beco	9,487	8,901	100.0%	459	100.0%	*****	*****	*****	*****
Female	2,435	2,255	25.3%	144	31.4%	*****	*****	*****	*****
Male	7,052	6,646	74.7%	315	68.6%	*****	*****	*****	*****
Copper Cu 64 Dotatate Injection	26,673	26,673	100.0%	0	NaN	0	NaN	0	NaN
Female	14,824	14,824	55.6%	0	NaN	0	NaN	0	NaN
Male	11,849	11,849	44.4%	0	NaN	0	NaN	0	NaN
Pralsetinib	1,843	1,831	100.0%	*****	*****	*****	*****	0	NaN
Female	1,125	*****	*****	*****	*****	0	0.0%	0	NaN
Male	718	*****	*****	0	0.0%	*****	*****	0	NaN
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-
Remdesivir	1,102,129	1,102,129	100.0%	0	NaN	0	NaN	0	NaN
Female	559,541	559,541	50.8%	0	NaN	0	NaN	0	NaN
Male	542,588	542,588	49.2%	0	NaN	0	NaN	0	NaN
Lonafarnib	83	*****	*****	*****	*****	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	41	*****	*****	*****	*****	0	NaN	0	NaN
Male	42	*****	*****	*****	*****	0	NaN	0	NaN
Lumasiran	223	199	100.0%	*****	*****	*****	*****	0	NaN
Female	90	69	34.7%	*****	*****	*****	*****	0	NaN
Male	133	130	65.3%	*****	*****	*****	*****	0	NaN
Setmelanotide	279	*****	*****	*****	*****	0	NaN	0	NaN
Female	221	*****	*****	*****	*****	0	NaN	0	NaN
Male	58	*****	*****	0	0.0%	0	NaN	0	NaN
Naxitamab-gqgk	300	300	100.0%	0	NaN	0	NaN	0	NaN
Female	114	114	38.0%	0	NaN	0	NaN	0	NaN
Male	186	186	62.0%	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	79,342	79,342	100.0%	0	NaN	0	NaN	0	NaN
Female	77	77	0.1%	0	NaN	0	NaN	0	NaN
Male	79,265	79,265	99.9%	0	NaN	0	NaN	0	NaN
Berotrastat	5,468	*****	*****	*****	*****	0	NaN	0	NaN
Female	4,094	*****	*****	0	0.0%	0	NaN	0	NaN
Male	1,374	*****	*****	*****	*****	0	NaN	0	NaN
Tirbanibulin	12,139	12,116	100.0%	12	100.0%	11	100.0%	0	NaN
Female	6,169	*****	*****	*****	*****	*****	*****	0	NaN
Male	5,970	*****	*****	*****	*****	*****	*****	0	NaN
Margetuximab (anti-HER2 mAB)	2,390	2,390	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Relugolix	238,115	233,925	100.0%	702	100.0%	3,446	100.0%	42	100.0%
Female	33,655	30,824	13.2%	298	42.5%	*****	*****	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	204,460	203,101	86.8%	404	57.5%	*****	*****	*****	*****
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-
Vibegron	1,309,247	1,005,289	100.0%	35,050	100.0%	268,506	100.0%	402	100.0%
Female	904,295	701,968	69.8%	22,998	65.6%	179,053	66.7%	276	68.7%
Male	404,952	303,321	30.2%	12,052	34.4%	89,453	33.3%	126	31.3%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Remimazolam	5,211	1	1	1	1	1	1.0	0.0
Female	2,501	1	1	1	1	1	1.0	0.0
Male	2,710	1	1	1	1	1	1.0	0.0
Fostemsavir	20,177	1	30	30	30	90	29.8	7.4
Female	3,241	1	30	30	30	90	29.5	6.9
Male	16,936	1	30	30	30	90	29.8	7.5
Decitabine and Cedazuridine	21,797	1	28	28	28	140	27.1	6.5
Female	7,881	1	28	28	28	140	27.2	7.1
Male	13,916	1	28	28	28	90	27.1	6.2
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	28,144	1	1	1	1	30	1.1	1.5
Female	13,326	1	1	1	1	30	1.1	1.9
Male	14,818	1	1	1	1	28	1.1	1.1
Belantamab Mafodotin-blmf	5,353	1	1	1	1	28	1.1	1.4
Female	2,516	1	1	1	1	21	1.1	1.4
Male	2,837	1	1	1	1	28	1.1	1.4
Nifurtimox	22	3	28	30	30	90	31.1	16.8
Female	*****	4	30	30	30	90	34.6	19.4
Male	*****	3	27	28	29	30	25.1	9.0
Risdiplam	26,408	1	24	24	24	105	24.3	5.1
Female	13,621	1	24	24	24	105	24.4	5.2
Male	12,787	1	24	24	24	70	24.1	4.9
Oliceridine	65	1	1	1	1	1	1.0	0.0
Female	49	1	1	1	1	1	1.0	0.0
Male	16	1	1	1	1	1	1.0	0.0

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Viltolarsen	1,280	1	1	1	1	56	3.6	7.3
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	1,280	1	1	1	1	56	3.6	7.3
Satralizumab-mwge	3,821	1	28	28	28	90	30.6	13.6
Female	3,176	1	28	28	28	90	30.7	13.8
Male	645	1	28	28	28	90	29.7	12.8
Clascoterone	96,572	1	30	30	30	420	29.4	5.9
Female	84,934	1	30	30	30	420	29.4	5.9
Male	11,638	1	30	30	30	120	29.4	5.7
Somapacitan-beco	9,487	1	21	25	28	105	24.6	9.3
Female	2,435	1	21	25	28	105	24.9	9.8
Male	7,052	1	21	25	28	93	24.6	9.1
Copper Cu 64 Dotatate Injection	26,673	1	1	1	1	1	1.0	0.0
Female	14,824	1	1	1	1	1	1.0	0.0
Male	11,849	1	1	1	1	1	1.0	0.0
Pralsetinib	1,843	1	30	30	30	90	29.0	5.5
Female	1,125	1	30	30	30	60	29.2	5.0
Male	718	3	30	30	30	90	28.7	6.3
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	1,102,129	1	1	1	1	28	1.0	0.0
Female	559,541	1	1	1	1	7	1.0	0.0
Male	542,588	1	1	1	1	28	1.0	0.0
Lonafarnib	83	3	30	30	30	60	31.5	8.4
Female	41	26	30	30	30	60	32.6	8.5
Male	42	3	30	30	30	60	30.5	8.3

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lumasiran	223	1	1	1	30	90	17.5	26.9
Female	90	1	1	28	30	90	29.9	34.1
Male	133	1	1	1	5	90	9.0	15.8
Setmelanotide	279	1	28	30	30	60	27.9	6.1
Female	221	2	30	30	30	60	28.0	6.1
Male	58	1	28	30	30	30	27.6	6.1
Naxitamab-gqgk	300	1	1	1	1	1	1.0	0.0
Female	114	1	1	1	1	1	1.0	0.0
Male	186	1	1	1	1	1	1.0	0.0
Gallium 68 PSMA-11	79,342	1	1	1	1	1	1.0	0.0
Female	77	1	1	1	1	1	1.0	0.0
Male	79,265	1	1	1	1	1	1.0	0.0
Berotrastat	5,468	1	28	28	28	56	27.3	3.5
Female	4,094	1	28	28	28	28	27.4	3.3
Male	1,374	1	28	28	28	56	27.2	3.9
Tirbanibulin	12,139	1	5	5	30	90	12.0	11.4
Female	6,169	1	5	5	30	90	12.1	11.4
Male	5,970	1	5	5	30	90	12.0	11.4
Margetuximab (anti-HER2 mAB)	2,390	1	1	1	1	21	1.2	2.2
Female	*****	1	1	1	1	21	1.2	2.2
Male	*****	1	1	1	1	1	1.0	0.0
Relugolix	238,115	1	30	30	30	365	29.6	8.3
Female	33,655	1	28	28	28	120	31.8	15.8
Male	204,460	1	30	30	30	365	29.3	6.1
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vibegron	1,309,247	1	30	30	30	180	38.7	26.8
Female	904,295	1	28	30	30	180	38.1	26.6
Male	404,952	1	30	30	31	180	40.0	27.3

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Remimazolam	5,211	5,211	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	37	37	0.7%	0	NaN	0	NaN	0	NaN
18-24 years	54	54	1.0%	0	NaN	0	NaN	0	NaN
25-40 years	194	194	3.7%	0	NaN	0	NaN	0	NaN
41-64 years	1,182	1,182	22.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,744	3,744	71.8%	0	NaN	0	NaN	0	NaN
Fostemsavir	20,177	19,918	100.0%	54	100.0%	205	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	32	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	1,516	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	12,628	12,491	62.7%	21	38.9%	116	56.6%	0	NaN
≥ 65 years	6,001	5,895	29.6%	*****	*****	*****	*****	0	NaN
Decitabine and Cedazuridine	21,797	21,170	100.0%	573	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	1,370	1,339	6.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	20,375	19,781	93.4%	541	94.4%	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-
Tafasitamab-cxix	28,144	28,144	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	15	15	0.1%	0	NaN	0	NaN	0	NaN
25-40 years	116	116	0.4%	0	NaN	0	NaN	0	NaN
41-64 years	1,769	1,769	6.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	26,244	26,244	93.2%	0	NaN	0	NaN	0	NaN
Belantamab Mafodotin-blmf	5,353	5,353	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	904	904	16.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	4,437	4,437	82.9%	0	NaN	0	NaN	0	NaN
Nifurtimox	22	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
Risdiplam	26,408	24,058	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	8,594	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	3,533	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	8,059	7,172	29.8%	887	37.8%	0	0.0%	0	0.0%
41-64 years	5,469	4,769	19.8%	700	29.8%	0	0.0%	0	0.0%
≥ 65 years	753	648	2.7%	105	4.5%	0	0.0%	0	0.0%
Oliceridine	65	65	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	52	52	80.0%	0	NaN	0	NaN	0	NaN
Viltolarsen	1,280	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	972	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	256	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	52	52	4.1%	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
Satralizumab-mwge	3,821	3,541	100.0%	81	100.0%	199	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	609	*****	*****	*****	*****	35	17.6%	0	NaN
41-64 years	1,783	1,667	47.1%	29	35.8%	87	43.7%	0	NaN
≥ 65 years	1,290	1,175	33.2%	38	46.9%	77	38.7%	0	NaN
Clascoterone	96,572	95,653	100.0%	651	100.0%	246	100.0%	22	100.0%
0-17 years	22,343	22,169	23.2%	121	18.6%	*****	*****	*****	*****
18-24 years	26,459	26,183	27.4%	194	29.8%	*****	*****	*****	*****
25-40 years	33,952	33,663	35.2%	206	31.6%	*****	*****	*****	*****
41-64 years	12,910	12,762	13.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	908	876	0.9%	*****	*****	*****	*****	0	0.0%
Somapacitan-beco	9,487	8,901	100.0%	459	100.0%	*****	*****	*****	*****
0-17 years	8,714	8,275	93.0%	346	75.4%	93	75.0%	0	0.0%
18-24 years	294	251	2.8%	*****	*****	*****	*****	0	0.0%
25-40 years	165	130	1.5%	*****	*****	*****	*****	*****	*****
41-64 years	222	185	2.1%	*****	*****	*****	*****	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	92	60	0.7%	*****	*****	*****	*****	0	0.0%
Copper Cu 64 Dotatate Injection	26,673	26,673	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	18	18	0.1%	0	NaN	0	NaN	0	NaN
18-24 years	90	90	0.3%	0	NaN	0	NaN	0	NaN
25-40 years	693	693	2.6%	0	NaN	0	NaN	0	NaN
41-64 years	5,768	5,768	21.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	20,104	20,104	75.4%	0	NaN	0	NaN	0	NaN
Pralsetinib	1,843	1,831	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	17	17	0.9%	0	0.0%	0	0.0%	0	NaN
25-40 years	50	50	2.7%	0	0.0%	0	0.0%	0	NaN
41-64 years	539	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	1,237	*****	*****	*****	*****	*****	*****	0	NaN
Atoltivimad Maftivimab and Odesivimab	0	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-
Remdesivir	1,102,129	1,102,129	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	5,527	5,527	0.5%	0	NaN	0	NaN	0	NaN
18-24 years	7,866	7,866	0.7%	0	NaN	0	NaN	0	NaN
25-40 years	53,166	53,166	4.8%	0	NaN	0	NaN	0	NaN
41-64 years	243,671	243,671	22.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	791,899	791,899	71.9%	0	NaN	0	NaN	0	NaN
Lonafarnib	83	*****	*****	*****	*****	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
Lumasiran	223	199	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	115	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	42	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	52	41	20.6%	0	0.0%	11	50.0%	0	NaN
≥ 65 years	14	14	7.0%	0	0.0%	0	0.0%	0	NaN
Setmelanotide	279	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	170	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	32	32	11.5%	0	0.0%	0	NaN	0	NaN
25-40 years	35	35	12.6%	0	0.0%	0	NaN	0	NaN
41-64 years	42	42	15.1%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
Naxitamab-gqgk	300	300	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	79,342	79,342	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	5,574	5,574	7.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	73,750	73,750	93.0%	0	NaN	0	NaN	0	NaN
Berotrastat	5,468	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	364	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	459	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	1,006	1,006	18.4%	0	0.0%	0	NaN	0	NaN
41-64 years	2,121	2,121	38.8%	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,518	1,518	27.8%	0	0.0%	0	NaN	0	NaN
Tirbanibulin	12,139	12,116	100.0%	12	100.0%	11	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	6,662	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	5,157	5,141	42.4%	*****	*****	*****	*****	0	NaN
Margetuximab (anti-HER2 mAB)	2,390	2,390	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	82	82	3.4%	0	NaN	0	NaN	0	NaN
41-64 years	985	985	41.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,323	1,323	55.4%	0	NaN	0	NaN	0	NaN
Relugolix	238,115	233,925	100.0%	702	100.0%	3,446	100.0%	42	100.0%
0-17 years	138	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	2,400	2,143	0.9%	24	3.4%	233	6.8%	0	0.0%
25-40 years	12,643	11,550	4.9%	131	18.7%	962	27.9%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	38,673	*****	*****	174	24.8%	*****	*****	*****	*****
≥ 65 years	184,261	182,981	78.2%	373	53.1%	*****	*****	*****	*****
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-
Vibegron	1,309,247	1,005,289	100.0%	35,050	100.0%	268,506	100.0%	402	100.0%
0-17 years	341	304	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	2,313	1,846	0.2%	*****	*****	*****	*****	*****	*****
25-40 years	17,912	14,167	1.4%	*****	*****	3,174	1.2%	*****	*****
41-64 years	197,723	152,142	15.1%	*****	*****	39,517	14.7%	*****	*****
≥ 65 years	1,090,958	836,830	83.2%	28,424	81.1%	225,354	83.9%	350	87.1%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Remimazolam	5,211	1	1	1	1	1	1.0	0.0
0-17 years	37	1	1	1	1	1	1.0	0.0
18-24 years	54	1	1	1	1	1	1.0	0.0
25-40 years	194	1	1	1	1	1	1.0	0.0
41-64 years	1,182	1	1	1	1	1	1.0	0.0
≥ 65 years	3,744	1	1	1	1	1	1.0	0.0
Fostemsavir	20,177	1	30	30	30	90	29.8	7.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	32	4	30	30	30	60	28.9	8.2
25-40 years	1,516	1	30	30	30	90	29.5	6.1
41-64 years	12,628	1	30	30	30	90	29.7	7.0
≥ 65 years	6,001	1	30	30	30	90	30.0	8.3
Decitabine and Cedazuridine	21,797	1	28	28	28	140	27.1	6.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	29	30	30	29.0	1.4
25-40 years	*****	8	28	28	28	31	27.5	4.2
41-64 years	1,370	1	28	28	28	61	26.1	7.2
≥ 65 years	20,375	1	28	28	28	140	27.2	6.5
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	28,144	1	1	1	1	30	1.1	1.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	15	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	116	1	1	1	1	1	1.0	0.0
41-64 years	1,769	1	1	1	1	30	1.1	1.2
≥ 65 years	26,244	1	1	1	1	28	1.1	1.6
Belantamab Mafodotin-blmf	5,353	1	1	1	1	28	1.1	1.4
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	904	1	1	1	1	21	1.0	0.7
≥ 65 years	4,437	1	1	1	1	28	1.1	1.5
Nifurtimox	22	3	28	30	30	90	31.1	16.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	4	30	30	30	60	30.5	15.0
≥ 65 years	11	3	27	28	30	90	31.9	20.8
Risdiplam	26,408	1	24	24	24	105	24.3	5.1
0-17 years	8,594	1	24	24	24	105	23.3	5.7
18-24 years	3,533	1	24	24	24	48	23.8	4.3
25-40 years	8,059	1	24	24	24	60	24.8	4.8
41-64 years	5,469	1	24	24	24	60	25.2	4.7
≥ 65 years	753	2	24	24	24	48	25.2	4.8
Oliceridine	65	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	52	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Viltolarsen	1,280	1	1	1	1	56	3.6	7.3
0-17 years	972	1	1	1	1	56	3.4	6.9
18-24 years	256	1	1	1	1	28	2.4	5.7
25-40 years	52	1	1	1	28	28	12.1	13.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	3,821	1	28	28	28	90	30.6	13.6
0-17 years	*****	3	17	27	28	28	21.8	9.2
18-24 years	*****	1	28	28	28	56	27.4	4.4
25-40 years	609	1	28	28	28	90	30.6	14.3
41-64 years	1,783	1	28	28	28	90	30.4	13.1
≥ 65 years	1,290	1	28	28	28	90	31.1	14.6
Clascoterone	96,572	1	30	30	30	420	29.4	5.9
0-17 years	22,343	1	30	30	30	120	29.4	5.4
18-24 years	26,459	1	30	30	30	120	29.5	5.8
25-40 years	33,952	1	30	30	30	128	29.3	5.8
41-64 years	12,910	1	30	30	30	420	29.6	6.7
≥ 65 years	908	1	30	30	30	90	28.9	9.8
Somapacitan-beco	9,487	1	21	25	28	105	24.6	9.3
0-17 years	8,714	1	21	25	28	90	24.3	8.7
18-24 years	294	2	21	27	30	84	26.9	10.1
25-40 years	165	3	21	23	30	105	29.3	17.6
41-64 years	222	1	21	23	30	87	27.2	12.7
≥ 65 years	92	6	22	30	35	90	32.8	17.8
Copper Cu 64 Dotatate Injection	26,673	1	1	1	1	1	1.0	0.0
0-17 years	18	1	1	1	1	1	1.0	0.0
18-24 years	90	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	693	1	1	1	1	1	1.0	0.0
41-64 years	5,768	1	1	1	1	1	1.0	0.0
≥ 65 years	20,104	1	1	1	1	1	1.0	0.0
Pralsetinib	1,843	1	30	30	30	90	29.0	5.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	9	14	14	30	30	18.4	7.8
25-40 years	50	3	30	30	30	30	28.2	6.1
41-64 years	539	1	30	30	30	90	28.5	6.4
≥ 65 years	1,237	3	30	30	30	90	29.4	4.8
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	1,102,129	1	1	1	1	28	1.0	0.0
0-17 years	5,527	1	1	1	1	1	1.0	0.0
18-24 years	7,866	1	1	1	1	1	1.0	0.0
25-40 years	53,166	1	1	1	1	3	1.0	0.0
41-64 years	243,671	1	1	1	1	28	1.0	0.1
≥ 65 years	791,899	1	1	1	1	5	1.0	0.0
Lonafarnib	83	3	30	30	30	60	31.5	8.4
0-17 years	*****	3	30	30	30	60	31.5	8.5
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	30	30	30.0	NaN

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	223	1	1	1	30	90	17.5	26.9
0-17 years	115	1	1	1	30	90	15.6	22.4
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	42	1	1	1	30	90	18.8	28.5
41-64 years	52	1	1	1	29	90	22.8	35.4
≥ 65 years	14	1	1	1	25	30	8.9	13.1
Setmelanotide	279	1	28	30	30	60	27.9	6.1
0-17 years	170	1	28	30	30	60	27.5	6.8
18-24 years	32	2	30	30	30	30	28.0	6.5
25-40 years	35	14	28	30	30	30	28.6	3.7
41-64 years	42	9	30	30	30	30	29.1	3.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	300	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Gallium 68 PSMA-11	79,342	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	5,574	1	1	1	1	1	1.0	0.0
≥ 65 years	73,750	1	1	1	1	1	1.0	0.0
Berotrastat	5,468	1	28	28	28	56	27.3	3.5
0-17 years	364	2	28	28	28	56	27.1	4.3

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	459	1	28	28	28	28	27.4	3.3
25-40 years	1,006	1	28	28	28	28	27.1	4.1
41-64 years	2,121	1	28	28	28	28	27.4	3.3
≥ 65 years	1,518	1	28	28	28	28	27.4	3.1
Tirbanibulin	12,139	1	5	5	30	90	12.0	11.4
0-17 years	*****	5	5	5	5	5	5.0	0.0
18-24 years	*****	5	5	30	30	30	21.7	14.4
25-40 years	*****	5	5	5	30	30	11.8	11.0
41-64 years	6,662	1	5	5	5	90	10.4	10.4
≥ 65 years	5,157	1	5	5	30	90	14.1	12.2
Margetuximab (anti-HER2 mAB)	2,390	1	1	1	1	21	1.2	2.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	82	1	1	1	1	1	1.0	0.0
41-64 years	985	1	1	1	1	21	1.0	0.6
≥ 65 years	1,323	1	1	1	1	21	1.4	2.8
Relugolix	238,115	1	30	30	30	365	29.6	8.3
0-17 years	138	1	28	28	28	90	29.1	10.8
18-24 years	2,400	1	28	28	28	90	32.9	17.7
25-40 years	12,643	1	28	28	28	90	31.7	16.0
41-64 years	38,673	1	28	30	30	180	30.3	11.5
≥ 65 years	184,261	1	30	30	30	365	29.3	6.2
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	0	-	-	-	-	-	-	-
Vibegron	1,309,247	1	30	30	30	180	38.7	26.8
0-17 years	341	1	30	30	30	90	34.6	18.5
18-24 years	2,313	1	30	30	30	120	39.5	24.5
25-40 years	17,912	1	30	30	30	120	38.2	24.6
41-64 years	197,723	1	30	30	30	180	38.7	26.4
≥ 65 years	1,090,958	1	30	30	30	180	38.7	27.0

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Remimazolam</i>	4,707	4,707	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fostemsavir</i>	1,519	159	10.5%	200	13.2%	568	37.4%	312	20.5%	280	18.4%
<i>Decitabine and Cedazuridine</i>	4,272	1,099	25.7%	1,288	30.1%	1,539	36.0%	281	6.6%	65	1.5%
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	1,836	1,586	86.4%	237	12.9%	*****	*****	*****	*****	0	0.0%
<i>Belantamab Mafodotin-blmf</i>	1,351	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Nifurtimox</i>	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Risdiplam</i>	1,654	117	7.1%	171	10.3%	803	48.5%	294	17.8%	269	16.3%
<i>Oliceridine</i>	59	59	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	52	24	46.2%	*****	*****	14	26.9%	*****	*****	0	0.0%
<i>Satralizumab-mwge</i>	328	27	8.2%	55	16.8%	143	43.6%	48	14.6%	55	16.8%
<i>Clascoterone</i>	48,919	28,450	58.2%	14,414	29.5%	5,834	11.9%	*****	*****	*****	*****
<i>Somapacitan-beco</i>	1,172	95	8.1%	226	19.3%	693	59.1%	158	13.5%	0	0.0%
<i>Copper Cu 64 Dotatate Injection</i>	18,172	18,172	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Pralsetinib</i>	227	31	13.7%	54	23.8%	99	43.6%	29	12.8%	14	6.2%
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	993,583	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Lonafarnib</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Lumasiran</i>	41	26	63.4%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Setmelanotide</i>	57	*****	*****	18	31.6%	21	36.8%	*****	*****	0	0.0%
<i>Naxitamab-gqgk</i>	36	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	66,552	66,552	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Berotrastat</i>	489	54	11.0%	87	17.8%	208	42.5%	96	19.6%	44	9.0%
<i>Tirbanibulin</i>	8,271	7,444	90.0%	692	8.4%	*****	*****	*****	*****	0	0.0%
<i>Margetuximab (anti-HER2 mAB)</i>	417	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Relugolix</i>	32,426	5,122	15.8%	6,941	21.4%	14,505	44.7%	4,491	13.8%	1,367	4.2%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Vibegron</i>	243,455	48,480	19.9%	58,137	23.9%	91,786	37.7%	36,526	15.0%	8,526	3.5%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	4,707	1	1	1	1	13	1.1	0.4
<i>Fostemsavir</i>	1,519	3	102	246	582	1,680	395.3	379.4
<i>Decitabine and Cedazuridine</i>	4,272	1	30	84	168	1,350	138.4	161.9
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	1,836	1	5	11	19	608	16.7	26.5
<i>Belantamab Mafodotin-blmf</i>	1,351	1	1	2	5	196	4.3	7.6
<i>Nifurtimox</i>	*****	34	60	84	90	117	76.1	24.7
<i>Risdiplam</i>	1,654	1	131	274	436	1,590	387.3	375.7
<i>Oliceridine</i>	59	1	1	1	1	2	1.1	0.3
<i>Viltolarsen</i>	52	1	15	36	137	452	87.7	109.2
<i>Satralizumab-mwge</i>	328	1	91	214	520	1,439	356.0	360.7
<i>Clascoterone</i>	48,919	1	30	30	60	921	58.1	55.8
<i>Somapacitan-beco</i>	1,172	2	84	175	299	555	199.5	134.2
<i>Copper Cu 64 Dotatate Injection</i>	18,172	1	1	1	2	12	1.5	1.0
<i>Pralsetinib</i>	227	4	60	137	293	1,427	235.5	269.9
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	993,583	1	1	1	1	62	1.1	0.5
<i>Lonafarnib</i>	*****	30	63	234	289	780	261.6	222.8
<i>Lumasiran</i>	41	1	4	10	153	696	94.9	151.6
<i>Setmelanotide</i>	57	1	57	88	173	466	136.7	125.8
<i>Naxitamab-gqgk</i>	36	1	3	6	10	38	8.3	8.8
<i>Gallium 68 PSMA-11</i>	66,552	1	1	1	1	9	1.2	0.6
<i>Berotrastat</i>	489	1	84	219	420	1,407	305.6	296.2
<i>Tirbanibulin</i>	8,271	1	5	5	30	715	17.7	26.7
<i>Margetuximab (anti-HER2 mAB)</i>	417	1	2	4	7	234	7.1	15.5
<i>Relugolix</i>	32,426	1	60	148	283	1,485	217.7	223.3
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	243,455	1	58	120	300	1,451	208.0	212.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Remimazolam	4,707	4,707	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,248	2,248	47.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,459	2,459	52.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	1,519	159	100.0%	200	100.0%	568	100.0%	312	100.0%	280	100.0%
Female	319	54	34.0%	54	27.0%	119	21.0%	57	18.3%	35	12.5%
Male	1,200	105	66.0%	146	73.0%	449	79.0%	255	81.7%	245	87.5%
Decitabine and Cedazuridine	4,272	1,099	100.0%	1,288	100.0%	1,539	100.0%	281	100.0%	65	100.0%
Female	1,660	476	43.3%	510	39.6%	555	36.1%	96	34.2%	23	35.4%
Male	2,612	623	56.7%	778	60.4%	984	63.9%	185	65.8%	42	64.6%
Abametapir	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1,586	100.0%	237	100.0%	*****	*****	*****	*****	0	NaN
Female	847	714	45.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	989	872	55.0%	*****	*****	*****	*****	*****	*****	0	NaN
Belantamab Mafodotin-blmf	1,351	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	637	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	714	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nifurtimox	*****	0	NaN	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	0	NaN	*****	*****	0	0.0%	0	NaN	0	NaN
Male	*****	0	NaN	*****	*****	*****	*****	0	NaN	0	NaN
Risdiplam	1,654	117	100.0%	171	100.0%	803	100.0%	294	100.0%	269	100.0%
Female	878	64	54.7%	100	58.5%	426	53.1%	148	50.3%	140	52.0%
Male	776	53	45.3%	71	41.5%	377	46.9%	146	49.7%	129	48.0%
Oliceridine	59	59	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	44	44	74.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	15	15	25.4%	0	NaN	0	NaN	0	NaN	0	NaN
Viltolarsen	52	24	100.0%	*****	*****	14	100.0%	*****	*****	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Male	52	24	100.0%	*****	*****	14	100.0%	*****	*****	0	NaN
Satralizumab-mwge	328	27	100.0%	55	100.0%	143	100.0%	48	100.0%	55	100.0%
Female	276	*****	*****	*****	*****	118	82.5%	*****	*****	*****	*****
Male	52	*****	*****	*****	*****	25	17.5%	*****	*****	*****	*****
Clascoterone	48,919	28,450	100.0%	14,414	100.0%	5,834	100.0%	*****	*****	*****	*****
Female	43,522	25,497	89.6%	12,762	88.5%	5,080	87.1%	*****	*****	*****	*****
Male	5,397	2,953	10.4%	1,652	11.5%	754	12.9%	38	17.9%	0	0.0%
Somapacitan-beco	1,172	95	100.0%	226	100.0%	693	100.0%	158	100.0%	0	NaN
Female	323	29	30.5%	64	28.3%	201	29.0%	29	18.4%	0	NaN
Male	849	66	69.5%	162	71.7%	492	71.0%	129	81.6%	0	NaN
Copper Cu 64 Dotatate Injection	18,172	18,172	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	10,136	10,136	55.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	8,036	8,036	44.2%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	227	31	100.0%	54	100.0%	99	100.0%	29	100.0%	14	100.0%
Female	121	17	54.8%	27	50.0%	48	48.5%	*****	*****	*****	*****
Male	106	14	45.2%	27	50.0%	51	51.5%	*****	*****	*****	*****
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	993,583	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	505,231	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	488,352	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
Male	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
Lumasiran	41	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	19	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	22	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
Setmelanotide	57	*****	*****	18	100.0%	21	100.0%	*****	*****	0	NaN
Female	39	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	18	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Naxitamab-gqgk	36	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	13	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	23	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	66,552	66,552	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	72	72	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	66,480	66,480	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	489	54	100.0%	87	100.0%	208	100.0%	96	100.0%	44	100.0%
Female	357	35	64.8%	64	73.6%	148	71.2%	77	80.2%	33	75.0%
Male	132	19	35.2%	23	26.4%	60	28.8%	19	19.8%	11	25.0%
Tirbanibulin	8,271	7,444	100.0%	692	100.0%	*****	*****	*****	*****	0	NaN
Female	4,365	3,971	53.3%	320	46.2%	*****	*****	*****	*****	0	NaN
Male	3,906	3,473	46.7%	372	53.8%	*****	*****	*****	*****	0	NaN
Margetuximab (anti-HER2 mAB)	417	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Relugolix	32,426	5,122	100.0%	6,941	100.0%	14,505	100.0%	4,491	100.0%	1,367	100.0%
Female	7,492	2,021	39.5%	2,196	31.6%	2,607	18.0%	609	13.6%	59	4.3%
Male	24,934	3,101	60.5%	4,745	68.4%	11,898	82.0%	3,882	86.4%	1,308	95.7%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vibegron	243,455	48,480	100.0%	58,137	100.0%	91,786	100.0%	36,526	100.0%	8,526	100.0%
Female	164,172	32,509	67.1%	38,683	66.5%	62,053	67.6%	25,107	68.7%	5,820	68.3%
Male	79,283	15,971	32.9%	19,454	33.5%	29,733	32.4%	11,419	31.3%	2,706	31.7%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	4,707	1	1	1	1	13	1.1	0.4
Female	2,248	1	1	1	1	7	1.1	0.4
Male	2,459	1	1	1	1	13	1.1	0.4
Fostemsavir	1,519	3	102	246	582	1,680	395.3	379.4
Female	319	3	60	196	429	1,564	299.8	315.3
Male	1,200	3	119	284	615	1,680	420.8	390.9
Decitabine and Cedazuridine	4,272	1	30	84	168	1,350	138.4	161.9
Female	1,660	1	28	78	168	1,350	129.1	160.0
Male	2,612	1	35	84	178	1,260	144.3	162.8
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1	5	11	19	608	16.7	26.5
Female	847	1	5	11	20	563	18.0	28.5
Male	989	1	5	10	19	608	15.7	24.6
Belantamab Mafodotin-blmf	1,351	1	1	2	5	196	4.3	7.6
Female	637	1	2	3	5	105	4.3	6.7
Male	714	1	1	2	5	196	4.3	8.4
Nifurtimox	*****	34	60	84	90	117	76.1	24.7
Female	*****	34	60	60	90	90	69.1	21.6
Male	*****	84	84	101	117	117	100.5	23.3
Risdiplam	1,654	1	131	274	436	1,590	387.3	375.7
Female	878	1	120	264	427	1,575	378.7	376.5
Male	776	1	144	288	451	1,590	397.1	374.8

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Oliceridine	59	1	1	1	1	2	1.1	0.3
Female	44	1	1	1	1	2	1.1	0.3
Male	15	1	1	1	1	2	1.1	0.3
Viltolarsen	52	1	15	36	137	452	87.7	109.2
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	52	1	15	36	137	452	87.7	109.2
Satralizumab-mwge	328	1	91	214	520	1,439	356.0	360.7
Female	276	1	84	211	512	1,439	353.8	358.9
Male	52	1	118	232	536	1,372	368.0	373.1
Clascoterone	48,919	1	30	30	60	921	58.1	55.8
Female	43,522	1	30	30	60	921	57.4	54.6
Male	5,397	1	30	30	60	690	63.4	64.3
Somapacitan-beco	1,172	2	84	175	299	555	199.5	134.2
Female	323	4	82	166	282	541	187.3	125.1
Male	849	2	84	179	301	555	204.2	137.3
Copper Cu 64 Dotatate Injection	18,172	1	1	1	2	12	1.5	1.0
Female	10,136	1	1	1	2	12	1.5	1.0
Male	8,036	1	1	1	2	11	1.5	1.0
Pralsetinib	227	4	60	137	293	1,427	235.5	269.9
Female	121	4	60	150	350	1,427	271.4	306.5
Male	106	5	60	122	217	1,238	194.6	215.2
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remdesivir	993,583	1	1	1	1	62	1.1	0.5
Female	505,231	1	1	1	1	62	1.1	0.5
Male	488,352	1	1	1	1	53	1.1	0.5
Lonafarnib	*****	30	63	234	289	780	261.6	222.8
Female	*****	30	59	232	236	780	267.4	302.0
Male	*****	63	188	289	289	450	255.8	142.9
Lumasiran	41	1	4	10	153	696	94.9	151.6
Female	19	2	4	68	179	696	141.7	193.4
Male	22	1	4	10	30	275	54.5	89.5
Setmelanotide	57	1	57	88	173	466	136.7	125.8
Female	39	3	58	127	208	466	158.7	132.5
Male	18	1	28	58	90	390	88.9	96.8
Naxitamab-gqgk	36	1	3	6	10	38	8.3	8.8
Female	13	1	1	5	11	38	8.8	11.0
Male	23	1	3	6	9	34	8.1	7.6
Gallium 68 PSMA-11	66,552	1	1	1	1	9	1.2	0.6
Female	72	1	1	1	1	3	1.1	0.3
Male	66,480	1	1	1	1	9	1.2	0.6
Berotrastat	489	1	84	219	420	1,407	305.6	296.2
Female	357	1	84	223	454	1,407	313.9	298.0
Male	132	8	68	196	343	1,337	283.2	291.2
Tirbanibulin	8,271	1	5	5	30	715	17.7	26.7
Female	4,365	1	5	5	30	715	17.1	27.1
Male	3,906	1	5	5	30	465	18.3	26.3

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Margetuximab (anti-HER2 mAB)	417	1	2	4	7	234	7.1	15.5
Female	*****	1	2	4	7	234	7.1	15.6
Male	*****	1	1	3	3	3	2.3	1.2
Relugolix	32,426	1	60	148	283	1,485	217.7	223.3
Female	7,492	1	30	84	188	1,100	142.7	153.4
Male	24,934	1	77	168	326	1,485	240.3	235.7
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Vibegron	243,455	1	58	120	300	1,451	208.0	212.9
Female	164,172	1	58	120	300	1,415	209.7	213.8
Male	79,283	1	56	120	288	1,451	204.4	211.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Remimazolam	4,707	4,707	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	35	35	0.7%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	50	50	1.1%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	181	181	3.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,034	1,034	22.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,407	3,407	72.4%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	1,519	159	100.0%	200	100.0%	568	100.0%	312	100.0%	280	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	21	6.7%	17	6.1%
41-64 years	931	83	52.2%	122	61.0%	356	62.7%	193	61.9%	177	63.2%
≥ 65 years	411	38	23.9%	47	23.5%	142	25.0%	98	31.4%	86	30.7%
Decitabine and Cedazuridine	4,272	1,099	100.0%	1,288	100.0%	1,539	100.0%	281	100.0%	65	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	312	*****	*****	*****	*****	*****	*****	11	3.9%	*****	*****
≥ 65 years	3,941	*****	*****	1,188	92.2%	1,425	92.6%	270	96.1%	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1,586	100.0%	237	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	145	130	8.2%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,676	1,441	90.9%	*****	*****	*****	*****	*****	*****	0	NaN
Belantamab Mafodotin-blmf	1,351	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,068	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nifurtimox	*****	0	NaN	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	NaN	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	0	NaN	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	0	NaN	*****	*****	*****	*****	0	NaN	0	NaN
Risdiplam	1,654	117	100.0%	171	100.0%	803	100.0%	294	100.0%	269	100.0%
0-17 years	728	61	52.1%	78	45.6%	430	53.5%	125	42.5%	34	12.6%
18-24 years	239	26	22.2%	24	14.0%	116	14.4%	40	13.6%	33	12.3%
25-40 years	403	16	13.7%	35	20.5%	171	21.3%	73	24.8%	108	40.1%
41-64 years	239	14	12.0%	*****	*****	69	8.6%	*****	*****	83	30.9%
≥ 65 years	45	0	0.0%	*****	*****	17	2.1%	*****	*****	11	4.1%
Oliceridine	59	59	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	48	48	81.4%	0	NaN	0	NaN	0	NaN	0	NaN
Viltolarsen	52	24	100.0%	*****	*****	14	100.0%	*****	*****	0	NaN
0-17 years	38	19	79.2%	*****	*****	*****	*****	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Satralizumab-mwge	328	27	100.0%	55	100.0%	143	100.0%	48	100.0%	55	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	63	*****	*****	*****	*****	34	23.8%	*****	*****	*****	*****
41-64 years	143	11	40.7%	26	47.3%	62	43.4%	*****	*****	*****	*****
≥ 65 years	106	13	48.1%	15	27.3%	38	26.6%	19	39.6%	21	38.2%
Clascoterone	48,919	28,450	100.0%	14,414	100.0%	5,834	100.0%	*****	*****	*****	*****
0-17 years	11,033	6,070	21.3%	3,522	24.4%	1,391	23.8%	*****	*****	*****	*****
18-24 years	13,465	7,771	27.3%	4,012	27.8%	1,636	28.0%	46	21.7%	0	0.0%
25-40 years	17,542	10,514	37.0%	4,962	34.4%	1,994	34.2%	*****	*****	*****	*****
41-64 years	6,485	3,864	13.6%	1,817	12.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	394	231	0.8%	101	0.7%	*****	*****	*****	*****	0	0.0%
Somapacitan-beco	1,172	95	100.0%	226	100.0%	693	100.0%	158	100.0%	0	NaN
0-17 years	1,033	*****	*****	193	85.4%	609	87.9%	*****	*****	0	NaN
18-24 years	46	*****	*****	12	5.3%	*****	*****	*****	*****	0	NaN
25-40 years	30	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	40	*****	*****	*****	*****	24	3.5%	*****	*****	0	NaN
≥ 65 years	23	*****	*****	*****	*****	11	1.6%	*****	*****	0	NaN
Copper Cu 64 Dotatate Injection	18,172	18,172	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	17	17	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	82	82	0.5%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	548	548	3.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	4,086	4,086	22.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	13,439	13,439	74.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Pralsetinib	227	31	100.0%	54	100.0%	99	100.0%	29	100.0%	14	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	57	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	159	*****	*****	35	64.8%	72	72.7%	*****	*****	*****	*****
Odesivimab-ebgn	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	993,583	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	5,098	5,098	0.5%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	7,326	7,326	0.7%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	48,929	48,929	4.9%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	221,807	221,807	22.3%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	710,423	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lumasiran	41	26	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	19	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	11	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
Setmelanotide	57	12	100.0%	18	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	37	*****	*****	*****	*****	14	66.7%	*****	*****	0	NaN
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Naxitamab-gqgk	36	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	66,552	66,552	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	4,804	4,804	7.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	61,736	61,736	92.8%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	489	54	100.0%	87	100.0%	208	100.0%	96	100.0%	44	100.0%
0-17 years	34	*****	*****	*****	*****	19	9.1%	*****	*****	*****	*****
18-24 years	46	*****	*****	*****	*****	17	8.2%	*****	*****	*****	*****
25-40 years	102	12	22.2%	21	24.1%	47	22.6%	*****	*****	*****	*****
41-64 years	178	18	33.3%	29	33.3%	76	36.5%	33	34.4%	22	50.0%
≥ 65 years	129	13	24.1%	22	25.3%	49	23.6%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Tirbanibulin	8,271	7,444	100.0%	692	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	4,665	4,298	57.7%	326	47.1%	41	31.5%	0	0.0%	0	NaN
≥ 65 years	3,349	2,908	39.1%	347	50.1%	*****	*****	*****	*****	0	NaN
Margetuximab (anti-HER2 mAB)	417	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	17	17	4.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	177	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	223	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Relugolix	32,426	5,122	100.0%	6,941	100.0%	14,505	100.0%	4,491	100.0%	1,367	100.0%
0-17 years	21	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	522	*****	*****	*****	*****	*****	*****	48	1.1%	*****	*****
25-40 years	3,042	826	16.1%	943	13.6%	1,059	7.3%	*****	*****	*****	*****
41-64 years	6,520	1,391	27.2%	1,563	22.5%	2,680	18.5%	749	16.7%	137	10.0%
≥ 65 years	22,321	2,788	54.4%	4,280	61.7%	10,547	72.7%	3,488	77.7%	1,218	89.1%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Vibegron	243,455	48,480	100.0%	58,137	100.0%	91,786	100.0%	36,526	100.0%	8,526	100.0%
0-17 years	60	11	0.0%	18	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	526	138	0.3%	147	0.3%	*****	*****	*****	*****	*****	*****
25-40 years	3,482	717	1.5%	873	1.5%	1,318	1.4%	469	1.3%	105	1.2%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by A

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	34,019	5,914	12.2%	7,628	13.1%	13,468	14.7%	5,522	15.1%	1,487	17.4%
≥ 65 years	205,368	41,700	86.0%	49,471	85.1%	76,818	83.7%	30,457	83.4%	6,922	81.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	4,707	1	1	1	1	13	1.1	0.4
0-17 years	35	1	1	1	1	2	1.1	0.2
18-24 years	50	1	1	1	1	4	1.1	0.4
25-40 years	181	1	1	1	1	5	1.1	0.4
41-64 years	1,034	1	1	1	1	13	1.1	0.6
≥ 65 years	3,407	1	1	1	1	6	1.1	0.4
Fostemsavir	1,519	3	102	246	582	1,680	395.3	379.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	10	30	62	150	240	92.6	74.4
25-40 years	*****	3	60	150	360	1,503	267.7	307.8
41-64 years	931	5	117	259	586	1,646	402.6	381.2
≥ 65 years	411	6	118	320	636	1,680	438.0	392.3
Decitabine and Cedazuridine	4,272	1	30	84	168	1,350	138.4	161.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	58	58	58	58	58	58.0	NaN
25-40 years	*****	8	28	56	112	198	76.3	56.4
41-64 years	312	1	28	59	140	911	114.6	136.3
≥ 65 years	3,941	1	30	84	168	1,350	140.6	163.9
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1	5	11	19	608	16.7	26.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	13	13	5.0	6.9
25-40 years	*****	1	5	10	14	23	9.7	6.4
41-64 years	145	1	4	8	15	101	13.1	16.0

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,676	1	5	11	20	608	17.1	27.3
Belantamab Mafodotin-blmf	1,351	1	1	2	5	196	4.3	7.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	2	2	1.4	0.5
41-64 years	*****	1	1	2	4	30	3.4	3.5
≥ 65 years	1,068	1	2	3	5	196	4.5	8.4
Nifurtimox	*****	34	60	84	90	117	76.1	24.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	90	90	90	90	90	90.0	NaN
41-64 years	*****	34	47	60	75	90	61.0	22.9
≥ 65 years	*****	60	72	87	104	117	87.8	23.4
Risdiplam	1,654	1	131	274	436	1,590	387.3	375.7
0-17 years	728	1	120	239	355	1,590	274.9	248.6
18-24 years	239	2	102	247	417	1,574	351.5	362.4
25-40 years	403	4	168	336	803	1,575	495.2	429.2
41-64 years	239	3	144	446	984	1,496	577.3	472.6
≥ 65 years	45	35	95	312	600	1,319	421.7	400.1
Oliceridine	59	1	1	1	1	2	1.1	0.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	2	1.2	0.4
≥ 65 years	48	1	1	1	1	2	1.1	0.3
Viltolarsen	52	1	15	36	137	452	87.7	109.2
0-17 years	38	1	10	29	86	452	87.1	122.4
18-24 years	*****	17	18	86	126	203	88.7	65.4
25-40 years	*****	10	19	137	145	159	89.7	68.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	328	1	91	214	520	1,439	356.0	360.7
0-17 years	*****	17	17	87	157	157	87.0	99.0
18-24 years	*****	28	107	182	355	977	256.1	251.1
25-40 years	63	18	112	224	382	1,040	295.7	242.8
41-64 years	143	1	84	223	530	1,439	379.5	398.1
≥ 65 years	106	1	84	219	584	1,367	378.6	376.8
Clascoterone	48,919	1	30	30	60	921	58.1	55.8
0-17 years	11,033	1	30	30	60	780	59.6	55.5
18-24 years	13,465	1	30	30	60	721	58.0	53.1
25-40 years	17,542	1	30	30	60	921	56.7	54.9
41-64 years	6,485	1	30	30	60	900	58.9	62.1
≥ 65 years	394	4	30	30	60	650	66.5	76.1
Somapacitan-beco	1,172	2	84	175	299	555	199.5	134.2
0-17 years	1,033	2	84	186	304	555	205.3	136.1
18-24 years	46	15	84	144	226	462	171.7	114.8
25-40 years	30	14	100	139	184	487	161.1	103.1
41-64 years	40	16	71	120	247	420	151.1	108.6
≥ 65 years	23	6	42	93	204	371	131.2	113.2
Copper Cu 64 Dotatate Injection	18,172	1	1	1	2	12	1.5	1.0
0-17 years	17	1	1	1	1	2	1.1	0.2
18-24 years	82	1	1	1	1	5	1.1	0.5
25-40 years	548	1	1	1	1	9	1.3	0.8
41-64 years	4,086	1	1	1	1	10	1.4	0.9
≥ 65 years	13,439	1	1	1	2	12	1.5	1.1
Pralsetinib	227	4	60	137	293	1,427	235.5	269.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	150	150	157	163	163	156.5	9.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	33	65	90	120	697	156.7	205.9
41-64 years	57	5	60	146	360	1,427	269.2	309.5
≥ 65 years	159	4	60	135	270	1,219	228.9	259.3
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	993,583	1	1	1	1	62	1.1	0.5
0-17 years	5,098	1	1	1	1	5	1.1	0.4
18-24 years	7,326	1	1	1	1	7	1.1	0.4
25-40 years	48,929	1	1	1	1	13	1.1	0.4
41-64 years	221,807	1	1	1	1	28	1.1	0.4
≥ 65 years	710,423	1	1	1	1	62	1.1	0.5
Lonafarnib	*****	30	63	234	289	780	261.6	222.8
0-17 years	*****	59	188	236	289	780	287.3	220.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	30	30	30.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	41	1	4	10	153	696	94.9	151.6
0-17 years	19	2	6	30	179	275	94.3	105.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	2	3	16	169	474	112.7	172.7
41-64 years	11	1	2	6	68	696	107.8	226.3
≥ 65 years	*****	3	3	4	60	115	31.3	55.8
Setmelanotide	57	1	57	88	173	466	136.7	125.8
0-17 years	37	1	57	88	164	466	126.3	114.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	150	152	198	297	351	224.3	94.6
25-40 years	*****	14	58	73	157	411	125.1	128.8
41-64 years	*****	9	28	44	313	442	152.6	182.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-ggqk	36	1	3	6	10	38	8.3	8.8
0-17 years	*****	1	3	6	11	38	8.6	9.0
18-24 years	*****	7	7	7	7	7	7.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Gallium 68 PSMA-11	66,552	1	1	1	1	9	1.2	0.6
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	5	1.5	1.3
41-64 years	4,804	1	1	1	1	8	1.2	0.5
≥ 65 years	61,736	1	1	1	1	9	1.2	0.6
Berotrastat	489	1	84	219	420	1,407	305.6	296.2
0-17 years	34	15	86	200	336	1,407	290.6	303.5
18-24 years	46	1	56	123	381	1,253	273.1	305.3
25-40 years	102	8	73	196	360	1,205	267.3	256.0
41-64 years	178	23	86	221	448	1,319	326.3	318.5
≥ 65 years	129	6	84	258	510	1,337	322.9	289.0
Tirbanibulin	8,271	1	5	5	30	715	17.7	26.7
0-17 years	*****	10	10	10	10	10	10.0	NaN
18-24 years	*****	5	5	33	60	60	32.5	38.9
25-40 years	*****	5	5	5	30	90	14.6	15.6
41-64 years	4,665	1	5	5	25	360	14.9	19.4
≥ 65 years	3,349	1	5	7	30	715	21.7	34.6
Margetuximab (anti-HER2 mAB)	417	1	2	4	7	234	7.1	15.5

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	17	1	2	2	6	20	4.8	5.3
41-64 years	177	1	3	4	7	35	5.7	5.2
≥ 65 years	223	1	2	4	7	234	8.3	20.6
Relugolix	32,426	1	60	148	283	1,485	217.7	223.3
0-17 years	21	19	56	90	308	672	191.2	184.0
18-24 years	522	1	54	91	210	764	151.5	139.5
25-40 years	3,042	1	30	84	168	1,072	131.7	137.9
41-64 years	6,520	1	55	112	238	1,360	179.8	188.5
≥ 65 years	22,321	1	76	168	328	1,485	242.1	238.5
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Vibegron	243,455	1	58	120	300	1,451	208.0	212.9
0-17 years	60	18	60	101	327	885	196.4	198.5
18-24 years	526	1	30	90	240	1,134	173.8	194.9
25-40 years	3,482	1	56	120	270	1,290	196.3	206.0
41-64 years	34,019	1	60	147	327	1,415	224.7	223.6
≥ 65 years	205,368	1	56	120	294	1,451	205.5	211.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Remimazolam</i>	5,192	5,192	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fostemsavir</i>	5,196	2,639	50.8%	1,202	23.1%	985	19.0%	247	4.8%	123	2.4%
<i>Decitabine and Cedazuridine</i>	13,556	9,455	69.7%	3,204	23.6%	858	6.3%	*****	*****	*****	*****
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	27,985	27,963	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Belantamab Mafodotin-blmf</i>	5,328	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Nifurtimox</i>	18	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Risdiplam</i>	6,252	2,636	42.2%	1,840	29.4%	1,468	23.5%	184	2.9%	124	2.0%
<i>Oliceridine</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	1,131	1,112	98.3%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Satralizumab-mwge</i>	1,238	586	47.3%	376	30.4%	225	18.2%	33	2.7%	18	1.5%
<i>Clascoterone</i>	83,955	76,429	91.0%	6,143	7.3%	1,363	1.6%	*****	*****	*****	*****
<i>Somapacitan-beco</i>	3,805	2,083	54.7%	1,060	27.9%	613	16.1%	49	1.3%	0	0.0%
<i>Copper Cu 64 Dotatate Injection</i>	26,670	26,670	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Pralsetinib</i>	626	327	52.2%	180	28.8%	101	16.1%	*****	*****	*****	*****
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	1,033,157	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Lonafarnib</i>	53	33	62.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lumasiran</i>	187	155	82.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Setmelanotide</i>	129	71	55.0%	39	30.2%	19	14.7%	0	0.0%	0	0.0%
<i>Naxitamab-gqgk</i>	300	300	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	79,335	79,335	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Berotrastat</i>	1,242	558	44.9%	293	23.6%	300	24.2%	67	5.4%	24	1.9%
<i>Tirbanibulin</i>	11,323	10,989	97.1%	308	2.7%	26	0.2%	0	0.0%	0	0.0%
<i>Margetuximab (anti-HER2 mAB)</i>	2,367	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Relugolix</i>	77,070	36,008	46.7%	21,559	28.0%	16,813	21.8%	2,242	2.9%	448	0.6%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Vibegron</i>	590,500	273,082	46.2%	194,136	32.9%	106,901	18.1%	14,499	2.5%	1,882	0.3%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	5,192	1	1	1	1	3	1.0	0.1
<i>Fostemsavir</i>	5,196	1	30	30	114	1,680	115.6	188.8
<i>Decitabine and Cedazuridine</i>	13,556	1	28	28	56	1,115	43.6	47.4
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	27,985	1	1	1	1	308	1.1	3.4
<i>Belantamab Mafodotin-blmf</i>	5,328	1	1	1	1	196	1.1	2.9
<i>Nifurtimox</i>	18	3	28	30	60	90	38.1	21.9
<i>Risdiplam</i>	6,252	1	24	48	96	1,574	102.5	183.6
<i>Oliceridine</i>	61	1	1	1	1	2	1.1	0.2
<i>Viltolarsen</i>	1,131	1	1	1	1	452	4.0	24.1
<i>Satralizumab-mwge</i>	1,238	1	28	47	84	1,406	94.3	154.5
<i>Clascoterone</i>	83,955	1	30	30	30	806	33.8	21.0
<i>Somapacitan-beco</i>	3,805	1	23	30	65	555	61.5	73.6
<i>Copper Cu 64 Dotatate Injection</i>	26,670	1	1	1	1	2	1.0	0.0
<i>Pralsetinib</i>	626	4	30	30	90	1,247	85.4	137.6
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	1,033,157	1	1	1	1	47	1.1	0.4
<i>Lonafarnib</i>	53	3	30	30	60	232	49.4	39.3
<i>Lumasiran</i>	187	1	1	1	28	185	20.8	41.5
<i>Setmelanotide</i>	129	1	30	30	62	352	60.4	56.2
<i>Naxitamab-gqgk</i>	300	1	1	1	1	1	1.0	0.0
<i>Gallium 68 PSMA-11</i>	79,335	1	1	1	1	2	1.0	0.0
<i>Berotrastat</i>	1,242	1	28	56	112	1,407	120.3	180.0
<i>Tirbanibulin</i>	11,323	1	5	5	30	330	12.9	14.7
<i>Margetuximab (anti-HER2 mAB)</i>	2,367	1	1	1	1	105	1.2	3.8
<i>Relugolix</i>	77,070	1	30	56	96	1,462	91.6	118.7
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	590,500	1	30	53	90	1,415	85.7	104.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remimazolam	5,192	5,192	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,490	2,490	48.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,702	2,702	52.0%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	5,196	2,639	100.0%	1,202	100.0%	985	100.0%	247	100.0%	123	100.0%
Female	1,049	567	21.5%	264	22.0%	167	17.0%	40	16.2%	11	8.9%
Male	4,147	2,072	78.5%	938	78.0%	818	83.0%	207	83.8%	112	91.1%
Decitabine and Cedazuridine	13,556	9,455	100.0%	3,204	100.0%	858	100.0%	*****	*****	*****	*****
Female	5,055	3,602	38.1%	1,162	36.3%	277	32.3%	*****	*****	*****	*****
Male	8,501	5,853	61.9%	2,042	63.7%	581	67.7%	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	27,985	27,963	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	13,247	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	14,738	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	5,328	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	2,505	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	2,823	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Nifurtimox	18	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Risdiplam	6,252	2,636	100.0%	1,840	100.0%	1,468	100.0%	184	100.0%	124	100.0%
Female	3,294	1,373	52.1%	1,004	54.6%	762	51.9%	91	49.5%	64	51.6%
Male	2,958	1,263	47.9%	836	45.4%	706	48.1%	93	50.5%	60	48.4%
Oliceridine	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	45	45	73.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	16	16	26.2%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Viltolarsen	1,131	1,112	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Male	1,131	1,112	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Satralizumab-mwge	1,238	586	100.0%	376	100.0%	225	100.0%	33	100.0%	18	100.0%
Female	1,054	492	84.0%	334	88.8%	*****	*****	*****	*****	*****	*****
Male	184	94	16.0%	42	11.2%	*****	*****	*****	*****	*****	*****
Clascoterone	83,955	76,429	100.0%	6,143	100.0%	1,363	100.0%	*****	*****	*****	*****
Female	74,061	67,545	88.4%	5,328	86.7%	*****	*****	*****	*****	*****	*****
Male	9,894	8,884	11.6%	815	13.3%	*****	*****	*****	*****	0	0.0%
Somapacitan-beco	3,805	2,083	100.0%	1,060	100.0%	613	100.0%	49	100.0%	0	NaN
Female	998	545	26.2%	286	27.0%	155	25.3%	12	24.5%	0	NaN
Male	2,807	1,538	73.8%	774	73.0%	458	74.7%	37	75.5%	0	NaN
Copper Cu 64 Dotatate Injection	26,670	26,670	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	14,822	14,822	55.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	11,848	11,848	44.4%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	626	327	100.0%	180	100.0%	101	100.0%	*****	*****	*****	*****
Female	350	179	54.7%	103	57.2%	*****	*****	*****	*****	*****	*****
Male	276	148	45.3%	77	42.8%	*****	*****	*****	*****	*****	*****
ebgn	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	1,033,157	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	524,099	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	509,058	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	53	33	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	21	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	32	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lumasiran	187	155	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	72	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	115	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Setmelanotide	129	71	100.0%	39	100.0%	19	100.0%	0	NaN	0	NaN
Female	100	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	29	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Naxitamab-gqgk	300	300	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	114	114	38.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	186	186	62.0%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	79,335	79,335	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	77	77	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	79,258	79,258	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	1,242	558	100.0%	293	100.0%	300	100.0%	67	100.0%	24	100.0%
Female	931	420	75.3%	219	74.7%	223	74.3%	*****	*****	*****	*****
Male	311	138	24.7%	74	25.3%	77	25.7%	*****	*****	*****	*****
Tirbanibulin	11,323	10,989	100.0%	308	100.0%	26	100.0%	0	NaN	0	NaN
Female	5,750	5,582	50.8%	156	50.6%	12	46.2%	0	NaN	0	NaN
Male	5,573	5,407	49.2%	152	49.4%	14	53.8%	0	NaN	0	NaN
Margetuximab (anti-HER2 mAB)	2,367	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Relugolix	77,070	36,008	100.0%	21,559	100.0%	16,813	100.0%	2,242	100.0%	448	100.0%
Female	16,404	9,442	26.2%	4,502	20.9%	2,251	13.4%	186	8.3%	23	5.1%
Male	60,666	26,566	73.8%	17,057	79.1%	14,562	86.6%	2,056	91.7%	425	94.9%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	590,500	273,082	100.0%	194,136	100.0%	106,901	100.0%	14,499	100.0%	1,882	100.0%
Female	405,052	189,648	69.4%	131,509	67.7%	72,824	68.1%	9,806	67.6%	1,265	67.2%
Male	185,448	83,434	30.6%	62,627	32.3%	34,077	31.9%	4,693	32.4%	617	32.8%

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	5,192	1	1	1	1	3	1.0	0.1
Female	2,490	1	1	1	1	2	1.0	0.1
Male	2,702	1	1	1	1	3	1.0	0.1
Fostemsavir	5,196	1	30	30	114	1,680	115.6	188.8
Female	1,049	1	30	30	90	1,338	91.2	140.3
Male	4,147	1	30	31	120	1,680	121.8	198.8
Decitabine and Cedazuridine	13,556	1	28	28	56	1,115	43.6	47.4
Female	5,055	1	28	28	56	952	42.4	47.9
Male	8,501	1	28	28	56	1,115	44.3	47.1
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	27,985	1	1	1	1	308	1.1	3.4
Female	13,247	1	1	1	1	252	1.1	3.9
Male	14,738	1	1	1	1	308	1.1	2.9
Belantamab Mafodotin-blmf	5,328	1	1	1	1	196	1.1	2.9
Female	2,505	1	1	1	1	42	1.1	1.6
Male	2,823	1	1	1	1	196	1.1	3.7
Nifurtimox	18	3	28	30	60	90	38.1	21.9
Female	*****	4	30	30	60	90	44.0	23.9
Male	*****	3	27	28	30	57	28.7	15.6
Risdiplam	6,252	1	24	48	96	1,574	102.5	183.6
Female	3,294	1	24	48	96	1,574	100.9	182.5
Male	2,958	1	24	48	96	1,496	104.2	184.9
Oliceridine	61	1	1	1	1	2	1.1	0.2
Female	45	1	1	1	1	2	1.1	0.3

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	16	1	1	1	1	1	1.0	0.0
Viltolarsen	1,131	1	1	1	1	452	4.0	24.1
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	1,131	1	1	1	1	452	4.0	24.1
Satralizumab-mwge	1,238	1	28	47	84	1,406	94.3	154.5
Female	1,054	1	28	53	84	1,406	92.6	147.8
Male	184	1	28	30	98	1,372	104.0	188.4
Clascoterone	83,955	1	30	30	30	806	33.8	21.0
Female	74,061	1	30	30	30	806	33.7	20.8
Male	9,894	1	30	30	30	421	34.6	22.1
Somapacitan-beco	3,805	1	23	30	65	555	61.5	73.6
Female	998	1	21	30	63	541	60.6	72.9
Male	2,807	1	23	30	67	555	61.8	73.8
Copper Cu 64 Dotatate Injection	26,670	1	1	1	1	2	1.0	0.0
Female	14,822	1	1	1	1	2	1.0	0.0
Male	11,848	1	1	1	1	2	1.0	0.0
Pralsetinib	626	4	30	30	90	1,247	85.4	137.6
Female	350	4	30	30	90	1,247	93.8	161.9
Male	276	5	30	30	90	900	74.7	97.9
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	1,033,157	1	1	1	1	47	1.1	0.4
Female	524,099	1	1	1	1	47	1.1	0.4
Male	509,058	1	1	1	1	37	1.1	0.4
Lonafarnib	53	3	30	30	60	232	49.4	39.3

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	21	26	30	60	60	232	63.7	51.9
Male	32	3	30	30	49	120	40.0	25.1
Lumasiran	187	1	1	1	28	185	20.8	41.5
Female	72	1	1	1	85	180	37.4	51.5
Male	115	1	1	1	1	185	10.4	29.5
Setmelanotide	129	1	30	30	62	352	60.4	56.2
Female	100	3	30	30	75	352	61.9	54.8
Male	29	1	28	30	35	260	55.2	61.6
Naxitamab-gqgk	300	1	1	1	1	1	1.0	0.0
Female	114	1	1	1	1	1	1.0	0.0
Male	186	1	1	1	1	1	1.0	0.0
Gallium 68 PSMA-11	79,335	1	1	1	1	2	1.0	0.0
Female	77	1	1	1	1	1	1.0	0.0
Male	79,258	1	1	1	1	2	1.0	0.0
Berotrastat	1,242	1	28	56	112	1,407	120.3	180.0
Female	931	1	28	56	112	1,407	120.4	178.8
Male	311	1	28	56	140	1,337	120.2	183.8
Tirbanibulin	11,323	1	5	5	30	330	12.9	14.7
Female	5,750	1	5	5	30	330	13.0	14.6
Male	5,573	1	5	5	30	210	12.8	14.7
Margetuximab (anti-HER2 mAB)	2,367	1	1	1	1	105	1.2	3.8
Female	*****	1	1	1	1	105	1.2	3.8
Male	*****	1	1	1	1	1	1.0	0.0
Relugolix	77,070	1	30	56	96	1,462	91.6	118.7
Female	16,404	1	28	30	84	1,100	65.2	78.9
Male	60,666	1	30	60	120	1,462	98.7	126.4

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Vibegron	590,500	1	30	53	90	1,415	85.7	104.7
Female	405,052	1	30	48	90	1,415	85.0	104.0
Male	185,448	1	30	59	90	1,386	87.4	106.2

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remimazolam	5,192	5,192	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	37	37	0.7%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	54	54	1.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	194	194	3.7%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,181	1,181	22.7%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,726	3,726	71.8%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	5,196	2,639	100.0%	1,202	100.0%	985	100.0%	247	100.0%	123	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	19	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	543	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	3,255	1,637	62.0%	764	63.6%	628	63.8%	*****	*****	*****	*****
≥ 65 years	1,379	659	25.0%	314	26.1%	280	28.4%	83	33.6%	43	35.0%
Decitabine and Cedazuridine	13,556	9,455	100.0%	3,204	100.0%	858	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	845	579	6.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	12,681	8,858	93.7%	2,985	93.2%	802	93.5%	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tafasitamab-cxix	27,985	27,963	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	15	15	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	116	116	0.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,761	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	26,093	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	5,328	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	900	900	16.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	4,416	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nifurtimox	18	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Risdiplam	6,252	2,636	100.0%	1,840	100.0%	1,468	100.0%	184	100.0%	124	100.0%
0-17 years	2,293	1,005	38.1%	668	36.3%	547	37.3%	56	30.4%	17	13.7%
18-24 years	781	350	13.3%	201	10.9%	189	12.9%	20	10.9%	21	16.9%
25-40 years	1,849	727	27.6%	580	31.5%	438	29.8%	57	31.0%	47	37.9%
41-64 years	1,143	473	17.9%	337	18.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	186	81	3.1%	54	2.9%	*****	*****	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Oliceridine	61	61	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	50	50	82.0%	0	NaN	0	NaN	0	NaN	0	NaN
Viltolarsen	1,131	1,112	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	839	824	74.1%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	249	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	43	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Satralizumab-mwge	1,238	586	100.0%	376	100.0%	225	100.0%	33	100.0%	18	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	11	4.9%	*****	*****	0	0.0%
25-40 years	248	129	22.0%	*****	*****	47	20.9%	*****	*****	0	0.0%
41-64 years	541	247	42.2%	166	44.1%	104	46.2%	*****	*****	*****	*****
≥ 65 years	397	181	30.9%	131	34.8%	63	28.0%	*****	*****	*****	*****
Clascoterone	83,955	76,429	100.0%	6,143	100.0%	1,363	100.0%	*****	*****	*****	*****
0-17 years	19,339	17,565	23.0%	1,456	23.7%	*****	*****	*****	*****	0	0.0%
18-24 years	22,927	20,832	27.3%	1,688	27.5%	*****	*****	*****	*****	0	0.0%
25-40 years	29,619	27,033	35.4%	2,114	34.4%	*****	*****	*****	*****	*****	*****
41-64 years	11,259	10,258	13.4%	831	13.5%	*****	*****	*****	*****	0	0.0%
≥ 65 years	811	741	1.0%	54	0.9%	16	1.2%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Somapacitan-beco	3,805	2,083	100.0%	1,060	100.0%	613	100.0%	49	100.0%	0	NaN
0-17 years	3,421	1,890	90.7%	929	87.6%	*****	*****	*****	*****	0	NaN
18-24 years	131	68	3.3%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	78	33	1.6%	31	2.9%	14	2.3%	0	0.0%	0	NaN
41-64 years	122	74	3.6%	30	2.8%	18	2.9%	0	0.0%	0	NaN
≥ 65 years	53	18	0.9%	*****	*****	*****	*****	0	0.0%	0	NaN
Copper Cu 64 Dotatate Injection	26,670	26,670	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	18	18	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	90	90	0.3%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	693	693	2.6%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	5,768	5,768	21.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	20,101	20,101	75.4%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	626	327	100.0%	180	100.0%	101	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	173	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	436	231	70.6%	124	68.9%	69	68.3%	*****	*****	*****	*****
Odesivimab-ebgn	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remdesivir	1,033,157	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	5,214	5,214	0.5%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	7,511	7,511	0.7%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	50,376	50,376	4.9%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	230,248	230,248	22.3%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	739,808	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	53	33	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Lumasiran	187	155	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	93	79	51.0%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	34	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	48	36	23.2%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	12	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Setmelanotide	129	71	100.0%	39	100.0%	19	100.0%	0	NaN	0	NaN
0-17 years	74	39	54.9%	22	56.4%	13	68.4%	0	NaN	0	NaN
18-24 years	17	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	18	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Naxitamab-gqgk	300	300	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	79,335	79,335	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	5,574	5,574	7.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	73,743	73,743	93.0%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	1,242	558	100.0%	293	100.0%	300	100.0%	67	100.0%	24	100.0%
0-17 years	80	33	5.9%	19	6.5%	*****	*****	*****	*****	*****	*****
18-24 years	86	40	7.2%	17	5.8%	*****	*****	*****	*****	*****	*****
25-40 years	275	132	23.7%	65	22.2%	65	21.7%	*****	*****	*****	*****
41-64 years	503	232	41.6%	128	43.7%	110	36.7%	22	32.8%	11	45.8%
≥ 65 years	298	121	21.7%	64	21.8%	82	27.3%	*****	*****	*****	*****
Tirbanibulin	11,323	10,989	100.0%	308	100.0%	26	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	6,164	6,004	54.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	4,854	4,688	42.7%	*****	*****	*****	*****	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Margetuximab (anti-HER2 mAB)	2,367	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,301	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Relugolix	77,070	36,008	100.0%	21,559	100.0%	16,813	100.0%	2,242	100.0%	448	100.0%
0-17 years	49	22	0.1%	16	0.1%	11	0.1%	0	0.0%	0	0.0%
18-24 years	1,262	731	2.0%	360	1.7%	158	0.9%	*****	*****	*****	*****
25-40 years	6,475	3,800	10.6%	1,779	8.3%	829	4.9%	*****	*****	*****	*****
41-64 years	14,949	7,790	21.6%	4,073	18.9%	2,733	16.3%	*****	*****	*****	*****
≥ 65 years	54,335	23,665	65.7%	15,331	71.1%	13,082	77.8%	1,870	83.4%	387	86.4%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Vibegron	590,500	273,082	100.0%	194,136	100.0%	106,901	100.0%	14,499	100.0%	1,882	100.0%
0-17 years	176	109	0.0%	38	0.0%	*****	*****	0	0.0%	*****	*****
18-24 years	1,254	691	0.3%	382	0.2%	*****	*****	17	0.1%	*****	*****
25-40 years	8,306	4,011	1.5%	2,746	1.4%	*****	*****	191	1.3%	*****	*****
41-64 years	85,477	38,796	14.2%	27,876	14.4%	16,083	15.0%	2,347	16.2%	375	19.9%
≥ 65 years	495,287	229,475	84.0%	163,094	84.0%	89,302	83.5%	11,944	82.4%	1,472	78.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	5,192	1	1	1	1	3	1.0	0.1
0-17 years	37	1	1	1	1	1	1.0	0.0
18-24 years	54	1	1	1	1	1	1.0	0.0
25-40 years	194	1	1	1	1	1	1.0	0.0
41-64 years	1,181	1	1	1	1	2	1.0	0.0
≥ 65 years	3,726	1	1	1	1	3	1.0	0.1
Fostemsavir	5,196	1	30	30	114	1,680	115.6	188.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	19	10	30	30	60	150	48.7	36.3
25-40 years	543	2	30	30	60	1,338	82.3	146.8
41-64 years	3,255	1	30	30	120	1,616	115.2	186.5
≥ 65 years	1,379	1	30	58	120	1,680	130.6	207.5
Decitabine and Cedazuridine	13,556	1	28	28	56	1,115	43.6	47.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	29	30	30	29.0	1.4
25-40 years	*****	8	28	28	65	114	49.0	30.8
41-64 years	845	1	28	28	56	760	42.3	48.5
≥ 65 years	12,681	1	28	28	56	1,115	43.7	47.3
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	27,985	1	1	1	1	308	1.1	3.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	15	1	1	1	1	1	1.0	0.0
25-40 years	116	1	1	1	1	1	1.0	0.0
41-64 years	1,761	1	1	1	1	58	1.1	1.8
≥ 65 years	26,093	1	1	1	1	308	1.1	3.5
Belantamab Mafodotin-blmf	5,328	1	1	1	1	196	1.1	2.9
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	900	1	1	1	1	21	1.0	0.7
≥ 65 years	4,416	1	1	1	1	196	1.1	3.2
Nifurtimox	18	3	28	30	60	90	38.1	21.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	45	60	60	45.0	21.2
41-64 years	*****	4	30	30	60	60	34.9	19.6
≥ 65 years	*****	3	28	28	57	90	39.0	25.6
Risdiplam	6,252	1	24	48	96	1,574	102.5	183.6
0-17 years	2,293	1	24	47	96	1,567	87.3	137.0
18-24 years	781	1	24	48	96	1,574	107.6	206.5
25-40 years	1,849	1	24	48	96	1,546	107.9	196.6
41-64 years	1,143	1	24	48	96	1,496	120.7	221.0
≥ 65 years	186	3	24	43	96	1,317	102.0	184.0
Oliceridine	61	1	1	1	1	2	1.1	0.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	*****	1	1	1	1	2	1.2	0.4
≥ 65 years	50	1	1	1	1	2	1.0	0.2
Viltolarsen	1,131	1	1	1	1	452	4.0	24.1
0-17 years	839	1	1	1	1	452	3.9	26.6
18-24 years	249	1	1	1	1	112	2.5	9.6
25-40 years	43	1	1	1	28	145	14.6	30.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	1,238	1	28	47	84	1,406	94.3	154.5
0-17 years	*****	3	14	27	28	55	24.9	16.1
18-24 years	*****	11	28	28	112	388	79.7	87.7
25-40 years	248	1	28	28	84	726	75.1	97.9
41-64 years	541	1	28	56	84	1,406	100.3	169.9
≥ 65 years	397	1	28	50	84	1,277	101.1	167.1
Clascoterone	83,955	1	30	30	30	806	33.8	21.0
0-17 years	19,339	1	30	30	30	510	34.0	20.6
18-24 years	22,927	1	30	30	30	524	34.0	20.7
25-40 years	29,619	1	30	30	30	806	33.6	20.9
41-64 years	11,259	1	30	30	30	646	33.9	22.5
≥ 65 years	811	1	30	30	30	240	32.3	20.9
Somapacitan-beco	3,805	1	23	30	65	555	61.5	73.6
0-17 years	3,421	1	23	30	65	555	62.0	75.1
18-24 years	131	2	25	30	60	390	60.3	68.6
25-40 years	78	4	21	42	77	258	61.9	60.0
41-64 years	122	6	23	30	69	252	49.5	42.4
≥ 65 years	53	6	28	35	60	322	56.9	55.4

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Copper Cu 64 Dotatate Injection	26,670	1	1	1	1	2	1.0	0.0
0-17 years	18	1	1	1	1	1	1.0	0.0
18-24 years	90	1	1	1	1	1	1.0	0.0
25-40 years	693	1	1	1	1	1	1.0	0.0
41-64 years	5,768	1	1	1	1	1	1.0	0.0
≥ 65 years	20,101	1	1	1	1	2	1.0	0.0
Pralsetinib	626	4	30	30	90	1,247	85.4	137.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	14	42	60	90	107	62.6	37.1
25-40 years	*****	30	42	60	102	697	117.5	185.0
41-64 years	173	5	30	30	90	1,247	88.7	148.4
≥ 65 years	436	4	30	30	90	1,155	83.5	132.6
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	1,033,157	1	1	1	1	47	1.1	0.4
0-17 years	5,214	1	1	1	1	5	1.1	0.3
18-24 years	7,511	1	1	1	1	6	1.0	0.3
25-40 years	50,376	1	1	1	1	8	1.1	0.3
41-64 years	230,248	1	1	1	1	28	1.1	0.3
≥ 65 years	739,808	1	1	1	1	47	1.1	0.4
Lonafarnib	53	3	30	30	60	232	49.4	39.3
0-17 years	*****	3	30	30	60	232	49.7	39.6

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	30	30	30.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	187	1	1	1	28	185	20.8	41.5
0-17 years	93	1	1	1	29	185	19.3	39.8
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	34	1	1	1	1	180	23.2	50.1
41-64 years	48	1	1	1	42	180	24.7	41.8
≥ 65 years	12	1	1	1	1	85	10.4	24.9
Setmelanotide	129	1	30	30	62	352	60.4	56.2
0-17 years	74	1	30	30	66	260	63.1	56.8
18-24 years	17	6	30	30	60	210	52.8	51.2
25-40 years	18	14	30	42	88	148	55.6	35.7
41-64 years	20	9	30	30	60	352	61.1	73.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	300	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Gallium 68 PSMA-11	79,335	1	1	1	1	2	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	5,574	1	1	1	1	1	1.0	0.0
≥ 65 years	73,743	1	1	1	1	2	1.0	0.0
Berotrastat	1,242	1	28	56	112	1,407	120.3	180.0
0-17 years	80	2	28	56	140	1,407	123.5	189.2
18-24 years	86	1	28	56	150	1,253	146.1	228.4
25-40 years	275	1	28	49	112	981	99.1	141.8
41-64 years	503	4	28	56	112	1,291	115.5	180.1
≥ 65 years	298	4	28	56	168	1,337	139.8	191.2
Tirbanibulin	11,323	1	5	5	30	330	12.9	14.7
0-17 years	*****	5	5	5	5	5	5.0	0.0
18-24 years	*****	5	5	33	60	60	32.5	38.9
25-40 years	*****	5	5	5	30	90	12.3	13.1
41-64 years	6,164	1	5	5	10	189	11.3	12.8
≥ 65 years	4,854	1	5	5	30	330	15.0	16.6
Margetuximab (anti-HER2 mAB)	2,367	1	1	1	1	105	1.2	3.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	21	1.0	0.6
≥ 65 years	1,301	1	1	1	1	105	1.4	5.0
Relugolix	77,070	1	30	56	96	1,462	91.6	118.7
0-17 years	49	9	28	56	90	337	81.9	88.0
18-24 years	1,262	1	28	30	84	764	62.7	72.2
25-40 years	6,475	1	28	28	84	986	61.9	73.5
41-64 years	14,949	1	28	30	88	1,360	78.4	101.3
≥ 65 years	54,335	1	30	60	120	1,462	99.5	127.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Vibegron	590,500	1	30	53	90	1,415	85.7	104.7
0-17 years	176	1	30	30	87	855	67.0	87.3
18-24 years	1,254	1	30	30	90	1,104	72.9	97.4
25-40 years	8,306	1	30	42	90	1,187	82.3	102.3
41-64 years	85,477	1	30	57	90	1,415	89.4	111.5
≥ 65 years	495,287	1	30	52	90	1,386	85.2	103.6

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Remimazolam</i>	4,707	4,707	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fostemsavir</i>	1,519	661	43.5%	313	20.6%	346	22.8%	128	8.4%	71	4.7%
<i>Decitabine and Cedazuridine</i>	4,272	2,671	62.5%	1,214	28.4%	371	8.7%	*****	*****	*****	*****
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	1,836	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Belantamab Mafodotin-blmf</i>	1,351	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Nifurtimox</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Risdiplam</i>	1,654	449	27.1%	405	24.5%	587	35.5%	118	7.1%	95	5.7%
<i>Oliceridine</i>	59	59	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	52	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Satralizumab-mwge</i>	328	126	38.4%	108	32.9%	70	21.3%	*****	*****	*****	*****
<i>Clascoterone</i>	48,919	44,518	91.0%	3,513	7.2%	875	1.8%	*****	*****	*****	*****
<i>Somapacitan-beco</i>	1,172	484	41.3%	381	32.5%	275	23.5%	32	2.7%	0	0.0%
<i>Copper Cu 64 Dotatate Injection</i>	18,172	18,172	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Pralsetinib</i>	227	112	49.3%	64	28.2%	*****	*****	*****	*****	*****	*****
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	993,583	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Lonafarnib</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lumasiran</i>	41	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Setmelanotide</i>	57	26	45.6%	17	29.8%	14	24.6%	0	0.0%	0	0.0%
<i>Naxitamab-gqgk</i>	36	36	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	66,552	66,552	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Berotralstat</i>	489	175	35.8%	101	20.7%	149	30.5%	45	9.2%	19	3.9%
<i>Tirbanibulin</i>	8,271	8,069	97.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Margetuximab (anti-HER2 mAB)</i>	417	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Relugolix</i>	32,426	13,809	42.6%	8,391	25.9%	8,574	26.4%	1,344	4.1%	308	0.9%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Vibegron</i>	243,455	108,636	44.6%	78,716	32.3%	46,858	19.2%	7,979	3.3%	1,266	0.5%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	4,707	1	1	1	1	3	1.0	0.1
<i>Fostemsavir</i>	1,519	3	30	60	180	1,680	165.1	250.3
<i>Decitabine and Cedazuridine</i>	4,272	1	28	28	56	760	48.6	50.1
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	1,836	1	1	1	1	140	1.4	4.9
<i>Belantamab Mafodotin-blmf</i>	1,351	1	1	1	1	196	1.2	5.5
<i>Nifurtimox</i>	*****	28	30	30	60	90	46.4	22.0
<i>Risdiplam</i>	1,654	1	25	75	210	1,574	189.2	283.5
<i>Oliceridine</i>	59	1	1	1	1	2	1.1	0.3
<i>Viltolarsen</i>	52	1	1	1	26	452	35.1	89.0
<i>Satralizumab-mwge</i>	328	1	28	56	112	1,406	122.8	204.1
<i>Clascoterone</i>	48,919	1	30	30	30	806	34.1	21.3
<i>Somapacitan-beco</i>	1,172	1	28	42	96	555	83.5	95.6
<i>Copper Cu 64 Dotatate Injection</i>	18,172	1	1	1	1	2	1.0	0.0
<i>Pralsetinib</i>	227	4	30	34	90	1,110	89.8	131.6
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	993,583	1	1	1	1	37	1.1	0.4
<i>Lonafarnib</i>	*****	30	30	30	60	232	62.2	66.2
<i>Lumasiran</i>	41	1	1	1	30	179	27.6	44.5
<i>Setmelanotide</i>	57	1	28	57	90	260	70.6	59.1
<i>Naxitamab-gqgk</i>	36	1	1	1	1	1	1.0	0.0
<i>Gallium 68 PSMA-11</i>	66,552	1	1	1	1	2	1.0	0.0
<i>Berotrastat</i>	489	1	28	68	224	1,407	172.4	231.1
<i>Tirbanibulin</i>	8,271	1	5	5	30	189	12.6	13.5
<i>Margetuximab (anti-HER2 mAB)</i>	417	1	1	1	1	86	1.4	4.9
<i>Relugolix</i>	32,426	1	30	58	123	1,462	108.3	140.2
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	243,455	1	30	60	90	1,415	94.7	118.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Remimazolam	4,707	4,707	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,248	2,248	47.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,459	2,459	52.2%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	1,519	661	100.0%	313	100.0%	346	100.0%	128	100.0%	71	100.0%
Female	319	169	25.6%	70	22.4%	55	15.9%	*****	*****	*****	*****
Male	1,200	492	74.4%	243	77.6%	291	84.1%	*****	*****	*****	*****
Decitabine and Cedazuridine	4,272	2,671	100.0%	1,214	100.0%	371	100.0%	*****	*****	*****	*****
Female	1,660	1,076	40.3%	467	38.5%	*****	*****	*****	*****	0	0.0%
Male	2,612	1,595	59.7%	747	61.5%	*****	*****	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	847	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	989	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Belantamab Mafodotin-blmf	1,351	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	637	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	714	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Nifurtimox	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Risdiplam	1,654	449	100.0%	405	100.0%	587	100.0%	118	100.0%	95	100.0%
Female	878	230	51.2%	225	55.6%	314	53.5%	63	53.4%	46	48.4%
Male	776	219	48.8%	180	44.4%	273	46.5%	55	46.6%	49	51.6%
Oliceridine	59	59	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	44	44	74.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	15	15	25.4%	0	NaN	0	NaN	0	NaN	0	NaN
Viltolarsen	52	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Male	52	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Satralizumab-mwge	328	126	100.0%	108	100.0%	70	100.0%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	276	104	82.5%	96	88.9%	*****	*****	*****	*****	*****	*****
Male	52	22	17.5%	12	11.1%	*****	*****	*****	*****	*****	*****
Clascoterone	48,919	44,518	100.0%	3,513	100.0%	875	100.0%	*****	*****	*****	*****
Female	43,522	39,682	89.1%	3,061	87.1%	*****	*****	*****	*****	*****	*****
Male	5,397	4,836	10.9%	452	12.9%	*****	*****	*****	*****	0	0.0%
Somapacitan-beco	1,172	484	100.0%	381	100.0%	275	100.0%	32	100.0%	0	NaN
Female	323	130	26.9%	107	28.1%	*****	*****	*****	*****	0	NaN
Male	849	354	73.1%	274	71.9%	*****	*****	*****	*****	0	NaN
Copper Cu 64 Dotatate Injection	18,172	18,172	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	10,136	10,136	55.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	8,036	8,036	44.2%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	227	112	100.0%	64	100.0%	*****	*****	*****	*****	*****	*****
Female	121	61	54.5%	36	56.3%	*****	*****	*****	*****	*****	*****
Male	106	51	45.5%	28	43.8%	*****	*****	*****	*****	0	0.0%
ebgn	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	993,583	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	505,231	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	488,352	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Lumasiran	41	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	19	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	22	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Setmelanotide	57	26	100.0%	17	100.0%	14	100.0%	0	NaN	0	NaN
Female	39	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	18	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Naxitamab-gqgk	36	36	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	13	13	36.1%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	23	23	63.9%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	66,552	66,552	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	72	72	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	66,480	66,480	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
Berotralstat	489	175	100.0%	101	100.0%	149	100.0%	45	100.0%	19	100.0%
Female	357	124	70.9%	74	73.3%	111	74.5%	*****	*****	*****	*****
Male	132	51	29.1%	27	26.7%	38	25.5%	*****	*****	*****	*****
Tirbanibulin	8,271	8,069	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	4,365	4,265	52.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,906	3,804	47.1%	*****	*****	*****	*****	0	NaN	0	NaN
Margetuximab (anti-HER2 mAB)	417	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Relugolix	32,426	13,809	100.0%	8,391	100.0%	8,574	100.0%	1,344	100.0%	308	100.0%
Female	7,492	4,031	29.2%	2,120	25.3%	1,194	13.9%	127	9.4%	20	6.5%
Male	24,934	9,778	70.8%	6,271	74.7%	7,380	86.1%	1,217	90.6%	288	93.5%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Vibegron	243,455	108,636	100.0%	78,716	100.0%	46,858	100.0%	7,979	100.0%	1,266	100.0%
Female	164,172	74,243	68.3%	52,260	66.4%	31,511	67.2%	5,317	66.6%	841	66.4%
Male	79,283	34,393	31.7%	26,456	33.6%	15,347	32.8%	2,662	33.4%	425	33.6%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	4,707	1	1	1	1	3	1.0	0.1
Female	2,248	1	1	1	1	2	1.0	0.1
Male	2,459	1	1	1	1	3	1.0	0.1
Fostemsavir	1,519	3	30	60	180	1,680	165.1	250.3
Female	319	3	30	30	97	999	108.3	154.8
Male	1,200	3	30	60	196	1,680	180.3	268.1
Decitabine and Cedazuridine	4,272	1	28	28	56	760	48.6	50.1
Female	1,660	1	28	28	56	695	46.1	46.6
Male	2,612	1	28	28	56	760	50.3	52.2
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1	1	1	1	140	1.4	4.9
Female	847	1	1	1	1	140	1.6	6.3
Male	989	1	1	1	1	56	1.3	3.2
Belantamab Mafodotin-blmf	1,351	1	1	1	1	196	1.2	5.5
Female	637	1	1	1	1	42	1.1	2.0
Male	714	1	1	1	1	196	1.3	7.3
Nifurtimox	*****	28	30	30	60	90	46.4	22.0
Female	*****	30	30	60	60	90	51.4	22.7
Male	*****	28	28	29	30	30	29.0	1.4
Risdiplam	1,654	1	25	75	210	1,574	189.2	283.5
Female	878	1	28	72	210	1,574	185.6	276.5
Male	776	1	24	81	209	1,496	193.3	291.3
Oliceridine	59	1	1	1	1	2	1.1	0.3
Female	44	1	1	1	1	2	1.1	0.3
Male	15	1	1	1	1	1	1.0	0.0

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Viltolarsen	52	1	1	1	26	452	35.1	89.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	52	1	1	1	26	452	35.1	89.0
Satralizumab-mwge	328	1	28	56	112	1,406	122.8	204.1
Female	276	1	28	56	112	1,406	116.8	187.6
Male	52	1	28	56	152	1,372	154.8	275.7
Clascoterone	48,919	1	30	30	30	806	34.1	21.3
Female	43,522	1	30	30	30	806	34.0	21.4
Male	5,397	1	30	30	30	397	34.7	21.3
Somapacitan-beco	1,172	1	28	42	96	555	83.5	95.6
Female	323	4	28	42	96	541	83.6	95.4
Male	849	1	28	42	96	555	83.5	95.7
Copper Cu 64 Dotatate Injection	18,172	1	1	1	1	2	1.0	0.0
Female	10,136	1	1	1	1	2	1.0	0.0
Male	8,036	1	1	1	1	1	1.0	0.0
Pralsetinib	227	4	30	34	90	1,110	89.8	131.6
Female	121	4	30	30	90	1,110	89.0	149.3
Male	106	5	30	56	96	613	90.7	108.7
ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	993,583	1	1	1	1	37	1.1	0.4
Female	505,231	1	1	1	1	26	1.1	0.4
Male	488,352	1	1	1	1	37	1.1	0.4
Lonafarnib	*****	30	30	30	60	232	62.2	66.2
Female	*****	30	30	30	120	232	88.4	89.2
Male	*****	30	30	30	30	60	36.0	13.4

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lumasiran	41	1	1	1	30	179	27.6	44.5
Female	19	1	1	28	90	179	45.7	58.6
Male	22	1	1	1	30	60	12.0	16.8
Setmelanotide	57	1	28	57	90	260	70.6	59.1
Female	39	3	28	60	118	210	75.2	55.7
Male	18	1	28	29	58	260	60.6	66.7
Naxitamab-gqgk	36	1	1	1	1	1	1.0	0.0
Female	13	1	1	1	1	1	1.0	0.0
Male	23	1	1	1	1	1	1.0	0.0
Gallium 68 PSMA-11	66,552	1	1	1	1	2	1.0	0.0
Female	72	1	1	1	1	1	1.0	0.0
Male	66,480	1	1	1	1	2	1.0	0.0
Berotrastat	489	1	28	68	224	1,407	172.4	231.1
Female	357	1	28	74	250	1,407	175.9	233.0
Male	132	8	28	56	196	1,337	163.2	226.5
Tirbanibulin	8,271	1	5	5	30	189	12.6	13.5
Female	4,365	1	5	5	30	120	12.5	13.2
Male	3,906	1	5	5	30	189	12.8	13.9
Margetuximab (anti-HER2 mAB)	417	1	1	1	1	86	1.4	4.9
Female	*****	1	1	1	1	86	1.5	4.9
Male	*****	1	1	1	1	1	1.0	0.0
Relugolix	32,426	1	30	58	123	1,462	108.3	140.2
Female	7,492	1	28	30	84	1,100	74.4	93.7
Male	24,934	1	30	60	150	1,462	118.5	149.9
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vibegron	243,455	1	30	60	90	1,415	94.7	118.9
Female	164,172	1	30	60	90	1,415	93.9	118.2
Male	79,283	1	30	60	90	1,386	96.3	120.3

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Remimazolam	4,707	4,707	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	35	35	0.7%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	50	50	1.1%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	181	181	3.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,034	1,034	22.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,407	3,407	72.4%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	1,519	661	100.0%	313	100.0%	346	100.0%	128	100.0%	71	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	931	385	58.2%	201	64.2%	227	65.6%	75	58.6%	43	60.6%
≥ 65 years	411	169	25.6%	84	26.8%	87	25.1%	*****	*****	*****	*****
Decitabine and Cedazuridine	4,272	2,671	100.0%	1,214	100.0%	371	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	312	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	3,941	2,470	92.5%	1,117	92.0%	*****	*****	*****	*****	0	0.0%
Abametapir	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	145	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,676	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	1,351	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,068	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Nifurtimox	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Risdiplam	1,654	449	100.0%	405	100.0%	587	100.0%	118	100.0%	95	100.0%
0-17 years	728	224	49.9%	199	49.1%	248	42.2%	43	36.4%	14	14.7%
18-24 years	239	77	17.1%	53	13.1%	79	13.5%	14	11.9%	16	16.8%
25-40 years	403	88	19.6%	94	23.2%	154	26.2%	32	27.1%	35	36.8%
41-64 years	239	*****	*****	46	11.4%	91	15.5%	*****	*****	*****	*****
≥ 65 years	45	*****	*****	13	3.2%	15	2.6%	*****	*****	*****	*****
Oliceridine	59	59	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	48	48	81.4%	0	NaN	0	NaN	0	NaN	0	NaN
Viltolarsen	52	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	38	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Satralizumab-mwge	328	126	100.0%	108	100.0%	70	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	63	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	143	54	42.9%	48	44.4%	28	40.0%	*****	*****	*****	*****
≥ 65 years	106	37	29.4%	35	32.4%	*****	*****	*****	*****	*****	*****
Clascoterone	48,919	44,518	100.0%	3,513	100.0%	875	100.0%	*****	*****	*****	*****
0-17 years	11,033	9,991	22.4%	838	23.9%	*****	*****	*****	*****	0	0.0%
18-24 years	13,465	12,193	27.4%	993	28.3%	*****	*****	*****	*****	0	0.0%
25-40 years	17,542	16,021	36.0%	1,229	35.0%	*****	*****	*****	*****	*****	*****
41-64 years	6,485	5,948	13.4%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	394	365	0.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
Somapacitan-beco	1,172	484	100.0%	381	100.0%	275	100.0%	32	100.0%	0	NaN
0-17 years	1,033	438	90.5%	323	84.8%	*****	*****	*****	*****	0	NaN
18-24 years	46	15	3.1%	19	5.0%	*****	*****	*****	*****	0	NaN
25-40 years	30	*****	*****	15	3.9%	*****	*****	0	0.0%	0	NaN
41-64 years	40	17	3.5%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	23	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Copper Cu 64 Dotatate Injection	18,172	18,172	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	17	17	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	82	82	0.5%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	548	548	3.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	4,086	4,086	22.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	13,439	13,439	74.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Pralsetinib	227	112	100.0%	64	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	57	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	159	83	74.1%	42	65.6%	*****	*****	*****	*****	*****	*****
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	993,583	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	5,098	5,098	0.5%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	7,326	7,326	0.7%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	48,929	48,929	4.9%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	221,807	221,807	22.3%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	710,423	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Lumasiran	41	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	19	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	11	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Setmelanotide	57	26	100.0%	17	100.0%	14	100.0%	0	NaN	0	NaN
0-17 years	37	16	61.5%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Naxitamab-gqgk	36	36	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	66,552	66,552	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	4,804	4,804	7.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	61,736	61,736	92.8%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	489	175	100.0%	101	100.0%	149	100.0%	45	100.0%	19	100.0%
0-17 years	34	13	7.4%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	46	18	10.3%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	102	35	20.0%	27	26.7%	*****	*****	*****	*****	*****	*****
41-64 years	178	61	34.9%	34	33.7%	59	39.6%	*****	*****	*****	*****
≥ 65 years	129	48	27.4%	23	22.8%	39	26.2%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Tirbanibulin	8,271	8,069	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	4,665	4,557	56.5%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	3,349	3,263	40.4%	*****	*****	*****	*****	0	NaN	0	NaN
Margetuximab (anti-HER2 mAB)	417	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	17	17	4.1%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	177	177	42.7%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	223	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Relugolix	32,426	13,809	100.0%	8,391	100.0%	8,574	100.0%	1,344	100.0%	308	100.0%
0-17 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	522	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	3,042	1,637	11.9%	881	10.5%	475	5.5%	*****	*****	*****	*****
41-64 years	6,520	3,190	23.1%	1,684	20.1%	1,406	16.4%	*****	*****	*****	*****
≥ 65 years	22,321	8,717	63.1%	5,655	67.4%	6,596	76.9%	1,094	81.4%	259	84.1%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Vibegron	243,455	108,636	100.0%	78,716	100.0%	46,858	100.0%	7,979	100.0%	1,266	100.0%
0-17 years	60	38	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	526	286	0.3%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	3,482	1,607	1.5%	1,129	1.4%	604	1.3%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	34,019	14,551	13.4%	10,839	13.8%	7,072	15.1%	1,299	16.3%	258	20.4%
≥ 65 years	205,368	92,154	84.8%	66,579	84.6%	39,101	83.4%	6,549	82.1%	985	77.8%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	4,707	1	1	1	1	3	1.0	0.1
0-17 years	35	1	1	1	1	1	1.0	0.0
18-24 years	50	1	1	1	1	1	1.0	0.0
25-40 years	181	1	1	1	1	1	1.0	0.0
41-64 years	1,034	1	1	1	1	1	1.0	0.0
≥ 65 years	3,407	1	1	1	1	3	1.0	0.1
Fostemsavir	1,519	3	30	60	180	1,680	165.1	250.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	10	30	30	64	119	49.3	33.8
25-40 years	*****	3	30	30	90	1,020	103.1	171.4
41-64 years	931	4	30	60	180	1,608	165.4	246.4
≥ 65 years	411	3	30	60	223	1,680	192.6	282.1
Decitabine and Cedazuridine	4,272	1	28	28	56	760	48.6	50.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	8	28	43	84	114	53.8	34.7
41-64 years	312	1	28	28	56	760	49.7	65.2
≥ 65 years	3,941	1	28	28	56	695	48.5	48.8
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,836	1	1	1	1	140	1.4	4.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	145	1	1	1	1	44	1.5	3.9
≥ 65 years	1,676	1	1	1	1	140	1.4	5.0
Belantamab Mafodotin-blmf	1,351	1	1	1	1	196	1.2	5.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	21	1.1	1.2
≥ 65 years	1,068	1	1	1	1	196	1.3	6.2
Nifurtimox	*****	28	30	30	60	90	46.4	22.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	60	60	60	60	60.0	NaN
41-64 years	*****	30	30	30	45	60	37.5	15.0
≥ 65 years	*****	28	29	45	75	90	52.0	29.3
Risdiplam	1,654	1	25	75	210	1,574	189.2	283.5
0-17 years	728	1	24	72	176	1,567	137.4	195.5
18-24 years	239	1	24	72	185	1,574	188.3	309.3
25-40 years	403	1	41	96	245	1,546	225.6	320.0
41-64 years	239	3	48	131	360	1,496	280.0	367.8
≥ 65 years	45	24	36	87	264	1,317	224.3	316.1
Oliceridine	59	1	1	1	1	2	1.1	0.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	2	1.2	0.4
≥ 65 years	48	1	1	1	1	2	1.0	0.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Viltolarsen	52	1	1	1	26	452	35.1	89.0
0-17 years	38	1	1	1	14	452	37.8	101.5
18-24 years	*****	1	1	7	28	86	19.7	30.8
25-40 years	*****	1	1	28	28	145	36.0	49.6
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	328	1	28	56	112	1,406	122.8	204.1
0-17 years	*****	14	14	21	27	27	20.5	9.2
18-24 years	*****	27	28	28	140	388	95.6	108.3
25-40 years	63	14	28	42	84	726	83.6	119.3
41-64 years	143	1	28	56	112	1,406	137.4	243.2
≥ 65 years	106	1	28	56	168	1,277	132.0	195.6
Clascoterone	48,919	1	30	30	30	806	34.1	21.3
0-17 years	11,033	1	30	30	30	510	34.2	20.6
18-24 years	13,465	1	30	30	30	387	34.4	21.0
25-40 years	17,542	1	30	30	30	806	33.8	22.0
41-64 years	6,485	1	30	30	30	646	33.8	21.7
≥ 65 years	394	4	30	30	30	240	32.5	15.8
Somapacitan-beco	1,172	1	28	42	96	555	83.5	95.6
0-17 years	1,033	1	28	42	98	555	84.9	98.6
18-24 years	46	15	30	42	91	390	81.5	85.9
25-40 years	30	14	30	58	90	258	76.0	60.5
41-64 years	40	16	28	70	93	252	67.7	49.1
≥ 65 years	23	6	30	42	70	322	63.7	68.9
Copper Cu 64 Dotatate Injection	18,172	1	1	1	1	2	1.0	0.0
0-17 years	17	1	1	1	1	1	1.0	0.0
18-24 years	82	1	1	1	1	1	1.0	0.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	548	1	1	1	1	1	1.0	0.0
41-64 years	4,086	1	1	1	1	1	1.0	0.0
≥ 65 years	13,439	1	1	1	1	2	1.0	0.0
Pralsetinib	227	4	30	34	90	1,110	89.8	131.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	42	42	66	90	90	66.0	33.9
25-40 years	*****	30	51	65	120	697	140.0	211.4
41-64 years	57	5	30	34	90	562	87.2	102.8
≥ 65 years	159	4	30	30	90	1,110	88.2	136.4
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-
0-17 years	0	-	-
18-24 years	0	-	-
25-40 years	0	-	-
41-64 years	0	-	-
≥ 65 years	0	-	-
Remdesivir	993,583	1	1	1	1	37	1.1	0.4
0-17 years	5,098	1	1	1	1	5	1.1	0.3
18-24 years	7,326	1	1	1	1	5	1.0	0.3
25-40 years	48,929	1	1	1	1	6	1.1	0.3
41-64 years	221,807	1	1	1	1	28	1.1	0.3
≥ 65 years	710,423	1	1	1	1	37	1.1	0.4
Lonafarnib	*****	30	30	30	60	232	62.2	66.2
0-17 years	*****	30	30	30	60	232	65.8	69.2
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	30	30	30.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lumasiran	41	1	1	1	30	179	27.6	44.5
0-17 years	19	1	1	30	30	179	34.1	48.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	30	169	33.0	61.4
41-64 years	11	1	1	1	56	90	20.2	33.7
≥ 65 years	*****	1	1	1	16	30	8.3	14.5
Setmelanotide	57	1	28	57	90	260	70.6	59.1
0-17 years	37	1	28	57	126	260	76.9	66.2
18-24 years	*****	28	29	30	86	141	57.3	55.8
25-40 years	*****	14	28	58	97	148	66.0	45.6
41-64 years	*****	9	28	44	75	118	52.6	36.8
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	36	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Gallium 68 PSMA-11	66,552	1	1	1	1	2	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	4,804	1	1	1	1	1	1.0	0.0
≥ 65 years	61,736	1	1	1	1	2	1.0	0.0
Berotrastat	489	1	28	68	224	1,407	172.4	231.1
0-17 years	34	15	28	66	178	1,407	162.3	259.3
18-24 years	46	1	28	60	252	1,253	205.3	291.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	102	8	28	56	196	840	139.7	170.8
41-64 years	178	14	28	84	219	1,232	181.0	239.2
≥ 65 years	129	6	28	56	252	1,337	177.5	230.0
Tirbanibulin	8,271	1	5	5	30	189	12.6	13.5
0-17 years	*****	5	5	5	5	5	5.0	NaN
18-24 years	*****	5	5	33	60	60	32.5	38.9
25-40 years	*****	5	5	5	30	90	12.6	13.5
41-64 years	4,665	1	5	5	10	189	11.4	12.6
≥ 65 years	3,349	1	5	5	30	185	14.3	14.6
Margetuximab (anti-HER2 mAB)	417	1	1	1	1	86	1.4	4.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	17	1	1	1	1	1	1.0	0.0
41-64 years	177	1	1	1	1	21	1.1	1.5
≥ 65 years	223	1	1	1	1	86	1.7	6.6
Relugolix	32,426	1	30	58	123	1,462	108.3	140.2
0-17 years	21	19	30	56	112	337	112.9	110.0
18-24 years	522	1	28	33	84	764	78.5	92.1
25-40 years	3,042	1	28	30	84	930	71.7	87.5
41-64 years	6,520	1	28	40	94	1,360	91.8	123.6
≥ 65 years	22,321	1	30	60	150	1,462	118.9	149.8
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vibegron	243,455	1	30	60	90	1,415	94.7	118.9
0-17 years	60	15	30	30	75	360	65.5	72.6
18-24 years	526	1	30	30	90	1,064	77.9	109.7
25-40 years	3,482	1	30	59	90	1,187	93.3	120.9
41-64 years	34,019	1	30	60	96	1,415	101.7	130.0
≥ 65 years	205,368	1	30	60	90	1,386	93.6	116.9

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Remimazolam</i>	485	485	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Fostemsavir</i>	3,677	1,978	53.8%	889	24.2%	639	17.4%	119	3.2%	52	1.4%
<i>Decitabine and Cedazuridine</i>	9,284	6,784	73.1%	1,990	21.4%	487	5.2%	*****	*****	*****	*****
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	26,149	26,135	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Belantamab Mafodotin-blmf</i>	3,977	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Nifurtimox</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Risdiplam</i>	4,598	2,187	47.6%	1,435	31.2%	881	19.2%	66	1.4%	29	0.6%
<i>Oliceridine</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	1,079	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Satralizumab-mwge</i>	910	460	50.5%	268	29.5%	155	17.0%	*****	*****	*****	*****
<i>Clascoterone</i>	35,036	31,911	91.1%	2,630	7.5%	*****	*****	*****	*****	0	0.0%
<i>Somapacitan-beco</i>	2,633	1,599	60.7%	679	25.8%	338	12.8%	17	0.6%	0	0.0%
<i>Copper Cu 64 Dotatate Injection</i>	8,498	8,498	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Pralsetinib</i>	399	215	53.9%	116	29.1%	56	14.0%	*****	*****	*****	*****
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	39,574	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Lonafarnib</i>	43	26	60.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Lumasiran</i>	146	122	83.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Setmelanotide</i>	72	45	62.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Naxitamab-gqgk</i>	264	264	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	12,783	12,783	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Berotrastat</i>	753	383	50.9%	192	25.5%	151	20.1%	*****	*****	*****	*****
<i>Tirbanibulin</i>	3,052	2,920	95.7%	115	3.8%	17	0.6%	0	0.0%	0	0.0%
<i>Margetuximab (anti-HER2 mAB)</i>	1,950	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Relugolix</i>	44,644	22,199	49.7%	13,168	29.5%	8,239	18.5%	898	2.0%	140	0.3%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Vibegron</i>	347,045	164,446	47.4%	115,420	33.3%	60,043	17.3%	6,520	1.9%	616	0.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	485	1	1	1	1	2	1.0	0.1
<i>Fostemsavir</i>	3,677	1	30	30	90	1,616	95.1	151.9
<i>Decitabine and Cedazuridine</i>	9,284	1	28	28	42	1,115	41.3	45.9
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	26,149	1	1	1	1	308	1.1	3.3
<i>Belantamab Mafodotin-blmf</i>	3,977	1	1	1	1	42	1.0	1.0
<i>Nifurtimox</i>	*****	3	27	28	30	60	29.7	19.5
<i>Risdiplam</i>	4,598	1	24	35	72	1,448	71.3	115.2
<i>Oliceridine</i>	*****	1	1	1	1	1	1.0	0.0
<i>Viltolarsen</i>	1,079	1	1	1	1	254	2.5	13.7
<i>Satralizumab-mwge</i>	910	1	28	30	84	1,355	84.1	130.8
<i>Clascoterone</i>	35,036	1	30	30	30	570	33.5	20.5
<i>Somapacitan-beco</i>	2,633	1	21	30	56	468	51.7	58.7
<i>Copper Cu 64 Dotatate Injection</i>	8,498	1	1	1	1	2	1.0	0.0
<i>Pralsetinib</i>	399	5	30	30	66	1,247	82.9	141.0
<i>Atoltivimad Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	39,574	1	1	1	1	47	1.1	0.6
<i>Lonafarnib</i>	43	3	30	30	60	150	46.4	30.5
<i>Lumasiran</i>	146	1	1	1	1	185	18.9	40.5
<i>Setmelanotide</i>	72	6	30	30	60	352	52.3	52.8
<i>Naxitamab-gqgk</i>	264	1	1	1	1	1	1.0	0.0
<i>Gallium 68 PSMA-11</i>	12,783	1	1	1	1	2	1.0	0.0
<i>Berotrastat</i>	753	1	28	28	84	1,291	86.5	126.2
<i>Tirbanibulin</i>	3,052	1	5	5	30	330	13.6	17.3
<i>Margetuximab (anti-HER2 mAB)</i>	1,950	1	1	1	1	105	1.2	3.5
<i>Relugolix</i>	44,644	1	30	34	90	1,254	79.5	98.5
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	347,045	1	30	43	90	1,230	79.5	93.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remimazolam	485	485	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	242	242	49.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	243	243	50.1%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	3,677	1,978	100.0%	889	100.0%	639	100.0%	119	100.0%	52	100.0%
Female	730	398	20.1%	194	21.8%	112	17.5%	*****	*****	*****	*****
Male	2,947	1,580	79.9%	695	78.2%	527	82.5%	*****	*****	*****	*****
Decitabine and Cedazuridine	9,284	6,784	100.0%	1,990	100.0%	487	100.0%	*****	*****	*****	*****
Female	3,395	2,526	37.2%	695	34.9%	*****	*****	*****	*****	*****	*****
Male	5,889	4,258	62.8%	1,295	65.1%	*****	*****	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	26,135	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	12,400	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	13,749	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	3,977	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	1,868	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,109	2,109	53.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Nifurtimox	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Risdiplam	4,598	2,187	100.0%	1,435	100.0%	881	100.0%	66	100.0%	29	100.0%
Female	2,416	1,143	52.3%	779	54.3%	448	50.9%	28	42.4%	18	62.1%
Male	2,182	1,044	47.7%	656	45.7%	433	49.1%	38	57.6%	11	37.9%
Oliceridine	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Viltolarsen	1,079	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Male	1,079	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Satralizumab-mwge	910	460	100.0%	268	100.0%	155	100.0%	*****	*****	*****	*****
Female	778	388	84.3%	238	88.8%	*****	*****	*****	*****	*****	*****
Male	132	72	15.7%	30	11.2%	*****	*****	*****	*****	*****	*****
Clascoterone	35,036	31,911	100.0%	2,630	100.0%	*****	*****	*****	*****	0	NaN
Female	30,539	27,863	87.3%	2,267	86.2%	*****	*****	*****	*****	0	NaN
Male	4,497	4,048	12.7%	363	13.8%	*****	*****	*****	*****	0	NaN
Somapacitan-beco	2,633	1,599	100.0%	679	100.0%	338	100.0%	17	100.0%	0	NaN
Female	675	415	26.0%	179	26.4%	*****	*****	*****	*****	0	NaN
Male	1,958	1,184	74.0%	500	73.6%	*****	*****	*****	*****	0	NaN
Copper Cu 64 Dotatate Injection	8,498	8,498	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	4,686	4,686	55.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	3,812	3,812	44.9%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	399	215	100.0%	116	100.0%	56	100.0%	*****	*****	*****	*****
Female	229	118	54.9%	67	57.8%	*****	*****	*****	*****	*****	*****
Male	170	97	45.1%	49	42.2%	*****	*****	*****	*****	*****	*****
ebgn	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	39,574	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	18,868	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	20,706	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	43	26	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	16	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lumasiran	146	122	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	53	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	93	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Setmelanotide	72	45	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	61	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	11	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Naxitamab-gqgk	264	264	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	101	101	38.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	163	163	61.7%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	12,783	12,783	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	753	383	100.0%	192	100.0%	151	100.0%	*****	*****	*****	*****
Female	574	296	77.3%	145	75.5%	*****	*****	*****	*****	*****	*****
Male	179	87	22.7%	47	24.5%	*****	*****	*****	*****	*****	*****
Tirbanibulin	3,052	2,920	100.0%	115	100.0%	17	100.0%	0	NaN	0	NaN
Female	1,385	1,317	45.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,667	1,603	54.9%	*****	*****	*****	*****	0	NaN	0	NaN
Margetuximab (anti-HER2 mAB)	1,950	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Relugolix	44,644	22,199	100.0%	13,168	100.0%	8,239	100.0%	898	100.0%	140	100.0%
Female	8,912	5,411	24.4%	2,382	18.1%	1,057	12.8%	*****	*****	*****	*****
Male	35,732	16,788	75.6%	10,786	81.9%	7,182	87.2%	*****	*****	*****	*****
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	347,045	164,446	100.0%	115,420	100.0%	60,043	100.0%	6,520	100.0%	616	100.0%
Female	240,880	115,405	70.2%	79,249	68.7%	41,313	68.8%	4,489	68.8%	424	68.8%
Male	106,165	49,041	29.8%	36,171	31.3%	18,730	31.2%	2,031	31.2%	192	31.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	485	1	1	1	1	2	1.0	0.1
Female	242	1	1	1	1	2	1.0	0.1
Male	243	1	1	1	1	2	1.0	0.1
Fostemsavir	3,677	1	30	30	90	1,616	95.1	151.9
Female	730	1	30	30	90	1,338	83.7	132.8
Male	2,947	1	30	30	90	1,616	97.9	156.2
Decitabine and Cedazuridine	9,284	1	28	28	42	1,115	41.3	45.9
Female	3,395	1	28	28	32	952	40.6	48.5
Male	5,889	1	28	28	48	1,115	41.7	44.3
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	1	1	1	1	308	1.1	3.3
Female	12,400	1	1	1	1	252	1.1	3.7
Male	13,749	1	1	1	1	308	1.0	2.9
Belantamab Mafodotin-blmf	3,977	1	1	1	1	42	1.0	1.0
Female	1,868	1	1	1	1	42	1.1	1.5
Male	2,109	1	1	1	1	1	1.0	0.0
Nifurtimox	*****	3	27	28	30	60	29.7	19.5
Female	*****	4	17	30	45	60	31.0	22.9
Male	*****	3	27	28	28	57	28.6	19.1
Risdiplam	4,598	1	24	35	72	1,448	71.3	115.2
Female	2,416	1	24	35	72	1,448	70.2	118.7
Male	2,182	1	24	35	72	1,327	72.5	111.2
Oliceridine	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	1	1	1.0	NaN
Viltolarsen	1,079	1	1	1	1	254	2.5	13.7
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,079	1	1	1	1	254	2.5	13.7
Satralizumab-mwge	910	1	28	30	84	1,355	84.1	130.8
Female	778	1	28	36	84	1,355	84.1	129.9
Male	132	1	28	30	84	1,071	84.0	136.3
Clascoterone	35,036	1	30	30	30	570	33.5	20.5
Female	30,539	1	30	30	30	570	33.4	20.1
Male	4,497	1	30	30	30	421	34.5	23.1
Somapacitan-beco	2,633	1	21	30	56	468	51.7	58.7
Female	675	1	21	30	56	444	49.7	56.1
Male	1,958	1	21	30	56	468	52.3	59.5
Copper Cu 64 Dotatate Injection	8,498	1	1	1	1	2	1.0	0.0
Female	4,686	1	1	1	1	2	1.0	0.0
Male	3,812	1	1	1	1	2	1.0	0.0
Pralsetinib	399	5	30	30	66	1,247	82.9	141.0
Female	229	5	30	30	90	1,247	96.4	168.4
Male	170	7	30	30	60	900	64.8	89.4
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	39,574	1	1	1	1	47	1.1	0.6
Female	18,868	1	1	1	1	47	1.1	0.6
Male	20,706	1	1	1	1	37	1.1	0.6
Lonafarnib	43	3	30	30	60	150	46.4	30.5
Female	16	26	30	60	60	150	55.9	34.7
Male	27	3	30	30	60	120	40.7	26.8
Lumasiran	146	1	1	1	1	185	18.9	40.5
Female	53	1	1	1	84	180	34.4	49.0
Male	93	1	1	1	1	185	10.1	31.8
Setmelanotide	72	6	30	30	60	352	52.3	52.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	61	6	30	30	60	352	53.4	52.9
Male	11	30	30	30	30	210	46.4	54.3
Naxitamab-ggqk	264	1	1	1	1	1	1.0	0.0
Female	101	1	1	1	1	1	1.0	0.0
Male	163	1	1	1	1	1	1.0	0.0
Gallium 68 PSMA-11	12,783	1	1	1	1	2	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	2	1.0	0.0
Berotrastat	753	1	28	28	84	1,291	86.5	126.2
Female	574	2	28	28	84	1,130	85.9	122.8
Male	179	1	28	36	91	1,291	88.5	136.7
Tirbanibulin	3,052	1	5	5	30	330	13.6	17.3
Female	1,385	1	5	5	30	330	14.4	18.3
Male	1,667	1	5	5	20	210	13.0	16.4
Margetuximab (anti-HER2 mAB)	1,950	1	1	1	1	105	1.2	3.5
Female	*****	1	1	1	1	105	1.2	3.5
Male	*****	1	1	1	1	1	1.0	0.0
Relugolix	44,644	1	30	34	90	1,254	79.5	98.5
Female	8,912	1	28	28	60	986	57.4	62.8
Male	35,732	1	30	56	90	1,254	84.9	104.9
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Vibegron	347,045	1	30	43	90	1,230	79.5	93.0
Female	240,880	1	30	42	90	1,230	78.9	92.6
Male	106,165	1	30	50	90	1,183	80.7	93.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remimazolam	485	485	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	147	147	30.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	319	319	65.8%	0	NaN	0	NaN	0	NaN	0	NaN
Fostemsavir	3,677	1,978	100.0%	889	100.0%	639	100.0%	119	100.0%	52	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,324	1,252	63.3%	563	63.3%	401	62.8%	79	66.4%	29	55.8%
≥ 65 years	968	490	24.8%	230	25.9%	193	30.2%	*****	*****	*****	*****
Decitabine and Cedazuridine	9,284	6,784	100.0%	1,990	100.0%	487	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	533	*****	*****	*****	*****	26	5.3%	0	0.0%	0	0.0%
≥ 65 years	8,740	6,388	94.2%	1,868	93.9%	461	94.7%	*****	*****	*****	*****
Abametapir	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	26,135	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	12	12	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	104	104	0.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,616	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	24,417	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belantamab Mafodotin-blmf	3,977	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,348	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Nifurtimox	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Risdiplam	4,598	2,187	100.0%	1,435	100.0%	881	100.0%	66	100.0%	29	100.0%
0-17 years	1,565	781	35.7%	469	32.7%	299	33.9%	*****	*****	*****	*****
18-24 years	542	273	12.5%	148	10.3%	*****	*****	*****	*****	*****	*****
25-40 years	1,446	639	29.2%	486	33.9%	284	32.2%	25	37.9%	12	41.4%
41-64 years	904	423	19.3%	291	20.3%	161	18.3%	*****	*****	*****	*****
≥ 65 years	141	71	3.2%	41	2.9%	*****	*****	*****	*****	*****	*****
Oliceridine	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Viltolarsen	1,079	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	801	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	242	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
25-40 years	36	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Satralizumab-mwge	910	460	100.0%	268	100.0%	155	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	185	104	22.6%	44	16.4%	*****	*****	*****	*****	0	0.0%
41-64 years	398	193	42.0%	118	44.0%	76	49.0%	*****	*****	*****	*****
≥ 65 years	291	144	31.3%	96	35.8%	37	23.9%	*****	*****	*****	*****
Clascoterone	35,036	31,911	100.0%	2,630	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	8,306	7,574	23.7%	618	23.5%	*****	*****	*****	*****	0	NaN
18-24 years	9,462	8,639	27.1%	695	26.4%	*****	*****	*****	*****	0	NaN
25-40 years	12,077	11,012	34.5%	885	33.7%	180	36.9%	0	0.0%	0	NaN
41-64 years	4,774	4,310	13.5%	402	15.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	417	376	1.2%	30	1.1%	11	2.3%	0	0.0%	0	NaN
Somapacitan-beco	2,633	1,599	100.0%	679	100.0%	338	100.0%	17	100.0%	0	NaN
0-17 years	2,388	1,452	90.8%	606	89.2%	313	92.6%	17	100.0%	0	NaN
18-24 years	85	53	3.3%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	48	25	1.6%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	82	57	3.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	30	12	0.8%	*****	*****	*****	*****	0	0.0%	0	NaN
Copper Cu 64 Dotatate Injection	8,498	8,498	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,682	1,682	19.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	6,662	6,662	78.4%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	399	215	100.0%	116	100.0%	56	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	277	148	68.8%	82	70.7%	*****	*****	*****	*****	*****	*****
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Remdesivir	39,574	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	116	116	0.3%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	185	185	0.5%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	1,447	1,447	3.7%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	8,441	8,441	21.3%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	29,385	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Lonafarnib	43	26	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	43	26	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lumasiran	146	122	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	74	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	37	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Setmelanotide	72	45	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	37	23	51.1%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	13	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Naxitamab-gqgk	264	264	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium 68 PSMA-11	12,783	12,783	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	12,007	12,007	93.9%	0	NaN	0	NaN	0	NaN	0	NaN
Berotrastat	753	383	100.0%	192	100.0%	151	100.0%	*****	*****	*****	*****
0-17 years	46	20	5.2%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	40	22	5.7%	*****	*****	*****	*****	*****	*****	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	173	97	25.3%	38	19.8%	*****	*****	*****	*****	*****	*****
41-64 years	325	171	44.6%	94	49.0%	*****	*****	*****	*****	*****	*****
≥ 65 years	169	73	19.1%	41	21.4%	43	28.5%	*****	*****	*****	*****
Tirbanibulin	3,052	2,920	100.0%	115	100.0%	17	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,499	1,447	49.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,505	1,425	48.8%	*****	*****	*****	*****	0	NaN	0	NaN
Margetuximab (anti-HER2 mAB)	1,950	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	65	65	3.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	807	807	41.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,078	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Relugolix	44,644	22,199	100.0%	13,168	100.0%	8,239	100.0%	898	100.0%	140	100.0%
0-17 years	28	16	0.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	740	472	2.1%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	3,433	2,163	9.7%	898	6.8%	354	4.3%	*****	*****	*****	*****
41-64 years	8,429	4,600	20.7%	2,389	18.1%	1,327	16.1%	*****	*****	*****	*****
≥ 65 years	32,014	14,948	67.3%	9,676	73.5%	6,486	78.7%	776	86.4%	128	91.4%
Ansuvimab-zykl	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	347,045	164,446	100.0%	115,420	100.0%	60,043	100.0%	6,520	100.0%	616	100.0%
0-17 years	116	71	0.0%	25	0.0%	*****	*****	0	0.0%	*****	*****
18-24 years	728	405	0.2%	226	0.2%	*****	*****	*****	*****	*****	*****
25-40 years	4,824	2,404	1.5%	1,617	1.4%	726	1.2%	*****	*****	*****	*****
41-64 years	51,458	24,245	14.7%	17,037	14.8%	9,011	15.0%	1,048	16.1%	117	19.0%
≥ 65 years	289,919	137,321	83.5%	96,515	83.6%	50,201	83.6%	5,395	82.7%	487	79.1%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	485	1	1	1	1	2	1.0	0.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	147	1	1	1	1	2	1.0	0.1
≥ 65 years	319	1	1	1	1	2	1.0	0.1
Fostemsavir	3,677	1	30	30	90	1,616	95.1	151.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	30	30	60	150	48.1	40.9
25-40 years	*****	2	30	30	60	1,338	73.1	133.7
41-64 years	2,324	1	30	30	90	1,616	95.0	151.7
≥ 65 years	968	1	30	30	102	1,328	104.2	159.0
Decitabine and Cedazuridine	9,284	1	28	28	42	1,115	41.3	45.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	28	28	28	28.0	NaN
25-40 years	*****	28	28	28	56	84	40.4	21.0
41-64 years	533	1	28	28	35	353	38.0	34.5
≥ 65 years	8,740	1	28	28	42	1,115	41.5	46.5
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	1	1	1	1	308	1.1	3.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	12	1	1	1	1	1	1.0	0.0
25-40 years	104	1	1	1	1	1	1.0	0.0
41-64 years	1,616	1	1	1	1	58	1.0	1.4
≥ 65 years	24,417	1	1	1	1	308	1.1	3.4
Belantamab Mafodotin-blmf	3,977	1	1	1	1	42	1.0	1.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	2	1.0	0.1
≥ 65 years	3,348	1	1	1	1	42	1.0	1.1
Nifurtimox	*****	3	27	28	30	60	29.7	19.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	NaN
41-64 years	*****	4	4	30	60	60	31.3	28.0
≥ 65 years	*****	3	27	28	28	57	28.6	19.1
Risdiplam	4,598	1	24	35	72	1,448	71.3	115.2
0-17 years	1,565	1	24	31	72	1,432	64.0	89.6
18-24 years	542	1	24	28	72	1,254	72.0	123.5
25-40 years	1,446	1	24	36	72	1,448	75.1	126.6
41-64 years	904	1	24	36	72	1,373	78.6	132.7
≥ 65 years	141	3	24	24	72	748	63.0	83.6
Oliceridine	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Viltolarsen	1,079	1	1	1	1	254	2.5	13.7
0-17 years	801	1	1	1	1	254	2.3	14.3
18-24 years	242	1	1	1	1	112	2.0	7.9
25-40 years	36	1	1	1	13	131	10.4	23.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	910	1	28	30	84	1,355	84.1	130.8
0-17 years	*****	3	19	28	28	55	26.6	18.9
18-24 years	*****	11	28	47	84	361	72.5	77.6
25-40 years	185	1	28	28	84	672	72.2	89.7
41-64 years	398	2	28	56	84	1,355	87.0	132.0
≥ 65 years	291	1	28	41	84	1,255	89.8	154.3
Clascoterone	35,036	1	30	30	30	570	33.5	20.5
0-17 years	8,306	1	30	30	30	383	33.8	20.5
18-24 years	9,462	1	30	30	30	524	33.5	20.2
25-40 years	12,077	1	30	30	30	363	33.2	19.2
41-64 years	4,774	1	30	30	30	570	34.0	23.5
≥ 65 years	417	1	30	30	30	240	32.1	24.7
Somapacitan-beco	2,633	1	21	30	56	468	51.7	58.7
0-17 years	2,388	1	21	29	56	468	52.1	59.6
18-24 years	85	2	21	30	42	262	48.8	54.4
25-40 years	48	4	21	30	44	258	53.1	58.6
41-64 years	82	6	23	30	42	249	40.7	35.8
≥ 65 years	30	15	25	33	60	174	51.8	42.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Copper Cu 64 Dotatate Injection	8,498	1	1	1	1	2	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	1,682	1	1	1	1	1	1.0	0.0
≥ 65 years	6,662	1	1	1	1	2	1.0	0.0
Pralsetinib	399	5	30	30	66	1,247	82.9	141.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	14	14	60	107	107	60.3	46.5
25-40 years	*****	30	30	60	60	60	50.0	17.3
41-64 years	*****	6	30	30	90	1,247	89.4	166.7
≥ 65 years	277	5	30	30	60	1,155	80.8	130.5
Atoltivimab Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	39,574	1	1	1	1	47	1.1	0.6
0-17 years	116	1	1	1	1	3	1.1	0.4
18-24 years	185	1	1	1	1	6	1.1	0.5
25-40 years	1,447	1	1	1	1	8	1.1	0.5
41-64 years	8,441	1	1	1	1	12	1.1	0.5
≥ 65 years	29,385	1	1	1	1	47	1.1	0.6
Lonafarnib	43	3	30	30	60	150	46.4	30.5
0-17 years	43	3	30	30	60	150	46.4	30.5
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	146	1	1	1	1	185	18.9	40.5
0-17 years	74	1	1	1	1	185	15.5	36.7
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	180	20.7	47.8
41-64 years	37	1	1	1	28	180	26.1	44.3
≥ 65 years	*****	1	1	1	1	85	11.5	29.7
Setmelanotide	72	6	30	30	60	352	52.3	52.8
0-17 years	37	20	30	30	60	210	49.4	42.2
18-24 years	13	6	30	30	60	210	51.4	52.0
25-40 years	*****	30	30	30	60	90	47.3	25.0
41-64 years	*****	30	30	30	59	352	66.7	91.9
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	264	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gallium 68 PSMA-11	12,783	1	1	1	1	2	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	12,007	1	1	1	1	2	1.0	0.0
Berotrastat	753	1	28	28	84	1,291	86.5	126.2
0-17 years	46	2	28	56	112	476	94.8	107.5
18-24 years	40	12	28	28	109	392	78.0	82.9
25-40 years	173	1	28	28	84	981	75.2	115.5
41-64 years	325	4	28	28	84	1,291	79.6	123.9
≥ 65 years	169	4	28	56	112	1,130	111.0	149.8
Tirbanibulin	3,052	1	5	5	30	330	13.6	17.3
0-17 years	*****	5	5	5	5	5	5.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	5	16	30	11.0	10.4
41-64 years	1,499	1	5	5	5	180	10.8	13.4
≥ 65 years	1,505	1	5	5	30	330	16.5	20.2
Margetuximab (anti-HER2 mAB)	1,950	1	1	1	1	105	1.2	3.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	65	1	1	1	1	1	1.0	0.0
41-64 years	807	1	1	1	1	1	1.0	0.0
≥ 65 years	1,078	1	1	1	1	105	1.4	4.7
Relugolix	44,644	1	30	34	90	1,254	79.5	98.5
0-17 years	28	9	28	28	70	308	58.7	59.1
18-24 years	740	1	28	28	56	523	51.5	51.1
25-40 years	3,433	1	28	28	56	986	53.2	57.1
41-64 years	8,429	1	28	30	84	1,009	68.1	78.4
≥ 65 years	32,014	1	30	58	90	1,254	85.9	106.5
Ansuvimab-zykl	0	-	-	-	-	-	-	-

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Vibegron	347,045	1	30	43	90	1,230	79.5	93.0
0-17 years	116	1	30	30	87	855	67.7	94.2
18-24 years	728	1	30	30	90	1,104	69.3	87.5
25-40 years	4,824	1	30	32	90	1,024	74.4	85.6
41-64 years	51,458	1	30	46	90	1,189	81.3	96.5
≥ 65 years	289,919	1	30	42	90	1,230	79.3	92.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	485	1	24	62	152	585	98.3	97.4
<i>Fostemsavir</i>	3,677	1	3	7	19	972	22.1	53.5
<i>Decitabine and Cedazuridine</i>	9,284	1	6	14	29	1,192	25.3	45.7
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	26,149	1	6	12	13	855	11.2	13.8
<i>Belantamab Mafodotin-blmf</i>	3,977	1	20	24	41	707	38.7	37.2
<i>Nifurtimox</i>	*****	5	7	20	41	84	29.0	28.1
<i>Risdiplam</i>	4,598	1	2	5	12	928	13.8	43.6
<i>Oliceridine</i>	*****	254	254	368	481	481	367.5	160.5
<i>Viltolarsen</i>	1,079	1	6	6	13	765	11.4	25.3
<i>Satralizumab-mwge</i>	910	1	2	5	11	768	14.8	47.0
<i>Clascoterone</i>	35,036	1	24	57	115	1,158	88.7	103.2
<i>Somapacitan-beco</i>	2,633	1	3	6	13	312	12.0	20.5
<i>Copper Cu 64 Dotatate Injection</i>	8,498	2	140	196	341	1,306	253.9	167.9
<i>Pralsetinib</i>	399	1	3	7	19	524	18.4	37.3
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	39,574	1	3	20	396	1,540	227.5	328.7
<i>Lonafarnib</i>	43	1	3	7	22	196	19.3	32.8
<i>Lumasiran</i>	146	1	27	30	89	435	53.8	48.8
<i>Setmelanotide</i>	72	1	3	7	13	409	18.0	53.6
<i>Naxitamab-gqgk</i>	264	1	1	1	23	415	12.3	34.4
<i>Gallium 68 PSMA-11</i>	12,783	1	123	191	310	1,136	233.8	148.2
<i>Berotrastat</i>	753	1	3	6	14	1,221	25.2	85.7
<i>Tirbanibulin</i>	3,052	1	25	75	182	1,158	137.5	168.4
<i>Margetuximab (anti-HER2 mAB)</i>	1,950	1	20	20	21	777	24.0	23.3
<i>Relugolix</i>	44,644	1	2	5	13	1,240	18.1	55.2
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	347,045	1	3	7	23	1,148	26.3	62.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representation

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	485	1	24	62	152	585	98.3	97.4
Female	242	1	18	62	156	461	95.9	95.0
Male	243	1	31	63	150	585	100.6	99.9
Fostemsavir	3,677	1	3	7	19	972	22.1	53.5
Female	730	1	3	7	19	420	23.5	50.0
Male	2,947	1	3	6	19	972	21.8	54.4
Decitabine and Cedazuridine	9,284	1	6	14	29	1,192	25.3	45.7
Female	3,395	1	6	14	31	1,112	27.8	54.2
Male	5,889	1	6	14	28	1,192	23.8	39.9
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	1	6	12	13	855	11.2	13.8
Female	12,400	1	6	13	13	796	11.3	14.7
Male	13,749	1	6	12	13	855	11.1	12.9
Belantamab Mafodotin-blmf	3,977	1	20	24	41	707	38.7	37.2
Female	1,868	1	20	25	41	441	39.7	37.8
Male	2,109	1	20	23	41	707	37.8	36.7
Nifurtimox	*****	5	7	20	41	84	29.0	28.1
Female	*****	5	6	8	18	26	11.8	9.7
Male	*****	7	20	41	62	84	42.8	31.1
Risdiplam	4,598	1	2	5	12	928	13.8	43.6
Female	2,416	1	2	5	12	844	14.5	45.5
Male	2,182	1	2	5	11	928	13.1	41.3
Oliceridine	*****	254	254	368	481	481	367.5	160.5
Female	*****	481	481	481	481	481	481.0	NaN
Male	*****	254	254	254	254	254	254.0	NaN

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Viltolarsen	1,079	1	6	6	13	765	11.4	25.3
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	1,079	1	6	6	13	765	11.4	25.3
Satralizumab-mwge	910	1	2	5	11	768	14.8	47.0
Female	778	1	2	5	12	768	15.2	48.5
Male	132	1	2	5	9	373	12.5	37.3
Clascoterone	35,036	1	24	57	115	1,158	88.7	103.2
Female	30,539	1	25	59	118	1,158	90.9	104.4
Male	4,497	1	18	43	93	954	74.3	93.9
Somapacitan-beco	2,633	1	3	6	13	312	12.0	20.5
Female	675	1	3	6	14	215	12.0	19.0
Male	1,958	1	3	6	13	312	12.1	21.1
Copper Cu 64 Dotatate Injection	8,498	2	140	196	341	1,306	253.9	167.9
Female	4,686	2	141	197	342	1,212	253.8	164.9
Male	3,812	3	139	195	339	1,306	254.1	171.6
Pralsetinib	399	1	3	7	19	524	18.4	37.3
Female	229	1	3	8	21	524	21.7	45.8
Male	170	1	3	7	17	127	14.0	20.0
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	39,574	1	3	20	396	1,540	227.5	328.7
Female	18,868	1	3	28	420	1,518	241.9	334.3
Male	20,706	1	3	17	376	1,540	214.4	323.1
Lonafarnib	43	1	3	7	22	196	19.3	32.8
Female	16	1	4	6	19	51	13.6	16.1
Male	27	1	3	8	23	196	22.7	39.4

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lumasiran	146	1	27	30	89	435	53.8	48.8
Female	53	1	25	61	90	435	66.8	65.9
Male	93	4	27	28	88	140	46.3	33.7
Setmelanotide	72	1	3	7	13	409	18.0	53.6
Female	61	1	3	6	12	409	18.6	58.1
Male	11	2	6	12	22	32	14.7	9.9
Naxitamab-gqgk	264	1	1	1	23	415	12.3	34.4
Female	101	1	1	1	13	65	8.9	13.5
Male	163	1	1	1	23	415	14.4	42.4
Gallium 68 PSMA-11	12,783	1	123	191	310	1,136	233.8	148.2
Female	*****	73	118	132	134	152	121.8	29.8
Male	*****	1	123	191	310	1,136	233.8	148.2
Berotrastat	753	1	3	6	14	1,221	25.2	85.7
Female	574	1	2	6	14	1,221	22.8	78.0
Male	179	1	3	7	15	776	33.2	106.5
Tirbanibulin	3,052	1	25	75	182	1,158	137.5	168.4
Female	1,385	1	26	75	186	1,158	144.0	182.9
Male	1,667	1	25	76	178	1,111	132.1	155.1
Margetuximab (anti-HER2 mAB)	1,950	1	20	20	21	777	24.0	23.3
Female	*****	1	20	20	21	777	24.0	23.3
Male	*****	20	20	20	24	27	21.8	3.5
Relugolix	44,644	1	2	5	13	1,240	18.1	55.2
Female	8,912	1	3	7	16	1,010	19.0	44.9
Male	35,732	1	2	5	12	1,240	17.9	57.5
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vibegron	347,045	1	3	7	23	1,148	26.3	62.2
Female	240,880	1	3	7	23	1,148	26.2	61.7
Male	106,165	1	3	7	23	1,071	26.6	63.2

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	485	1	24	62	152	585	98.3	97.4
0-17 years	*****	233	233	266	299	299	266.0	46.7
18-24 years	*****	32	40	57	69	72	54.5	18.1
25-40 years	*****	6	15	43	111	427	107.2	134.9
41-64 years	147	3	30	69	139	533	100.7	94.2
≥ 65 years	319	1	20	59	154	585	96.3	97.3
Fostemsavir	3,677	1	3	7	19	972	22.1	53.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	7	87	149	307	103.4	111.5
25-40 years	*****	1	4	10	25	450	27.8	54.1
41-64 years	2,324	1	3	6	18	972	22.5	56.8
≥ 65 years	968	1	3	6	17	494	18.4	42.6
Decitabine and Cedazuridine	9,284	1	6	14	29	1,192	25.3	45.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	57	57	57	57	57	57.0	NaN
25-40 years	*****	3	5	15	29	118	24.9	34.3
41-64 years	533	1	5	13	27	725	25.6	56.3
≥ 65 years	8,740	1	6	14	29	1,192	25.3	45.0
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	26,149	1	6	12	13	855	11.2	13.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	13	13	13	13	27	14.2	4.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	104	2	6	6	13	43	9.3	7.3
41-64 years	1,616	1	6	6	13	855	11.6	26.5
≥ 65 years	24,417	1	6	13	13	796	11.1	12.5
Belantamab Mafodotin-blmf	3,977	1	20	24	41	707	38.7	37.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	20	27	55	55	34.0	18.5
41-64 years	*****	1	20	23	41	356	38.0	35.5
≥ 65 years	3,348	1	20	24	41	707	38.8	37.5
Nifurtimox	*****	5	7	20	41	84	29.0	28.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	26	26	26	26	26	26.0	NaN
41-64 years	*****	5	5	6	10	10	7.0	2.6
≥ 65 years	*****	7	20	41	62	84	42.8	31.1
Risdiplam	4,598	1	2	5	12	928	13.8	43.6
0-17 years	1,565	1	2	5	12	546	13.6	35.0
18-24 years	542	1	2	5	13	844	14.4	52.1
25-40 years	1,446	1	3	5	11	649	13.5	42.7
41-64 years	904	1	2	5	11	928	14.2	52.6
≥ 65 years	141	1	3	6	12	382	15.0	37.6
Oliceridine	*****	254	254	368	481	481	367.5	160.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	254	254	368	481	481	367.5	160.5

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Viltolarsen	1,079	1	6	6	13	765	11.4	25.3
0-17 years	801	1	6	6	13	765	12.2	28.2
18-24 years	242	1	6	6	6	83	7.3	6.4
25-40 years	36	1	6	13	24	188	20.3	32.3
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	910	1	2	5	11	768	14.8	47.0
0-17 years	*****	1	5	7	34	45	18.4	19.8
18-24 years	*****	1	3	4	9	31	7.7	7.9
25-40 years	185	1	3	6	14	330	16.8	44.2
41-64 years	398	1	2	5	10	374	13.4	35.6
≥ 65 years	291	1	2	5	9	768	16.1	62.7
Clascoterone	35,036	1	24	57	115	1,158	88.7	103.2
0-17 years	8,306	1	27	61	119	959	92.0	104.1
18-24 years	9,462	1	25	58	117	971	90.4	104.1
25-40 years	12,077	1	22	53	106	1,141	83.1	97.8
41-64 years	4,774	1	23	59	125	1,158	95.0	111.9
≥ 65 years	417	1	10	40	100	729	76.3	106.5
Somapacitan-beco	2,633	1	3	6	13	312	12.0	20.5
0-17 years	2,388	1	3	6	13	312	11.5	19.7
18-24 years	85	1	5	11	26	215	23.9	35.5
25-40 years	48	1	3	6	18	50	11.9	12.9
41-64 years	82	1	4	8	13	163	13.5	23.9
≥ 65 years	30	1	3	6	18	103	14.9	21.4
Copper Cu 64 Dotatate Injection	8,498	2	140	196	341	1,306	253.9	167.9
0-17 years	*****	343	343	343	343	343	343.0	NaN
18-24 years	*****	145	171	192	207	256	192.5	33.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	*****	13	125	205	367	881	258.4	163.8
41-64 years	1,682	3	142	206	349	1,159	264.8	178.1
≥ 65 years	6,662	2	140	195	336	1,306	251.1	165.3
Pralsetinib	399	1	3	7	19	524	18.4	37.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	3	10	10	5.0	4.4
25-40 years	*****	4	4	30	61	61	31.7	28.5
41-64 years	*****	1	3	7	17	175	15.7	26.5
≥ 65 years	277	1	4	8	20	524	19.6	41.2
Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	39,574	1	3	20	396	1,540	227.5	328.7
0-17 years	116	1	1	7	164	944	111.3	197.3
18-24 years	185	1	2	4	86	1,169	114.4	232.4
25-40 years	1,447	1	2	5	141	1,405	142.6	266.9
41-64 years	8,441	1	2	9	272	1,464	175.8	294.2
≥ 65 years	29,385	1	4	31	438	1,540	247.7	339.1
Lonafarnib	43	1	3	7	22	196	19.3	32.8
0-17 years	43	1	3	7	22	196	19.3	32.8
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lumasiran	146	1	27	30	89	435	53.8	48.8
0-17 years	74	1	27	28	30	435	37.7	53.2
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	28	90	94	132	71.3	34.8
41-64 years	37	2	27	83	90	168	67.5	41.5
≥ 65 years	*****	16	84	90	93	94	80.3	26.3
Setmelanotide	72	1	3	7	13	409	18.0	53.6
0-17 years	37	1	2	7	11	66	9.6	12.2
18-24 years	13	1	4	13	31	409	59.8	119.1
25-40 years	*****	2	3	5	9	20	7.0	5.9
41-64 years	*****	2	4	7	13	19	8.1	5.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	264	1	1	1	23	415	12.3	34.4
0-17 years	*****	1	1	1	22	415	12.2	34.7
18-24 years	*****	1	1	3	35	46	14.7	20.3
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gallium 68 PSMA-11	12,783	1	123	191	310	1,136	233.8	148.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	69	76	89	98	203	103.8	49.7
41-64 years	*****	3	118	184	307	1,013	228.5	150.2
≥ 65 years	12,007	1	124	191	310	1,136	234.2	148.1
Berotrastat	753	1	3	6	14	1,221	25.2	85.7
0-17 years	46	1	2	7	14	202	15.6	34.7
18-24 years	40	1	3	7	19	78	16.6	20.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	173	1	2	6	12	665	17.1	61.2
41-64 years	325	1	3	6	15	1,221	26.5	94.8
≥ 65 years	169	1	2	7	14	776	35.9	105.0
Tirbanibulin	3,052	1	25	75	182	1,158	137.5	168.4
0-17 years	*****	50	50	50	50	50	50.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	47	1	49	83	170	1,059	150.2	193.8
41-64 years	*****	1	27	80	211	1,158	154.7	186.3
≥ 65 years	1,505	1	23	69	162	1,152	120.0	145.6
Margetuximab (anti-HER2 mAB)	1,950	1	20	20	21	777	24.0	23.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	65	19	20	20	27	55	24.9	8.8
41-64 years	807	6	20	20	23	372	24.4	17.4
≥ 65 years	1,078	1	20	20	20	777	23.7	27.4
Relugolix	44,644	1	2	5	13	1,240	18.1	55.2
0-17 years	28	1	2	5	12	517	27.0	96.6
18-24 years	740	1	3	6	15	507	16.1	33.3
25-40 years	3,433	1	3	7	17	631	18.7	39.4
41-64 years	8,429	1	2	6	15	1,010	18.5	49.3
≥ 65 years	32,014	1	2	5	12	1,240	17.9	58.5
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vibegron	347,045	1	3	7	23	1,148	26.3	62.2
0-17 years	116	1	4	13	35	397	32.2	62.2
18-24 years	728	1	3	9	26	771	25.4	56.6
25-40 years	4,824	1	3	7	20	986	22.5	51.2
41-64 years	51,458	1	3	7	20	1,148	23.7	57.1
≥ 65 years	289,919	1	3	8	23	1,139	26.8	63.2

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Remimazolam</i>	378	1	25	69	160	585	103.1	99.9
<i>Fostemsavir</i>	963	1	3	6	20	972	25.9	69.9
<i>Decitabine and Cedazuridine</i>	2,536	1	5	12	26	1,112	23.5	47.7
<i>Abametapir</i>	0	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	1,741	1	2	2	4	90	4.2	6.2
<i>Belantamab Mafodotin-blmf</i>	1,001	1	20	20	27	467	30.2	31.1
<i>Nifurtimox</i>	*****	5	6	15	26	84	25.2	30.0
<i>Risdiplam</i>	1,056	1	2	5	13	928	18.4	59.2
<i>Oliceridine</i>	*****	254	254	368	481	481	367.5	160.5
<i>Viltolarsen</i>	39	1	6	8	16	83	14.4	15.9
<i>Satralizumab-mwge</i>	212	1	4	9	23	768	29.9	81.6
<i>Clascoterone</i>	17,377	1	29	66	134	1,158	103.5	116.9
<i>Somapacitan-beco</i>	771	1	3	7	13	249	13.5	23.7
<i>Copper Cu 64 Dotatate Injection</i>	4,671	2	155	226	371	1,306	290.0	191.0
<i>Pralsetinib</i>	132	1	4	7	21	524	23.5	54.5
<i>Atoltivimab Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-
<i>Remdesivir</i>	36,484	1	3	23	415	1,540	236.3	334.3
<i>Lonafarnib</i>	*****	1	3	5	10	33	8.6	10.3
<i>Lumasiran</i>	34	1	18	29	89	140	48.6	40.5
<i>Setmelanotide</i>	24	1	3	8	17	213	18.9	42.2
<i>Naxitamab-gqgk</i>	30	1	1	1	1	59	5.1	12.2
<i>Gallium 68 PSMA-11</i>	8,967	1	146	221	352	1,136	262.9	156.3
<i>Berotrastat</i>	252	1	2	6	14	1,221	25.0	92.2
<i>Tirbanibulin</i>	1,722	1	28	87	220	1,158	162.3	190.4
<i>Margetuximab (anti-HER2 mAB)</i>	366	3	20	20	23	777	25.5	40.9
<i>Relugolix</i>	16,388	1	2	6	16	1,240	21.6	65.0
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-
<i>Vibegron</i>	124,011	1	3	9	29	1,139	34.0	77.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	378	1	25	69	160	585	103.1	99.9
Female	189	1	17	62	156	409	97.4	95.3
Male	189	1	35	72	160	585	108.8	104.3
Fostemsavir	963	1	3	6	20	972	25.9	69.9
Female	198	1	3	7	23	347	27.9	57.7
Male	765	1	3	6	19	972	25.3	72.8
Decitabine and Cedazuridine	2,536	1	5	12	26	1,112	23.5	47.7
Female	932	1	5	13	27	1,112	26.3	58.8
Male	1,604	1	5	12	25	631	21.8	39.7
Abametapir	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,741	1	2	2	4	90	4.2	6.2
Female	805	1	2	2	5	90	4.3	6.4
Male	936	1	2	2	3	83	4.1	6.0
Belantamab Mafodotin-blmf	1,001	1	20	20	27	467	30.2	31.1
Female	481	1	20	20	27	356	30.1	29.4
Male	520	1	20	20	27	467	30.3	32.6
Nifurtimox	*****	5	6	15	26	84	25.2	30.0
Female	*****	5	6	8	18	26	11.8	9.7
Male	*****	20	20	52	84	84	52.0	45.3
Risdiplam	1,056	1	2	5	13	928	18.4	59.2
Female	549	1	2	4	14	546	17.7	50.1
Male	507	1	2	5	12	928	19.1	67.7
Oliceridine	*****	254	254	368	481	481	367.5	160.5
Female	*****	481	481	481	481	481	481.0	NaN

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	*****	254	254	254	254	254	254.0	NaN
Viltolarsen	39	1	6	8	16	83	14.4	15.9
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	39	1	6	8	16	83	14.4	15.9
Satralizumab-mwge	212	1	4	9	23	768	29.9	81.6
Female	181	1	4	9	24	768	30.7	83.7
Male	31	1	4	9	14	373	25.8	68.4
Clascoterone	17,377	1	29	66	134	1,158	103.5	116.9
Female	15,308	1	30	67	137	1,158	105.4	118.2
Male	2,069	1	22	55	115	954	89.3	106.2
Somapacitan-beco	771	1	3	7	13	249	13.5	23.7
Female	207	1	3	7	12	215	12.0	22.3
Male	564	1	3	7	14	249	14.0	24.2
Copper Cu 64 Dotatate Injection	4,671	2	155	226	371	1,306	290.0	191.0
Female	2,556	2	159	227	375	1,212	290.5	186.9
Male	2,115	3	154	224	369	1,306	289.3	195.9
Pralsetinib	132	1	4	7	21	524	23.5	54.5
Female	71	1	4	11	25	524	31.8	71.1
Male	61	1	4	6	16	118	13.9	20.5
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Remdesivir	36,484	1	3	23	415	1,540	236.3	334.3
Female	17,481	1	3	31	441	1,518	250.4	339.5
Male	19,003	1	3	18	393	1,540	223.4	328.9
Lonafarnib	*****	1	3	5	10	33	8.6	10.3

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	*****	1	1	5	5	5	3.7	2.3
Male	*****	3	3	8	11	33	11.6	12.4
Lumasiran	34	1	18	29	89	140	48.6	40.5
Female	16	1	17	40	89	93	48.1	36.1
Male	18	4	25	29	89	140	48.9	45.0
Setmelanotide	24	1	3	8	17	213	18.9	42.2
Female	*****	1	3	7	13	213	19.6	48.8
Male	*****	2	10	17	22	32	16.7	10.4
Naxitamab-gqgk	30	1	1	1	1	59	5.1	12.2
Female	*****	1	1	1	3	59	11.1	20.6
Male	*****	1	1	1	1	23	2.6	4.9
Gallium 68 PSMA-11	8,967	1	146	221	352	1,136	262.9	156.3
Female	*****	118	125	133	143	152	134.0	14.0
Male	*****	1	146	221	353	1,136	263.0	156.3
Berotrastat	252	1	2	6	14	1,221	25.0	92.2
Female	188	1	2	6	14	1,221	26.9	102.3
Male	64	1	3	7	14	385	19.6	52.9
Tirbanibulin	1,722	1	28	87	220	1,158	162.3	190.4
Female	814	1	30	91	230	1,158	174.3	208.1
Male	908	1	26	85	211	1,111	151.6	172.4
Targetuximab (anti-HER2 mAB)	366	3	20	20	23	777	25.5	40.9
Female	*****	3	20	20	23	777	25.5	41.0
Male	*****	20	20	20	20	20	20.0	0.0
Relugolix	16,388	1	2	6	16	1,240	21.6	65.0
Female	3,291	1	3	8	21	748	25.0	55.6
Male	13,097	1	2	5	14	1,240	20.8	67.2

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ansuvimab-zykl	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Vibegron	124,011	1	3	9	29	1,139	34.0	77.9
Female	84,714	1	3	9	29	1,139	33.9	77.4
Male	39,297	1	3	10	30	1,071	34.4	78.9

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Remimazolam	378	1	25	69	160	585	103.1	99.9
0-17 years	*****	233	233	266	299	299	266.0	46.7
18-24 years	*****	32	32	52	72	72	52.0	28.3
25-40 years	*****	6	15	43	111	427	104.9	142.0
41-64 years	95	3	48	87	156	533	109.9	92.4
≥ 65 years	270	1	20	62	160	585	99.9	100.8
Fostemsavir	963	1	3	6	20	972	25.9	69.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	44	111	135	56.0	66.5
25-40 years	*****	1	5	11	38	347	29.8	46.8
41-64 years	605	1	3	6	20	972	27.6	79.7
≥ 65 years	252	1	2	6	15	460	19.7	49.6
Decitabine and Cedazuridine	2,536	1	5	12	26	1,112	23.5	47.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	57	57	57	57	57	57.0	NaN
25-40 years	*****	3	8	16	32	118	30.1	39.8
41-64 years	*****	1	5	12	27	725	27.6	76.4
≥ 65 years	2,365	1	5	12	26	1,112	23.2	45.1
Abametapir	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Tafasitamab-cxix	1,741	1	2	2	4	90	4.2	6.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	13	13	13	13	13	13.0	NaN
25-40 years	*****	2	2	2	6	13	4.2	3.4
41-64 years	131	1	2	2	6	39	4.8	5.9
≥ 65 years	1,598	1	2	2	4	90	4.1	6.2
Belantamab Mafodotin-blmf	1,001	1	20	20	27	467	30.2	31.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	20	27	55	55	34.0	18.5
41-64 years	*****	1	20	20	28	356	33.1	38.3
≥ 65 years	808	1	20	20	27	467	29.5	29.2
Nifurtimox	*****	5	6	15	26	84	25.2	30.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	26	26	26	26	26	26.0	NaN
41-64 years	*****	5	5	6	10	10	7.0	2.6
≥ 65 years	*****	20	20	52	84	84	52.0	45.3
Risdiplam	1,056	1	2	5	13	928	18.4	59.2
0-17 years	475	1	2	5	15	546	18.6	51.1
18-24 years	137	1	2	4	12	101	11.4	18.3
25-40 years	278	1	2	5	12	608	21.8	71.3
41-64 years	144	1	2	4	9	928	17.5	82.2
≥ 65 years	22	1	3	6	19	180	18.9	38.8
Oliceridine	*****	254	254	368	481	481	367.5	160.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	254	254	368	481	481	367.5	160.5
Viltolarsen	39	1	6	8	16	83	14.4	15.9
0-17 years	28	1	6	7	21	57	13.0	12.8
18-24 years	*****	6	7	12	16	25	13.0	7.0
25-40 years	*****	3	8	14	14	83	24.4	33.1
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Satralizumab-mwge	212	1	4	9	23	768	29.9	81.6
0-17 years	*****	1	1	23	45	45	23.0	31.1
18-24 years	*****	3	9	12	23	31	15.0	9.2
25-40 years	48	1	5	9	16	317	26.2	61.7
41-64 years	85	1	4	8	28	341	27.1	57.8
≥ 65 years	67	1	4	11	24	768	38.7	118.9
Clascoterone	17,377	1	29	66	134	1,158	103.5	116.9
0-17 years	4,246	1	31	68	136	959	103.8	113.9
18-24 years	4,800	1	30	68	138	971	105.6	118.1
25-40 years	5,930	1	27	61	124	1,141	97.3	112.5
41-64 years	2,257	1	28	71	152	1,158	113.6	128.6
≥ 65 years	144	1	25	60	138	729	115.4	139.6
Somapacitan-beco	771	1	3	7	13	249	13.5	23.7
0-17 years	681	1	3	7	13	249	12.9	22.4
18-24 years	31	1	6	11	28	215	27.5	42.6
25-40 years	19	1	1	4	12	42	7.8	10.1
41-64 years	27	1	4	8	10	163	14.9	31.1
≥ 65 years	13	2	3	10	20	50	15.2	15.2

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Copper Cu 64 Dotatate Injection	4,671	2	155	226	371	1,306	290.0	191.0
0-17 years	*****	343	343	343	343	343	343.0	NaN
18-24 years	*****	145	163	193	207	209	185.0	29.4
25-40 years	*****	13	147	260	377	881	295.8	183.6
41-64 years	985	3	159	243	387	1,159	300.9	200.3
≥ 65 years	3,595	2	154	223	369	1,306	286.9	188.6
Pralsetinib	132	1	4	7	21	524	23.5	54.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	6	10	10	6.0	5.7
25-40 years	*****	4	4	33	61	61	32.5	40.3
41-64 years	*****	1	3	7	17	71	13.6	16.7
≥ 65 years	90	1	4	8	23	524	27.9	64.6
Atoltivimad Maftivimab and Odesivimab-ebgn	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Remdesivir	36,484	1	3	23	415	1,540	236.3	334.3
0-17 years	100	1	1	4	165	944	107.7	195.1
18-24 years	166	1	1	3	56	1,169	109.6	234.9
25-40 years	1,349	1	2	4	143	1,405	144.8	271.0
41-64 years	7,711	1	2	9	293	1,464	181.0	299.3
≥ 65 years	27,158	1	4	36	464	1,540	257.8	344.5
Lonafarnib	*****	1	3	5	10	33	8.6	10.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	*****	1	3	5	10	33	8.6	10.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	34	1	18	29	89	140	48.6	40.5
0-17 years	15	1	4	27	52	140	41.4	44.8
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	5	28	93	98	42.3	42.5
41-64 years	*****	6	29	59	89	97	55.4	35.2
≥ 65 years	*****	16	49	86	90	90	69.3	35.7
Setmelanotide	24	1	3	8	17	213	18.9	42.2
0-17 years	*****	2	6	10	14	32	11.3	8.4
18-24 years	*****	1	4	18	121	213	62.3	101.2
25-40 years	*****	3	3	14	20	20	12.3	8.6
41-64 years	*****	2	2	3	4	4	3.0	1.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Naxitamab-gqgk	30	1	1	1	1	59	5.1	12.2
0-17 years	*****	1	1	1	1	59	5.2	12.5
18-24 years	*****	3	3	3	3	3	3.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Gallium 68 PSMA-11	8,967	1	146	221	352	1,136	262.9	156.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	87	87	89	90	90	88.5	2.1
41-64 years	*****	3	138	209	343	1,013	255.1	160.1
≥ 65 years	8,421	1	146	222	354	1,136	263.5	156.0
Berotrastat	252	1	2	6	14	1,221	25.0	92.2
0-17 years	19	1	1	5	10	26	6.6	6.7
18-24 years	15	1	3	6	19	70	14.9	19.0
25-40 years	57	1	2	6	9	110	10.9	19.3
41-64 years	88	1	3	6	18	1,221	40.6	140.7
≥ 65 years	73	1	2	7	13	385	24.2	69.2
Tirbanibulin	1,722	1	28	87	220	1,158	162.3	190.4
0-17 years	*****	50	50	50	50	50	50.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	58	111	264	1,059	180.2	220.1
41-64 years	915	1	30	100	258	1,158	177.6	204.8
≥ 65 years	773	1	25	78	195	1,152	143.7	168.9
Margetuximab (anti-HER2 mAB)	366	3	20	20	23	777	25.5	40.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	19	20	21	27	41	26.0	8.1
41-64 years	158	13	20	20	27	125	24.2	11.8
≥ 65 years	195	3	20	20	21	777	26.5	55.0
Relugolix	16,388	1	2	6	16	1,240	21.6	65.0
0-17 years	*****	1	2	5	14	517	107.8	228.8
18-24 years	*****	1	4	9	21	203	21.2	33.8
25-40 years	1,324	1	3	9	21	631	23.7	46.7
41-64 years	3,082	1	3	7	19	748	23.1	58.5

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	11,721	1	2	5	14	1,240	21.0	68.7
Ansuvimab-zykl	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Vibegron	124,011	1	3	9	29	1,139	34.0	77.9
0-17 years	39	1	4	15	29	397	32.2	69.5
18-24 years	257	1	4	10	32	771	33.6	78.6
25-40 years	1,729	1	3	9	26	986	28.6	66.5
41-64 years	17,824	1	3	8	25	1,111	29.4	69.6
≥ 65 years	104,162	1	3	10	30	1,139	34.9	79.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025^{1,2}

Censoring Reason									
	End of Exposure Episode ³			Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Remimazolam</i>	5,192	5,192	100.0%	0	0.0%	18	0.3%	17	0.3%
<i>Fostemsavir</i>	5,196	5,148	99.1%	0	0.0%	983	18.9%	669	12.9%
<i>Decitabine and Cedazuridine</i>	13,556	13,174	97.2%	0	0.0%	722	5.3%	552	4.1%
<i>Abametapir</i>	0	-	-	-	-	-	-	-	-
<i>Tafasitamab-cxix</i>	27,985	27,985	100.0%	0	0.0%	33	0.1%	30	0.1%
<i>Belantamab Mafodotin-blmf</i>	5,328	5,328	100.0%	0	0.0%	*****	*****	0	0.0%
<i>Nifurtimox</i>	18	18	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Risdiplam</i>	6,252	6,236	99.7%	0	0.0%	1,131	18.1%	934	14.9%
<i>Oliceridine</i>	61	61	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Viltolarsen</i>	1,131	1,131	100.0%	0	0.0%	22	1.9%	23	2.0%
<i>Satralizumab-mwge</i>	1,238	1,230	99.4%	0	0.0%	218	17.6%	162	13.1%
<i>Clascoterone</i>	83,955	83,953	100.0%	0	0.0%	5,525	6.6%	2,824	3.4%
<i>Somapacitan-beco</i>	3,805	3,805	100.0%	0	0.0%	681	17.9%	269	7.1%
<i>Copper Cu 64 Dotatate Injection</i>	26,670	26,670	100.0%	0	0.0%	*****	*****	11	0.0%
<i>Pralsetinib</i>	626	607	97.0%	0	0.0%	84	13.4%	61	9.7%
<i>Atoltivimad Maftivimab and Odesivimab-ebgn</i>	0	-	-	-	-	-	-	-	-
<i>Remdesivir</i>	1,033,157	1,033,143	100.0%	0	0.0%	531	0.1%	108	0.0%
<i>Lonafarnib</i>	53	53	100.0%	0	0.0%	*****	*****	*****	*****
<i>Lumasiran</i>	187	187	100.0%	0	0.0%	13	7.0%	12	6.4%
<i>Setmelanotide</i>	129	129	100.0%	0	0.0%	28	21.7%	20	15.5%
<i>Naxitamab-gqgk</i>	300	300	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Gallium 68 PSMA-11</i>	79,335	79,335	100.0%	0	0.0%	204	0.3%	195	0.2%
<i>Berotrastat</i>	1,242	1,237	99.6%	0	0.0%	264	21.3%	172	13.8%
<i>Tirbanibulin</i>	11,323	11,322	100.0%	0	0.0%	223	2.0%	130	1.1%
<i>Margetuximab (anti-HER2 mAB)</i>	2,367	2,366	100.0%	0	0.0%	*****	*****	*****	*****
<i>Relugolix</i>	77,070	76,587	99.4%	0	0.0%	14,603	18.9%	10,731	13.9%
<i>Ansuvimab-zykl</i>	0	-	-	-	-	-	-	-	-

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025^{1,2}

Censoring Reason								
	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes
<i>Vibegron</i>	590,500	586,739	99.4%	0	0.0%	117,602	19.9%	91,714

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Remimazolam		Fostemsavir		Decitabine and Cedazuridine		Abametapir	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A ¹	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	5,147	217,535,468	1,853	217,538,762	4,555	217,536,060	0	217,540,615
Claim recorded during specified age range	5,147	0	1,853	0	4,555	0	0	0
Episode defining index claim recorded during the query period	5,147	0	1,853	0	4,555	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	4,707	440	1,519	334	4,272	283	0	0
Met inclusion and exclusion criteria	4,707	0	1,519	0	4,272	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	4,707	0	1,519	0	4,272	0	0	0
Final cohort								
Number of members	4,707	N/A	1,519	N/A	4,272	N/A	0	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Tafasitamab-cxix		Belantamab Mafodotin-blmf		Nifurtimox		Risdiplam	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	1,947	217,538,668	1,417	217,539,198	*****	*****	1,832	217,538,783
Claim recorded during specified age range	1,947	0	1,417	0	*****	0	1,832	0
Episode defining index claim recorded during the query period	1,947	0	1,417	0	*****	0	1,832	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,836	111	1,351	66	*****	*****	1,654	178
Met inclusion and exclusion criteria	1,836	0	1,351	0	*****	0	1,654	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,836	0	1,351	0	*****	0	1,654	0
Final cohort								
Number of members	1,836	N/A	1,351	N/A	*****	N/A	1,654	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Oliceridine		Viltolarsen		Satralizumab-mwge		Clascoterone	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	*****	*****	389	217,540,226	55,550	217,485,065
Claim recorded during specified age range	*****	0	*****	0	389	0	55,550	0
Episode defining index claim recorded during the query period	*****	0	*****	0	389	0	55,550	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	59	*****	52	*****	328	61	48,919	6,631
Met inclusion and exclusion criteria	59	0	52	0	328	0	48,919	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	59	0	52	0	328	0	48,919	0
Final cohort								
Number of members	59	N/A	52	N/A	328	N/A	48,919	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Somapacitan-beco		Copper Cu 64 Dotatate Injection		Pralsetinib		Atoltivimad Maftivimab and Odesivimab-ebgn	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	1,321	217,539,294	19,750	217,520,865	254	217,540,361	0	217,540,615
Claim recorded during specified age range	1,321	0	19,750	0	254	0	0	0
Episode defining index claim recorded during the query period	1,321	0	19,750	0	254	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,172	149	18,172	1,578	227	27	0	0
Met inclusion and exclusion criteria	1,172	0	18,172	0	227	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,172	0	18,172	0	227	0	0	0
Final cohort								
Number of members	1,172	N/A	18,172	N/A	227	N/A	0	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Remdesivir		Lonafernib		Lumasiran		Setmelanotide	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	*****	*****	*****	*****	69	217,540,546
Claim recorded during specified age range	*****	*****	*****	0	*****	0	69	0
Episode defining index claim recorded during the query period	*****	0	*****	0	*****	0	69	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	993,583	*****	*****	0	41	*****	57	12
Met inclusion and exclusion criteria	993,583	0	*****	0	41	0	57	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	993,583	0	*****	0	41	0	57	0
Final cohort								
Number of members	993,583	N/A	*****	N/A	41	N/A	57	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Naxitamab-gqgk		Gallium 68 PSMA-11		Berotralstat		Tirbanibulin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	72,388	217,468,227	585	217,540,030	9,125	217,531,490
Claim recorded during specified age range	*****	0	72,388	0	585	0	9,125	0
Episode defining index claim recorded during the query period	*****	0	72,388	0	585	0	9,125	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	36	*****	66,552	5,836	489	96	8,271	854
Met inclusion and exclusion criteria	36	0	66,552	0	489	0	8,271	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	36	0	66,552	0	489	0	8,271	0
Final cohort								
Number of members	36	N/A	66,552	N/A	489	N/A	8,271	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Margetuximab (anti-HER2 mAB)		Relugolix		Ansuvimab-zykl		Vibegron	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A	291,290,193	N/A
Had required coverage type (medical and/or drug coverage)	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408	217,633,785	73,656,408
Enrolled during specified age range	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916	217,627,869	5,916
Had requestable medical charts	217,627,869	0	217,627,869	0	217,627,869	0	217,627,869	0
Met demographic requirements (sex, race, and Hispanic origin)	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254	217,540,615	87,254
Members with a valid index event								
Had any cohort-defining claim during the query period	457	217,540,158	36,870	217,503,745	0	217,540,615	*****	*****
Claim recorded during specified age range	457	0	36,870	0	0	0	*****	*****
Episode defining index claim recorded during the query period	457	0	36,870	0	0	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	417	40	32,426	4,444	0	0	243,455	*****
Met inclusion and exclusion criteria	417	0	32,426	0	0	0	243,455	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	417	0	32,426	0	0	0	243,455	0
Final cohort								
Number of members	417	N/A	32,426	N/A	0	N/A	243,455	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Remimazolam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on July 2, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1b. Patient Entry into Study by Month for Fostemsavir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on July 2, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1c. Patient Entry into Study by Month for Decitabine and Cedazuridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on July 7, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1d. Patient Entry into Study by Month for Abametapir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on July 24, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

There was no use during the query period.

Figure 1e. Patient Entry into Study by Month for Tafasitamab-cxix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on July 31, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1f. Patient Entry into Study by Month for Belantamab Mafodotin-blmf in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 5, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1g. Patient Entry into Study by Month for Nifurtimox in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 6, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for Risdiplam in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 7, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1i. Patient Entry into Study by Month for Oliceridine in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 7, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1j. Patient Entry into Study by Month for Viltolarsen in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 12, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1k. Patient Entry into Study by Month for Satralizumab-mwge in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 14, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 11. Patient Entry into Study by Month for Clascoterone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on August 26, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>


Figure 1m. Patient Entry into Study by Month for Somapacitan-beco in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on August 28, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1n. Patient Entry into Study by Month for Copper Cu 64 Dotatate Injection in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on September 3, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>


Figure 1o. Patient Entry into Study by Month for Pralsetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on September 4, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1p. Patient Entry into Study by Month for Atoltivimad Maftivimab and Odesivimab-ebgn in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025




*The FDA approval date for this drug was on October 14, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

There was no use during the query period.

Figure 1q. Patient Entry into Study by Month for Remdesivir in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on October 22, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1r. Patient Entry into Study by Month for LonaFarnib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on November 20, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1s. Patient Entry into Study by Month for Lumasiran in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on November 23, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1t. Patient Entry into Study by Month for Setmelanotide in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on November 25, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1u. Patient Entry into Study by Month for Naxitamab-gqgk in the Sentinel Distributed Database from January 1, 2020 to April 30,

*The FDA approval date for this drug was on November 25, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1v. Patient Entry into Study by Month for Gallium 68 PSMA-11 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on December 1, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>


Figure 1w. Patient Entry into Study by Month for Berotralstat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on December 3, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1x. Patient Entry into Study by Month for Tirbanibulin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on December 14, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>


Figure 1y. Patient Entry into Study by Month for Margetuximab (anti-HER2 mAB) in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on December 16, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1z. Patient Entry into Study by Month for Relugolix in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on December 18, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1aa. Patient Entry into Study by Month for Ansuvimab-zykl in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025




*The FDA approval date for this drug was on December 21, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

There was no use during the query period.

Figure 1ab. Patient Entry into Study by Month for Vibegron in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on December 23, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2007	10/31/2024
DP02	01/01/2008	12/31/2024
DP03	01/01/2010	09/30/2024
DP04	01/01/2006	10/31/2024
DP05	01/01/2008	03/31/2025
DP06	01/01/2000	04/30/2024
DP07	01/01/2014	12/31/2021
DP08	01/01/2000	01/31/2024
DP09	01/01/2000	01/31/2024
DP10	01/01/2004	03/31/2024
DP11	01/01/2005	07/31/2022
DP12	01/01/2000	04/30/2024
DP13	01/01/2000	04/30/2025

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
remimazolam			
J2249	Injection, remimazolam, 1 mg	Procedure	HCPCS

Appendix C. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
	remimazolam
remimazolam besylate	Byfavo
	fostemsavir
fostemsavir tromethamine	Rukobia
	decitabine_cedaz
decitabine/cedazuridine	Inqovi
	abametapir
abametapir	Xeglyze
	tafasitamab_cxix
tafasitamab-cxix	Monjuvi
	belantamab_maf
belantamab mafodotin-blmf	Blenrep
	nifurtimox
nifurtimox	Lampit
	risdiplam
risdiplam	Evrysdi
	oliceridine
oliceridine fumarate	Olinvyk
	viltolarsen
viltolarsen	Viltepso
	satralizumab_mwge
satralizumab-mwge	Enspryng
	clascoterone
Clascoterone	Winlevi
clascoterone	Winlevi
	somapacitan_beco
somapacitan-beco	Sogroya
	copper_cu_64
copper Cu-64 dotatate	Detectnet
	pralsetinib
pralsetinib	Gavreto
	atoltivimad
atoltivimab-maftivimab-odesivimab-ebgn	Inmaze (National Stockpile)
	remdesivir
remdesivir	Veklury
remdesivir	remdesivir
	lonafarnib

Appendix C. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
lonafarnib	Zokinvy
lumasiran	
lumasiran sodium	Oxlumo
setmelanotide	
setmelanotide acetate	Imcivree
naxitamab_gqgk	
naxitamab-gqgk	Danyelza
gallium_68_psm11	
gallium Ga-68 gozetotide	gallium Ga-68 dotatoc
gallium Ga-68 gozetotide	gallium Ga-68 gozetotide
berotralstat	
berotralstat hydrochloride	Orladeyo
tirbanibulin	
tirbanibulin	Klisyri (250 mg)
tirbanibulin	Klisyri (350 mg)
margetuximab	
margetuximab-cmkb	Margenza
relugolix	
relugolix	Orgovyx
relugolix/estradiol/norethindrone acetate	Myfembree
ansuvimab_zykl	
ansuvimab-zykl	Ebanga
ansuvimab-zykl	Ebanga (National Stockpile)
vibegron	
vibegron	Gemtesa

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnesic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnesic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM

Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Breast Cancer			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal Cancer			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depression			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Hypertension			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Lung Cancer			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM

Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00X A	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.011 A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012 A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019 A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021 A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022 A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029 A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031 A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032 A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039 A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041 A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042 A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049 A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051 A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052 A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059 A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061 A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062 A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.069 A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071 A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072 A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079 A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08X A	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AX A	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80X A	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811 A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812 A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819 A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821 A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822 A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829 A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831 A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832 A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839 A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841 A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.842 A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849 A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851 A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852 A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859 A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861 A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862 A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869 A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871 A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872 A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879 A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88X A	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AX A	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Non-Proprietary Name	Proprietary Name
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

Appendix F.1 Specifications Defining Parameters in this Request

Specifications for Type 5 Request: cder_mpl1r_wp311

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2020 in the Sentinel Distributed Database (SDD).

Query period: 01/01/2020 - 04/30/2025
Coverage requirement: Medical and Drug Coverage
Minimum Pre-Index Enrollment Days: 183 days
Minimum Post-Index Required Days: 0 days
Enrollment Gap: 45 days
Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Sex: M, F
Other Demographic Restrictions: n/a
Stratifications: Age group, Sex, Calendar Month (for Figures only)
Data Restrictions: None
Chart Availability Restriction Indicator: N
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: N
Drop Censor Output Indicator: Yes (Indicates if counts of episodes censored by death and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure

Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	Remimazolam	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Exposure									
Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position	Treatment Episode Gap Type	Exposure Episode	Exposure Episode	Create Baseline Table?	End At-Risk Period at Evidence of
2	Fostemsavir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Decitabine and Cedazuridine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Abametapir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Exposure									
Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
5	Tafasitamab-cxix	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Belantamab Mafodotin-blmf	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Exposure									
Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
7	Nifurtimox	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	Risdiplam	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
9	Oliceridine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	Viltolarsen	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type					
11	Satralizumab-mwge	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.		0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Clascoterone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.		0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
13	Somapacitan-beco	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	Copper Cu 64 Dotatate Injection	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
15	Pralsetinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Atoltivimad, maftivimab, and odesivimab-ebgn	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
17	Remdesivir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	Lonafarnib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
19	Lumasiran	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	Setmelanotide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
21	Naxitamab-gqgk	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	Gallium 68 PSMA-11	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
23	Berotrastat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	Tirbanibulin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
25	Margetuximab (anti-HER2 mAB)	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	Relugolix	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Exposure									
Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
27	Ansuvimab-zykl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
28	Vibegron	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and CPT (Current Procedural Terminology) codes are provided by Optum360. National Drug Codes (NDCs) are checked against FirstDataBank's FDBMedKnowledge®									

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>									
Acute Myocardial Infarction	1	DX		IPP, IPS	1	-183	-1	N/A ¹	Y
Alzheimer's Disease	2	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	3	DX		Any	1	-183	-1	N/A	Y
Atrial Fibrillation	4	DX		IPP, IPS	1	-183	-1	N/A	Y
	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
Diabetes	7	DX		IP*, IS*	1	-183	-1	N/A	Y
	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	10	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
Hyperlipidemia	11	DX		IP*, IS*	1	-183	-1	N/A	Y
	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
Hypertension	14	DX		IP*, IS*	1	-183	-1	N/A	Y
	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	17	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	18	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	19	DX		Any	2	-183	-1	N/A	Y
Stroke/Transient Ischemic Attack (TIA)	20	DX		IP*	1	-183	-1	N/A	Y
	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y
Breast Cancer	23	DX		IP*, IS*	1	-183	-1	N/A	Y
	24	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A	Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	28	CC	26 or 27		1			N/A	Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A	Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Lung Cancer	31	CC	29 or 30		1			N/A	Y
	32	DX		IP*, IS*	1	-183	-1	N/A	Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	34	CC	32 or 33		1			N/A	Y
Endometrial Cancer	35	DX		IP*, IS*	1	-183	-1	N/A	Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	37	CC	35 or 36		1			N/A	Y
Acquired Hypothyroidism	38	DX		IP*, IS*,	1	-183	-1	N/A	Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	40	CC	38 or 39		1			N/A	Y
Anemia	41	DX		Any	1	-183	-1	N/A	Y
Asthma	42	DX		IP*, IS*,	1	-183	-1	N/A	Y
	43	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	44	CC	42 or 43		1			N/A	Y
Benign Prostatic Hyperplasia	45	DX		IP*, IS*,	1	-183	-1	N/A	Y
	46	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	47	CC	45 or 46		1			N/A	Y
Chronic Kidney Disease	48	DX		IP*, IS*,	1	-183	-1	N/A	Y
	49	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	50	CC	48 or 49		1			N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX		IP*, IS*,	1	-183	-1	N/A	Y
	52	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	53	CC	51 or 52		1			N/A	Y
Glaucoma	54	DX		AV*, ED*, OA*	1	-183	-1	N/A	Y
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
<i>Other</i>									
Obesity (Diagnosis or Procedure Codes)	58	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	59	RX		Any	1	-183	-1	N/A	Y
Overweight	60	DX		Any	1	-183	-1	N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Smoking (Diagnosis or Procedure Codes)	61	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	62	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	63	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	64	DX, PX		Any	1	-183	-1	N/A	Y
History of Cardiac Arrest	65	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	66	DX, PX		Any	1	-183	-1	N/A	Y
Liver Disease CCW	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or 81		1			N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Liver Disease Extended	83	DX		IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC	83 or 84		1			N/A	Y
	86	PX		AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC	86 and 87		1			N/A	Y
	89	PX		ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
	91	CC	89 and 90		1			N/A	Y
	92	PX		OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC	92 and 93		1			N/A	Y
	95	PX		IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y
	97	CC	95 and 96		1			N/A	Y
	98	CC	83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97		1			N/A	Y
			RX: Drug code DX: Diagnosis code PX: Procedure code CC: Complex covariates (multiple COVARNUM values are used to define a covariate)		IP*: inpatient hospital stays, any diagnoses IS*: non-acute institutional stays, any diagnoses ED*: emergency department encounters AV*: ambulatory visits OA*: other ambulatory visits		N: Lookback period should search for evidence of a date or an interval Y: Lookback period should search for evidence of a date only		

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
----------------	------------------	---------------	------------------------------	--	--	-----------------------------------	---------------------------------	--	---------------------------

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.


¹N/A: Not Applicable

Appendix F.3 Specifications Defining Utilization Parameters in this Request

Utilization			
Medical Utilization Evaluation Period Start	Medical Utilization Evaluation Period End	Drug Utilization Evaluation Period Start	Drug Utilization Evaluation Period End
-183	-1	-183	-1

Appendix G. Design Diagrams of Cohort Entry Requirements for this Request

Cohort Design for Part 2 QF-9450¹



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² Scenarios defined on initiation of NMEs approved in 2020 part 2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Race, Hispanic Ethnicity, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking, Liver Disease CCW, Liver Disease Extended

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date